WO2001027329A2 - Combinatorial oligonucleotide pcr: a method for rapid, global expression analysis - Google Patents

Combinatorial oligonucleotide pcr: a method for rapid, global expression analysis Download PDF

Info

Publication number
WO2001027329A2
WO2001027329A2 PCT/US2000/028076 US0028076W WO0127329A2 WO 2001027329 A2 WO2001027329 A2 WO 2001027329A2 US 0028076 W US0028076 W US 0028076W WO 0127329 A2 WO0127329 A2 WO 0127329A2
Authority
WO
WIPO (PCT)
Prior art keywords
dna
amplification
sequence
tissue
cell
Prior art date
Application number
PCT/US2000/028076
Other languages
French (fr)
Other versions
WO2001027329A3 (en
Inventor
Michael C. Macleod
C. Marcelo Aldaz
Sara S. Gaddis
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Priority to CA002386410A priority Critical patent/CA2386410A1/en
Priority to EP00970778A priority patent/EP1259641A2/en
Priority to AU80106/00A priority patent/AU8010600A/en
Publication of WO2001027329A2 publication Critical patent/WO2001027329A2/en
Publication of WO2001027329A3 publication Critical patent/WO2001027329A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection

Definitions

  • Patterns of gene expression are also expected to be useful in the diagnosis of pathological conditions, and for example, may provide a basis for the sub-classification of functionally different subtypes of cancerous conditions.
  • Differential display RT-PCRTM (DDRT) is one method for analyzing differential gene expression in which subpopulations of complementary DNA (cDNA) are generated by reverse transcription of mRNA by using a cDNA primer with a 3' extension (preferably two bases). Random 10-base primers are then used to generate PCRTM products of transcript-specific lengths. If the number of primer combinations used is large enough, it is statistically possible to detect almost all transcripts present in any given sample. PCRTM products obtained from two or more samples are then electrophoresed next to one another on a gel and differences in expression are directly compared. Differentially expressed bands can be cut out of the gel, reamplified and cloned for further analysis.
  • libraries of cDNA may to be dominated by repetitive elements, mitochondrial genes, ribosomal RNA genes, and other nuclear genes comprising common or housekeeping sequences. While some mRNAs are abundant, others are rare, resulting in cellular quantities of mRNA from various genes that can vary by several orders of magnitude. Therefore, sequencing of transcribed regions of the genome using cDNA libraries has been considered unsatisfactory.
  • Identification of differential patterns of expression has several utilities, including the identification of appropriate therapeutic targets, candidate genes for gene therapy (including gene replacement), tissue typing, forensic identification, mapping locations of disease-associated genes, and for the identification of diagnostic and prognostic indicator genes.
  • the immobilization will occur at the anchorable moiety via a means of adhering.
  • the means of adhering may facilitate either a covalent or non- covalent interaction.
  • the anchorable moiety may be located at either the 5' or 3' end of the DNA.
  • the anchorable moiety may be a ligand, for example biotin or an antibody. Where the anchorable moiety includes a ligand, it is envisioned that this ligand is the means through which the DNA is immobilized to a substrate. Where the ligand is biotin, the biotin may be attached to streptavidin.
  • the method could be used to compare a cell or tissue from two organisms of the same species. Such organisms could further have a known genetic difference.
  • the method may also be used to compare gene expression in a normal cell with gene expression in a diseased cell. It is envisioned that such diseases could include diseases that are infectious, metabolic, genetic, congenital, adaptational, constitutional, drug-related or hereditary.
  • the means necessary for performing the method of this invention are included in a kit for detection of gene expression.
  • a kit for detection of gene expression would consist essentially of a first restriction enzyme, a second restriction enzyme, a first, ligatable oligonucleotide tag, a second, ligatable oligonucleotide tag, a first amplification primer, wherein the 5' sequence of said primer is complementary to said first linker sequence and the 3' sequence comprises a specificity region, a second amplification primer, wherein the 5' sequence of said primer is complementary to said second linker sequence and the 3' sequence comprises a specificity region, and software capable of analyzing data generated from use of the kit.
  • the method described herein and suitable modifications thereof will be used for determining global changes in gene expression patterns in a cell or tissue at any selected time.
  • Appropriate examples include: changes in gene expression patterns due to developmental changes; changes in gene expression patterns due to cancerous transformation in cells; changes in gene expression patterns due to treatment of the cell or organism with a pharmaceutical compound; changes in gene expression patterns due to treatment of the cell or organism with a carcinogen.
  • the method will be used for determining gene expression of a transcriptome at any selected time, for new gene discovery, and for diagnostic and or prognostic purposes.
  • FIG. 8 Partial sequence of MLN 62 mRNA. Primers for COP are highlighted, and the poly(A) addition signal sequence is underlined.
  • the A-end primer sequence (C ATGCCTT), starting at position 1760, contains the CATG that is closest to the 3' end of the mRNA.
  • the highlighted B-end primer sequence (TGAGATC), starting at position 1880, contains the first GATC following the A-end primer. Note that the actual B-end primer contains the reverse complement of the highlighted sequence (GATCTCA). This decreases the number of positions queried at the B-end by one, thus reducing the number of experiments by a factor of four.
  • FIG. 18 Expression changes in mouse skin and keratinocytes.
  • RNA, cDNA & genetags were prepared from A. newborn keratinocytes or B. epidermal extracts derived from adult wild type (-) or K5 E2F1 transgenic (+) mice.
  • PCR reactions contained COP primers chosen to amplify:
  • DNA Polymerase I Klenow Fragment, Exonuclease Minus DNA Polymerase I
  • Labels Recognition moieties inco ⁇ orated into primers, inco ⁇ orated into the amplified product during amplification, or attached to probes are useful in identification of the amplified molecules.
  • a number of different labels may be used for the pu ⁇ ose such as fluorophores, chromophores, radio-isotopes, enzymatic tags, antibodies, chemiluminescence, electroluminescence, affinity labels, etc.
  • fluorophores fluorophores, chromophores, radio-isotopes, enzymatic tags, antibodies, chemiluminescence, electroluminescence, affinity labels, etc.
  • immobilization may occur by precoating a polystyrene or glass solid phase with poly-L-Lys or poly L-Lys, Phe, followed by the covalent attachment of either amino- or sulfhydryl-modified polynucleotides using bifunctional crosslinking reagents (Running, 1990 and Newton, 1993). Immobilization may also take place by the direct covalent attachment of short, 5'-phosphorylated primers to chemically modified polystyrene plates ("Covalink” plates, Nunc) Rasmussen, (1991). The covalent bond between the modified oligonucleotide and the solid phase surface is introduced by condensation with a water-soluble carbodiimide. This method facilitates a predominantly 5 '-attachment of the oligonucleotides via their 5'-phosphates.
  • Nikiforov et al. (U.S. Patent 5610287 inco ⁇ orated herein by reference) describes a method of non-covalently immobilizing nucleic acid molecules in the presence of a salt or cationic detergent on a hydrophilic polystyrene solid support containing a hydrophilic moiety or on a glass solid support.
  • the support is contacted with a solution having a pH of about 6 to about 8 containing the synthetic nucleic acid and a cationic detergent or salt.
  • the support containing the immobilized nucleic acid may be washed with an aqueous solution containing a non-ionic detergent without removing the attached molecules.
  • amplification products are separated by agarose, agarose-acrylamide or polyacrylamide gel electrophoresis using standard methods (Sambrook et al, 1989).
  • chromatographic techniques may be employed to effect separation.
  • chromatography There are many kinds of chromatography which may be used in the present invention: adso ⁇ tion, partition, ion-exchange and molecular sieve, and many specialized techniques for using them including column, paper, thin-layer and gas chromatography (Freifelder, 1982).
  • labeled cDNA products such as biotin or antigen can be captured with beads bearing avidin or antibody, respectively.
  • Microfluidic techniques include separation on a platform such as microcapillaries, designed by ACLARA BioSciences Inc., or the LabChipTM "liquid integrated circuits" made by Caliper Technologies Inc. These microfluidic platforms require only nanoliter volumes of sample, in contrast to the microliter volumes required by other separation technologies. Miniaturizing some of the processes involved in genetic analysis has been achieved using microfluidic devices. For example, published PCT Application No. WO 94/05414, to Northrup and White, inco ⁇ orated herein by reference, reports an integrated micro-PCRTM apparatus for collection and amplification of nucleic acids from a specimen. U.S. Patent Nos.
  • micro capillary arrays are contemplated to be used for the analysis.
  • Microcapillary array electrophoresis generally involves the use of a thin capillary or channel which may or may not be filled with a particular separation medium. Electrophoresis of a sample through the capillary provides a size based separation profile for the sample. The use of microcapillary electrophoresis in size separation of nucleic acids has been reported in, for example, Woolley and Mathies, 1994. Microcapillary array electrophoresis generally provides a rapid method for size-based sequencing, PCRTM product analysis and restriction fragment sizing.
  • microfluidic devices including microcapillary electrophoretic devices has been discussed in detail in, for example, Jacobsen et al, 1994; Effenhauser et al, 1994; Harrison et al, 1993; Effenhauser et al, 1993; Manz et al, 1992; and U.S. Patent No. 5,904,824, here inco ⁇ orated by reference.
  • the capillaries e.g., fused silica capillaries or channels etched, machined or molded into planar substrates, are filled with an appropriate separation/sieving matrix.
  • sieving matrices include, e.g., hydroxyethyl cellulose, polyacrylamide, agarose and the like.
  • the specific gel matrix, running buffers and running conditions are selected to maximize the separation characteristics of the particular application, e.g., the size of the nucleic acid fragments, the required resolution, and the presence of native or undenatured nucleic acid molecules.
  • running buffers may include denaturants, chaotropic agents such as urea or the like, to denature nucleic acids in the sample.
  • ES mass spectrometry was introduced by Fenn, 1984; PCT Application No. WO 90/14148 and its applications are summarized in review articles, for example, Smith 1990 and Ardrey, 1992.
  • a mass analyzer a quadrupole is most frequently used. The determination of molecular weights in femtomole amounts of sample is very accurate due to the presence of multiple ion peaks which all could be used for the mass calculation.
  • MALDI mass spectrometry in contrast, can be particularly attractive when a time-of-flight (TOF) configuration is used as a mass analyzer.
  • TOF time-of-flight
  • the MALDI-TOF mass spectrometry has been introduced by Hillenkamp 1990. Since, in most cases, no multiple molecular ion peaks are produced with this technique, the mass spectra, in principle, look simpler compared to ES mass spectrometry. DNA molecules up to a molecular weight of 410,000 daltons could be desorbed and volatilized (Williams, 1989).
  • FET fluorescence energy transfer
  • the excited-state energy of the donor fluorophore is transferred by a resonance dipole-induced dipole interaction to the neighboring acceptor. This results in quenching of donor fluorescence.
  • the acceptor is also a fluorophore, the intensity of its fluorescence may be enhanced.
  • the efficiency of energy transfer is highly dependent on the distance between the donor and acceptor, and equations predicting these relationships have been developed by Forster, 1948.
  • the distance between donor and acceptor dyes at which energy transfer efficiency is 50% is referred to as the Forster distance (Ro).
  • Other mechanisms of fluorescence quenching are also known including, for example, charge transfer and collisional quenching.
  • Published PCT application WO 96/21144 discloses continuous fluorometric assays in which enzyme-mediated cleavage of nucleic acids results in increased fluorescence. Fluorescence energy transfer is suggested for use in the methods, but only in the context of a method employing a single fluorescent label which is quenched by hybridization to the target.
  • the secondary amplification products generated from signal primers may be detected by means of a variety of labels and reporter groups, restriction sites in the signal primer which are cleaved to produce fragments of a characteristic size, capture groups, and structural features such as triple helices and recognition sites for double-stranded DNA binding proteins.
  • FITC tetramethylrhodamine isothiocyanate
  • TRITC tetramethylrhodamine isothiocyanate
  • FITC/Texas Red.TM. Molecular Probes
  • PYB FITC/N-hydroxysuccinimidyl 1 -pyrenebutyrate
  • EITC FITC/eosin isothiocyanate
  • FITC/Rhodamine X FITC/tetramethylrhodamine
  • TAMRA FITC/tetramethylrhodamine
  • Any dye pair which produces fluorescence quenching in the detector nucleic acids of the invention are suitable for use in the methods of the invention, regardless of the mechanism by which quenching occurs.
  • Terminal and internal labeling methods are both known in the art and maybe routinely used to link the donor and acceptor dyes at their respective sites in the detector nucleic acid.
  • chip-based DNA technologies such as those described by Hacia et al, 1996 and Shoemaker et al, 1996. These techniques involve quantitative methods for analyzing large numbers of genes rapidly and accurately. By tagging genes with oligonucleotides or using fixed probe arrays, one can employ chip technology to segregate target molecules as high density arrays and screen these molecules on the basis of hybridization, Pease et al, 1994; Fodor et ⁇ /., 1991.
  • the inventors contemplate the preparation of a high- density array of COP primers on a chip (or on any other solid surface) and conduct the DNA amplification on this solid-phase. ix. OIA
  • OIA uses the mirror-like surface of a silicon wafer as a substrate.
  • RNA or DNA may be quantitated using the Real-Time PCR technique (Higuchi, 1992).
  • the concentration of the amplified products of the target DNA in PCR reactions that have completed the same number of cycles and are in their linear ranges, it is possible to determine the relative concentrations of the specific target sequence in the original DNA mixture. If the DNA mixtures are cDNAs synthesized from RNAs isolated from different tissues or cells, the relative abundance of the specific mRNA from which the target sequence was derived can be determined for the respective tissues or cells. This direct proportionality between the concentration of the PCR products and the relative mRNA abundance is only true in the linear range of the PCR reaction.
  • the final concentration of the target DNA in the plateau portion of the curve is determined by the availability of reagents in the reaction mix and is independent of the original concentration of target DNA. Therefore, the first condition that must be met before the relative abundance of a RNA or DNA species can be determined by Real-Time PCR for a collection of RNA or DNA populations is that the concentrations of the amplified PCR products must be sampled when the PCR reactions are in the linear portion of their curves.
  • the second condition that must be met for an RT-PCR experiment to successfully determine the relative abundance of a particular mRNA species is that relative concentrations of the amplifiable cDNAs must be normalized to some independent standard.
  • the goal of an Real-Time PCR experiment is to determine the abundance of a particular RNA or DNA species relative to the average abundance of all RNA or DNA species in the sample.
  • the Luminex technology allows the quantitation of nucleic acid products immobilized on color coded microspheres.
  • the magnitude of the biomolecular reaction is measured using a second molecule called a reporter.
  • the reporter molecule signals the extent of the reaction by attaching to the molecules on the microspheres.
  • digital signal processing allows the translation of signals into real-time, quantitative data for each reaction.
  • PCRTM products The type of label inco ⁇ orated in PCRTM products is dictated by the method used for analysis.
  • capillary electrophoresis, microfluidic electrophoresis, HPLC, or LC separations either inco ⁇ orated or intercalated fluorescent dyes are used to label and detect the PCRTM products.
  • Samples are detected dynamically, in that fluorescence is quantitated as a labeled species moves past the detector. If any electrophoretic method, HPLC, or LC is used for separation, products can be detected by abso ⁇ tion of UV light, a property inherent to DNA and therefore not requiring addition of a label.
  • primers for the PCRTM can be labeled with a fluorophore, a chromophore or a radioisotope, or by associated enzymatic reaction.
  • Enzymatic detection involves binding an enzyme to primer, e.g., via a bioti avidin interaction, following separation of PCRTM products on a gel, then detection by chemical reaction, such as chemiluminescence generated with luminol. A fluorescent signal can be monitored dynamically.
  • Detection with a radioisotope or enzymatic reaction requires an initial separation by gel electrophoresis, followed by transfer of DNA molecules to a solid support (blot) prior to analysis. If blots are made, they can be analyzed more than once by probing, stripping the blot, and then reprobing. If PCRTM products are separated using a mass spectrometer no label is required because nucleic acids are detected directly.
  • microcapillary arrays may be scanned using lasers to excite fluorescently labeled targets that have hybridized to regions of probe arrays, which can then be imaged using charged coupled devices ("CCDs") for a wide field scanning of the array.
  • CCDs charged coupled devices
  • another particularly useful method for gathering data from the arrays is through the use of laser confocal microscopy which combines the ease and speed of a readily automated process with high resolution detection. Scanning devices of this kind are described in U.S. Patent Nos. 5,143,854 and 5,424,186.
  • the data will typically be reported to a data analysis operation.
  • the data obtained by a reader from the device will typically be analyzed using a digital computer.
  • the computer will be appropriately programmed for receipt and storage of the data from the device, as well as for analysis and reporting of the data gathered, i.e., inte ⁇ reting fluorescence data to determine the sequence of hybridizing probes, normalization of background and single base mismatch hybridizations, ordering of sequence data in SBH applications, and the like, as described in, e.g., U.S. Patent Nos. 4,683,194, 5,599,668 and 5,843,651 inco ⁇ orated herein by reference.
  • kits are those suitable for use in PCRTM.
  • two primers will preferably be provided that have sequences from, and that hybridize to, spatially distinct regions of the target gene.
  • Preferred pairs of primers will have two parts, a first subsequence, corresponding to a recognition-sequence of a four-base cutter and a second subsequence, corresponding to a specificity region designed to amplify any possible combination of nucleotides adjacent to the restriction site. Kits of this embodiment will be used to amplify all genes, unknown and/or known, that respond to certain treatments or stimuli.
  • the second subsequence following the restriction-enzyme sequence will correspond to a known gene or set of genes.
  • kits of this embodiment will be used to detect and quantitate all known genes that belong to a family or all known genes that respond to a treatment or stimulus.
  • Other preferred pairs of primers for amplifying nucleic acids are selected to amplify the sequences specified herein.
  • Also included in PCRTM kits may be enzymes suitable for amplifying nucleic acids, including various polymerases (RT, Taq, etc.), deoxynucleotides and buffers to provide the necessary reaction mixture for amplification.
  • kits of the present invention although containing at least one sequence corresponding to a restriction-enzyme recognition sequence, as disclosed herein, also may contain one or more of a variety of other target-gene sequences as described above.
  • the kits of the present invention may also include the anchorable moiety, components necessary for second strand cDNA synthesis, linkers, ligase, and kinase.
  • kits will preferably comprise distinct containers for each individual reagent and enzyme, as well as for each probe or primer pair.
  • Each biological agent will generally be suitable aliquoted in their respective containers.
  • the container means of the kits will generally include at least one vial or test tube. Flasks, bottles and other container means into which the reagents are placed and aliquoted are also possible.
  • the individual containers of the kit will preferably be maintained in close confinement for commercial sale. Suitable larger containers may include injection or blow-molded plastic containers into which the desired vials are retained. Instructions may be provided with the kit.
  • cDNA was synthesized with biotinylated oligo (dT) as first strand primer, digested with a frequent-cutting restriction endonuclease (Dpnll), and the 3'-most fragment recovered by binding to a streptavidin-coated bead.
  • Dpnll biotinylated oligo
  • B-linker 16-bp adapter with a Dpnll compatible sticky end
  • the fragments were then digested with a second frequent cutting restriction endonuclease, (Nlalll) and a second common priming site (“A-linker”) was added by ligation.
  • A-linker a second common priming site
  • B/A genetags a template preparation that contained a single gene-specific target sequence from each cDNA, with common A and B linkers at the two ends. Because each of the two enzymes used has a recognition site on average every 256 bp, the average size of the gene-specific target sequences was expected to be about 128 bp.
  • PCRTM reactions using primers containing only the A- and B- linker sequences would be expected to amplify all of the gene-specific targets in these genetag preparations.
  • the presence of relatively long common regions in the COP primers allows near optimal amplification with all primers under a single set of PCRTM conditions.
  • a single pair of primers that will amplify the gene-specific target in one genetag orientation can be predicted from the sequence, as well as the size of the resulting fragment (amplimer).
  • Current estimates of the number of genes in the human transcriptome range from about 60,000 to 100,000. Since the COP method effectively divides the transcriptome randomly among 32,768 unique reactions, each pair of COP primers tested may give several amplimers (2-3 on average), only one of which corresponds to the gene being assayed. In general, these amplimers can be distinguished by size.
  • Double stranded linkers with overhangs complementary to the ends created by restriction with Nla III (A-linker) and Dpn II (B-linker) were prepared separately by mixing equal amounts of the following oligonucleotides, warming to 90°C for 2 min and slowly cooling to room temperature: A-linker - 5'-CGTCTAGACAGC (previously phosphorylated with T4 polynucleotide kinase) and 5'- GCTGTCTAGACGCATG; B-linker - 5' - CGGTGATGCATC and 5' -GATCGATGCATCACCG (previously phosphorylated with T4 polynucleotide kinase).
  • A-linker (217 ng) under similar conditions. These fragments of cDNA, containing the gene-specific targets ligated to the B and A linkers, are referred to as B/A genetags.
  • two pairs of primers that differed by a single nucleotide from the Brcal primers were also chosen that were expected to produce amplimers of 117 and 197 bp from the genes for annexin III and an anonymous cDNA (clone 2C11B), respectively.
  • Two sets of primers for COP PCRTM reactions were synthesized, corresponding to the A- and B- linkers above, but containing 3 or 4 nucleotide specificity regions at the 3' end. The sequences of these primer sets were:
  • the 291 bp amplimer obtained with primers specific for the Brcal gene was gel-purified and sequenced in both directions with the same primers used in the initial reaction; the experimentally determined sequence exactly matched the predicted sequence.
  • primer pairs were selected for 9 other murine genes, including several high abundance, housekeeping genes, Ode, Rpl5, and Actg, and also lower abundance genes, Mdm2, Ccng, Cdkn2a, Cdkl and transcription factors Yyl and Hfl ⁇ 2.
  • primer pairs were selected for 14 human genes: HSPBl(t e gene for HSP27), TRAF4 (the gene for MLN62), RPS5, RPS16, RPL31, CAPN4, XPC, IGFBP2, ARF3, PSMD12, CREB2, TOP3, TCEB3, ETR101. Reactions were run with the appropriate primer pairs and genetag templates, reaction products of the expected size were again gel-purified and sequenced, and in each case the sequence obtained was greater than 95% identical to the expected product.
  • the signal must increase linearly with the amount of template and the PCRTM reactions must be in the exponential phase rather than the stationary phase, i.e. the signal must increase exponentially with cycle number.
  • Densitometry of the stained gel shown in FIG. 2A indicated that the integrated intensity of the amplimer bands increased linearly with the amount of genetag template up to about 0.6 ng cDNA for annexin III and up to about 4 ng cDNA for Brcal and 2C11B (FIG. 2B).
  • the integrated intensities increased exponentially with increasing cycle number from 22 to 28 (FIG. 2C).
  • the intensity of the bands increased linearly with template concentration over a defined range, and exponentially with PCRTM cycle number from 24 to 28 cycles.
  • the ultimate quantitative method for PCRTM determination of mRNA levels is competitive RT-PCRTM.
  • a competitive template must be made that is amplified by the same primers with approximately the same efficiency as the target.
  • concentration of the unknown target cDNA can be accurately evaluated.
  • the competitive template is engineered to contain the same sequences as the target, with a small insertion or mutation built in that allows the products derived from the target and the competitor to be distinguished, either by size or by sensitivity to digestion by one or more restriction enzyme.
  • a large amount of time and effort is expended to design, produce and validate the competitive template.
  • the inventors have designed a general strategy for the production of competitive templates for target genes of known sequence using COP.
  • a specific example of this strategy is outlined in FIG. 4, using the gene for HSP27 for illustration.
  • the COP genetag sequence for HSP27 and the associated COP primers (COP32 and COP46) are shown in the center of FIG. 4.
  • the inventors synthesized a primer (CRT004) that contains the COP32 sequence and 5 or more nucleotides of the target genetag sequence ("clamp"). Between the COP32 and clamp sequences the inventors inserted 5 bp of arbitrary sequence, in this case ACACA.
  • the target product obtained in the absence of competitor was easily distinguished from the 5 bp longer product obtained from the competitive template in the absence of genetags (lane 11).
  • the intensity of the longer band increased linearly.
  • the concentrations of the target genetag and the competitor are considered to be equal.
  • This equivalence point can be estimated from linear plots of the ratio of the intensities of the two bands versus the concentration of competitor.
  • some authorities recommend using log-log plots of the data to verify that the reactions are within the required parameters. Such plots should be linear with a slope of approximately 1. As shown in FIG.
  • MLN62 gene was constructed using methods analogous to those described in the previous section.
  • This template contained (FIG. 7A) the gene-specific target for the MLN62 gene with a 10 bp insertion, the A-end and B-end linkers, and a biotin label at one end.
  • amplification of this template with MLN62-specific COP primers gave rise to a product 10 bp longer than the MNL62-specific amplimer (FIG. 7B, lane 6, arrowheads).
  • HME87 human mammary epithelial cell line, HME87 (Gazdar et al, 1998), was grown in serum-free medium (MEGM, Clonetics, Walkersville, MD) and cDNA was prepared as described above for SKBR3 cells.
  • the ICM N62 DNA was mixed with cDNA prepared from HME87 normal human mammary epithelial cells at a 1 :20,000 weight ratio, and A B genetags were prepared.
  • PCRTM reactions were performed using the MLN-specific COP primers, and amplimers corresponding in size to the MLN62 cDNA (closed arrowhead) and to the
  • IC M LN 2 (open arrowhead) were obtained (FIG. 7B, lanes 2-5).
  • the intensity of both bands increased linearly with template concentration (FIG. 7C). From the ratio of intensities of these two bands in FIG. 7B and the known level of addition of the ICML N 6 2 to the cDNA, the molar concentration of the endogenous MLN62-specific genetag could be calculated as 0.6 amol/ng cDNA. Assuming an average mRNA length of
  • COP experiments can be normalized is by the use of sets of control or standardization genes. This method uses essentially an external standard approach. A set of genes is identified whose expression is relatively constant among different biological samples. These are usually comprised of "housekeeping" genes, such as ribosomal protein genes and genes for intermediary metabolic enzymes. COP amplifications for these genes are performed in parallel with COP amplification for the genes of interest, and the results compared. Tables 4 and 5 give examples of sets of standardization genes for both orientations of human and mouse genetags, respectively.
  • SKBR3 human breast cancer cell line
  • the mRNA sequences for these genes were obtained from GenBank and analyzed to design COP primers.
  • FIG. 8 shows a portion of the sequence of one of these genes, MLN62, and the location of the COP primers, and Table 6 shows the four genes chosen; their approximate expression levels from the SAGE data; the COP primers; and the lengths of the amplimers expected.
  • Poly A(+)RNA was prepared from SKBR3 cells, and a genetag preparation with A/B orientation was made using the enzymes Nlalll and Dpn II.
  • PCRTM reactions 25 ⁇ L were set up using the required primers and genetags were derived from 1.0 ng of cDNA per reaction. Aliquots of the PCRTM products were analyzed on 5% polyacrylamide gels and visualized by ethidium bromide staining. The results are shown in FIG. 9. For each pair of primers, reactions that lacked template gave no visible products. In the presence of the genetag template, each pair of primers produced a well-defined band ("amplimer") that matched the size expected for the corresponding gene.
  • each primer pair differed from each other by 1, 2 or 3 nucleotides, in no case did a primer pair produce an amplimer that matched in size the amplimer expected from a different primer pair in this set (compare, for example, FIG. 9: lanes 5 and 6 with lanes 9 and 10). In some cases (for example, FIG. 9: lanes 9 and 10) one or more amplimers that did not match the expected size were also seen. This is not unexpected, since on the average each COP primer pair should amplify a unique fragment from 3-4 different genes, and these fragments are likely to be of different sizes. The identity of the 100 bp fragment seen in lanes 9 and 10 is currently unknown.
  • the amplimer band was excised from the gel, purified and sequenced. In all cases, the derived sequence matched the expected sequence. In Table 7 the inventors list 10 genes that have been tested to date and for which COP produces an amplimer of the expected size and sequence.
  • Results obtained when the number of PCRTM cycles were varied from 24 through 28 are shown in FIG. 10 and FIG. 11. For all three bands, an exponential increase in the amount of the amplimer was seen for at least the 25th through the 27th cycle. Results obtained when the template concentration were varied from 0.1 to 1.0 ng are shown in FIG. 12 and FIG. 13. For all three bands, the amount of amplimer produced increased linearly with template over this range. These studies demonstrate that COP is a quantitative procedure.
  • the inventors have developed several kinds of bioinformatics tools needed to support the implementation of the methods described herein (Fig. 21). First they have developed several software programs that run on Macintosh digital computers. These include (1) a program to find the correct amplification primers for any given mRNA accession in GenBank; (2) a program to find all GenBank mRNA accessions that should be amplified from a suitable genetags preparation by a particular pair of amplification primers; (3) a program that analyzes and summarizes quantitative data obtained from COP experiments.
  • the COP technique is envisioned to have wide applications, both as a screening tool and as a low-cost adjunct to other global gene expression technologies.
  • the inventors demonstrate the use of this technology to study changes in gene expression. Changes in expression levels of genes in transgenic mouse keratinocytes overexpressing the human E2F1 gene, including the upregulation of several genes that act to increase p53 activity were determined using COP. Two genes not previously reported to be regulated by E2F1 : Brcal and CDK7, were also found to have an increased expression.
  • E2F1 Overexpression of the cell cycle-regulated transcription factor E2F1 can bypass growth arrest induced by a variety of methods. This is due to the ability of E2F1 to transactivate genes important for cell cycle progression, including genes for DNA biosynthetic enzymes, factors that control the initiation of DNA synthesis, cell cycle regulators, and several proto-oncogenes (Johnson and Schneider-Broussard, 1998; Slansky and Farnham, 1996). In contrast to its positive effects on cell growth, E2F1 has also been shown to have a role in apoptosis in some systems.
  • the inventors recently described the generation of transgenic mice expressing E2F1 under the control of a keratin 5 (K5) promoter (Pierce et al, 1998a; Pierce et al, 1998b).
  • Deregulated expression of E2F1 in basal keratinocytes results in epidermal hype ⁇ lasia, hype ⁇ roliferation and aberrant p53-dependent apoptosis.
  • E2F1 -induced apoptosis is significantly reduced while E2Fl-induced hype ⁇ roliferation is unchanged.
  • K5 E2F1 transgenic mice that are deficient (heterozygous or nullizygous) for p53 develop spontaneous skin carcinomas.
  • K5 E2F1 keratinocytes overexpress at least one endogenous E2F target, the cyclin E gene.
  • the inventors applied the COP technology to determine in further detail changes in endogenous gene expression resulting from overexpression of the K5 E2F1 transgene.
  • the details of the method for preparing genetags are shown in FIG. 1 using the cDNA for annexin III as an illustrative example.
  • the gene-specific targets are partially purified by cutting cDNA with one restriction enzyme, selecting the poly(A)-containing, 3 '-most fragment, and then cutting with a second restriction enzyme.
  • a and B linkers
  • the inventors call these fragments "genetags”. This ensures that each cDNA molecule will give rise to only one "genetag", reducing the sequence complexity of the template population by an order of magnitude.
  • mRNA was prepared using a QIAGEN kit, and double-stranded cDNA was synthesized using biotinylated p(dT) ⁇ as the primer for the first strand synthesis.
  • cDNA was digested with Dpn II, the 3'-most Dpn II fragment of each cDNA was adsorbed to magnetic beads coated with streptavidin (Dynal, Lake Success, NY) and non-biotinylated fragments were washed from the beads.
  • cDNA fragments still bound to the beads were ligated to the B-linker; then digested with Nla III; and fragments released from the beads by this treatment were selected and ligated to the A-linker.
  • Double stranded linkers with overhangs complementary to the ends created by restriction with Nla III (A-linker) and Dpn II (B-linker) were prepared separately by mixing equal amounts of the following oligonucleotides: warming to 90°C for 2 min and slowly cooling to room temperature: A-linker - 5'-CGTCTAGACAGC (previously phosphorylated with T4 polynucleotide kinase) and 5'-GCTGTCTAGACGCATG; B-linker - 5' - CGGTGATGCATC and 5' - GATCGATGCATCACCG (previously phosphorylated with T4 polynucleotide kinase).
  • the average gene specific target length is 128 bp, less than one-tenth the average mRNA length (2000 ntd).
  • the scheme illustrated in FIG. 1 will not produce an amplifiable genetag from cDNAs in which there is no Nla III restriction site between the last Dpn II restriction site and the poly(A) tail.
  • the inventors simply reverse the order in which the Dpn II and Nla III cuts are made.
  • cDNAs that lack one or both enzyme recognition sites or in which the restriction sites are separated by less than 6 bp are refractory to this analysis. The inventors empirically found that this corresponds to about 5-10% of the transcriptome.
  • the presence of relatively long common regions in the COP primers allows near optimal amplification with all primers under a single set of PCRTM conditions.
  • PCRTM reactions contained (in a total volume of 25 ⁇ L): genetags equivalent to 0.1 to 2 ng cDNA; 40 pg of each primer; 0.25 ⁇ L AmpliTaq (Perkin Elmer Co.); and lx "D" buffer (Epicentre Technologies, Madison WI). Reactions were run in a Stratagene RoboCycler with an initial denaturation of 5 min at 95°C, 2 min at 60°C and 1 min at 72°C followed by 26 cycles of 0.5 min at 95°C,1 min at 60°C and 1 min at 72°C. The final extension at 72°C was increased to 6 min.
  • a single pair of primers that will amplify the gene-specific target in one genetag orientation can be predicted from the sequence.
  • COP Specificity of COP is demonstrated herein with examples of the genes Brcal, annexin III and 2C11B.
  • primers specific for Brcal GenBank Accession No. U36475), annexin III (AJ001633), or 2C1 IB (UOl 139) were combined with B/A genetags and PCRTM amplification carried out for 27 cycles.
  • PCRTM reactions contained (in a total volume of 25 ⁇ L): genetags equivalent to 0.1 to 2 ng cDNA, 40 pg of each primer, 0.25 ⁇ L AmpliTaq (Perkin Elmer Co.) and lx "D" buffer (Epicentre Technologies, Madison WI).
  • Reactions were run in a Stratagene RoboCycler with an initial denaturation of 5 min at 95°C, 2 min at 60°C and 1 min at 72°C followed by 26 cycles of 0.5 min at 95°C, 1 min at 60°C and 1 min at 72°C. The final extension at 72°C was increased to 6 min.
  • the reactions were analyzed on 8% polyacrylamide gels, stained with Vistra Green (Molecular Probes, Eugene, OR) and digitized fluorescent images were obtained with a Fluorlmager (Molecular Dynamics, Sunnyvale, CA). Arrows to the right indicate the expected molecular sizes of the three amplimers.
  • the 291 bp Brcal amplimer was gel-purified and sequenced in both directions with the same primers used in the initial reaction. The experimentally determined sequence exactly matched the predicted sequence.
  • primers were selected for 9 other genes that varied widely in their expected expression levels and in the lengths of the predicted amplimers. Reaction products of the expected size were again gel-purified and sequenced. All 10 of the amplimers analyzed gave greater than 95% sequence identity to the expected product . These included the gene-specific targets of several high abundance, housekeeping genes, including ribosomal protein L5 and ⁇ -actin, and also lower abundance genes, including transcription factors YY-1 and Genesis.
  • mRNA was prepared using a QIAGEN kit, and double-stranded cDNA was synthesized using biotinylated p(dT) ⁇ g as the primer for first strand synthesis.
  • the relative concentrations of wild type and transgenic genetags were adjusted to give approximately equal expression ratios for a set of control genes (ribosomal proteins L5 and SI 7, GAPDH, ⁇ -actin and ⁇ -actin) whose expression was not expected to change significantly with E2F1 overexpression.
  • the inventors performed reactions for over 400 known murine genes, including genes previously shown to be regulated by E2F1 and other genes related to cell proliferation, apoptosis, transcriptional regulation and signal transduction.
  • the inventors were able to detect the expected amplimers in reactions with 223 pairs of primers.
  • the remaining genes may not be expressed in keratinocytes, or their expression levels may be below the detection limit of the COP technique.
  • the amplimers produced by COP primers for several representative genes are shown in FIG. 15.
  • Cdkn2a/pl9 ⁇ KF in the transgenic keratinocytes (FIG. 15, lane 7; Table 8).
  • E2F1 -target genes exhibited 2-5-fold increases in steady-state expression in E2F1 transgenic keratinocytes (Table 8), while two more targets changed less than 2-fold.
  • Ccnb2 the cyclin activating kinase Cdkl and Ode were upregulated 3 -6-fold in the transgenic keratinocytes.
  • the expression ratio is calculated as the band intensity seen with the transgenic template divided by the intensity seen with a paire reaction using wild type template. The statistical significance of alterations in this ratio for each gene in the first two groups compared to t expression ratio seen for the control genes was evaluated using unpaired t-tests. The differences were significant at the p ⁇ 0.01 level for all gen listed with the exception of Ccna.
  • COP analyses can also be conducted using tissue samples from experimental animals.
  • To prepare mouse epidermal RNA adult mice were sacrificed and dorsal skin was dissected, heated to 55°C in DEPC-treated H2O for 30 s, and cooled to 40°C for 30 s. Skin samples were placed epidermal side down in 5 ml Trizol (GIBCO/BRL) for 30 s, and the epidermal layer was then scraped into the Trizol with the edge of a glass microscope slide. RNA extraction proceeded as described above. RNA was prepared from the epidermis of wild type and E2F1 transgenic mice, and either used in Northern analyses or to prepare genetags for COP analysis. As shown in FIG. 18A and FIG.
  • COP analysis indicated a dramatic upregulation of expression of several genes, including Ode, Ccng, and Cdkn2a/pl9ARF, due to overexpression of the E2F1 transgene, in both newborn keratinocytes and adult epidermis.
  • the increase in Cdkn2a/pl9ARF was particularly striking, and this induction was confirmed by Northern analyses (FIG. 18C).
  • CDK7, Brcal and pW ⁇ 1 " on p53 are indicated in the model of FIG. 19.
  • Each has the potential to increase p53 activity by an independent post-translational mechanism, and therefore indicating that they may cooperate in p53 upregulation.
  • three downstream targets of p53, cyclin G, Bax- ⁇ and Mdm-2, are all modestly unregulated in the transgenic keratinocytes, while a fourth target- gene involved in growth arrest, p21, is unaffected. This indicates that not only is p53 activity increased, but it is increased in a differential manner, with some downstream targets induced more than others.
  • the set of reagents that must be maintained for COP analyses (256 A-end primers and 64 B-end primers) is fairly small, can be generated easily by synthetic methods, and is the same for all species. This contrasts with microarray technologies where much larger sets of clones must be maintained, or even larger sets of oligonucleotides must be designed and tested, and where each set of reagents is species-specific.
  • the inventors are currently working on ways to speed up the analyses of the amplimers, possibly allowing COP to be performed in a high-throughput mode in which the entire transcriptome could be analyzed in a short period of time.
  • compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

Abstract

The present invention relates to a method for the detection of gene expression and analysis of both known and unknown genes. The invention is a highly sensitive, rapid and cost-effective means of monitoring gene expression, as well as for the analysis and quantitation of changes in gene expression for a defined set of genes and in response to a wide variety of events. It is an important feature of the present invention that no single molecular species of cDNA gives rise to more than one fragment in the colleciton of products which are subsequently amplified and representative of each expressed gene. This achievement is facilitated by immobilizing the cDNA prior to digesting and then digesting with sequentially with two frequently cutting enzymes. Linker oligomers are ligated to each cut site following the respective digestion. Primers, complementary to the oligomer sequence with an additional 3' variable sequence are used to amplify the fragments. Using and array of fragments theoritically facilitates the amplification of all of the possible messages in a given sample.

Description

DESCRIPTION
COMBINATORIAL OLIGONUCLEOTIDE PCR: A METHOD FOR RAPID, GLOBAL EXPRESSION ANALYSIS
BACKGROUND OF THE INVENTION
The government may own rights in the present invention pursuant to grant number P30ES07784-01 from NIEHS and grant number CA35581 -12 from National Cancer Institute.
1. Field of the Invention
The present invention relates generally to detection of gene expression and analysis of both known and unknown genes. More particularly, it provides a method that can be used for global monitoring of gene expression, as well as for the analysis and quantitation of changes in gene expression for a defined set of genes and in response to a wide variety of events. The method is highly sensitive, rapid and cost- effective.
2. Description of Related Art
The degree of differentiation or physiological state of a cell, a tissue or an organism is characterized by a specific expression status, i.e., the degree of transcriptional activation of all genes or particular groups of genes. The molecular basis for numerous biological processes that result in a change in this state is the coordinated transcriptional activation or inactivation of particular genes or groups of genes in a cell, an organ or an organism. Characterization of this expression status is of key importance for answering many biological questions. Changes in gene expression in response to a stimulus, a developmental stage, a pathological state or a physiological state are important in determining the nature and mechanism of the change and in finding cures that could reverse a pathological condition. Patterns of gene expression are also expected to be useful in the diagnosis of pathological conditions, and for example, may provide a basis for the sub-classification of functionally different subtypes of cancerous conditions. Several methods that can analyze the expression status of genes are known in the art. Differential display RT-PCR™ (DDRT) is one method for analyzing differential gene expression in which subpopulations of complementary DNA (cDNA) are generated by reverse transcription of mRNA by using a cDNA primer with a 3' extension (preferably two bases). Random 10-base primers are then used to generate PCR™ products of transcript-specific lengths. If the number of primer combinations used is large enough, it is statistically possible to detect almost all transcripts present in any given sample. PCR™ products obtained from two or more samples are then electrophoresed next to one another on a gel and differences in expression are directly compared. Differentially expressed bands can be cut out of the gel, reamplified and cloned for further analysis.
It is possible to enrich the PCR™ amplification products for a particular subgroup of all mRNA molecules, e.g., members of a particular gene family by using one primer which has a sequence specific for a gene family in combination with one of the 10 base random primers. This technique of DDRT is described by (Liang and Pardee, 1992; Liang et al, 1993; Bauer et al, 1993; Stone and Wharton, 1994; Wang and Feuerstein, 1995; WO 93/18176; and DE 43 17 414).
There are a number of disadvantages to the experimental design of DDRT. The differential banding patterns are often only poorly reproducible. Due to the design of the primers even the use of longer random primers of, e.g., 20 bases in length does not satisfactorily solve the problem of reproducibility (Ito et al, 1994). In order to evaluate a significant portion of differentially expressed genes, a large number of primer combinations must be used and multiple replicates of each study must be done. The method often results in a high proportion of false positive results and rare transcripts cannot be detected in many DDRT studies (Bertioli et al, 1995.)
Due to the non-stringent PCR™ conditions and the use of only one arbitrary primer further analysis by sequencing is necessary to identify the gene. Sequencing of selected bands is problematic since the same primer often flanks DDRT products at both ends so that direct sequencing is not possible and an additional cloning step is necessary. Due to the use of short primers, a further reamplification step with primer molecules extended on the 5' side is necessary even if two different primers flank the product. Finally, due to the use of random primers, it is never quite possible to be sure that the primer combinations recognize all transcripts of a cell. This applies, even when using a high number of primers, to studies which are intended to detect the entirety of all transcripts as well as to studies which are directed towards the analysis of a subpopulation of transcripts such as a gene family (Bertioli et al. , 1995).
A variant of DDRT, known as GeneCalling, has recently been described (Shimkets et al, 1999) which addresses some of these problems. In this method, multiple pairs of restriction endonucleases are used to prepare specific fragments of a cDNA population prior to amplification with pairs of universal primers. This improves the reproducibility of the measurements and the false positive rate, but the patterns are very complex and identification of individual transcripts requires the synthesis of a unique oligonucleotide for each gene to be tested. In addition, the quantitative data obtained are apparently significant only for changes above 4-fold (Shimkets et α/.1999) and only a weak correlation with other techniques is obtained. The ability of the technique to distinguish the gene-specific band from the complex background for any arbitrarily chosen gene has not been documented (Shimkets et al, 1999).
AFLP based mRNA fingerprinting further addresses some of the deficiencies of DDRT. AFLP allows for the systematic comparison of the differential expression of genes between RNA samples (Habu, 1997) The technique involves the endonuclease digestion of immobilized cDNA by a single restriction enzyme. The digested fragments are then ligated with a linker specific for the restriction cut site. The tailed fragments are subsequently amplified by PCR™ employing primers complementary to the linkers added to the digest with the addition of variable nucleotides at the 3' end of the primers. The products of the amplification are visualized by PAGE and banding patterns compared to reveal differences in RNA transcription patterns between samples. Although AFLP based RNA fingerprinting provides a indication of the RNA message present in a given sample, it fails to restrict the potential number of signals produced by each individual RNA strand. With this technique, each RNA strand may potentially produce multiple fragments and therefore multiple signals upon amplification. This failure to restrict the number of signals from each message complicates the results that must be evaluated.
Song and Osborn, 1994, describe a method for examining the expression of homologous genes in plant polyploids in which the techniques of RT-PCR™ and RFLP (restriction fragment length polymorphism) analysis are combined with one another. In this method a cDNA is produced from RNA by reverse transcription, then amplified by using two gene-specific primers. The amplification products are transcript-specifically shortened by endonuclease cleavage, separated by electrophoresis according to their length, cloned, and then analyzed by sequencing. This method has the disadvantage of low sensitivity, as a cloning step is necessary to characterize the expression products. A further disadvantage of this method is that gene specific sequence information must be available on at least two regions within the analyzed genes in order to design suitable primers.
In principle, gene expression data for a particular biological sample could be obtained by large-scale sequencing of a cDNA library. The role of sequencing cDNA, generated by reverse transcription from mRNA, has been debated for its value in the human genome project. Proponents of genomic sequencing have argued the difficulty of finding every mRNA expressed in all tissues, cell types, and developmental stages. It is also believed that cDNA libraries do not provide all sequences corresponding to structural and regulatory polypeptides (Putney et al,
1983). In addition, libraries of cDNA may to be dominated by repetitive elements, mitochondrial genes, ribosomal RNA genes, and other nuclear genes comprising common or housekeeping sequences. While some mRNAs are abundant, others are rare, resulting in cellular quantities of mRNA from various genes that can vary by several orders of magnitude. Therefore, sequencing of transcribed regions of the genome using cDNA libraries has been considered unsatisfactory.
Techniques based on cDNA subtraction or differential display can be used to compare gene expression patterns between two cell types (Hedrick et al, 1984; Liang and Pardee, 1992), but provide only a partial analysis, with no quantitative information regarding the abundance of messenger RNA. Expressed sequence tags
(EST) have been valuable for gene discovery (Adams et al, 1993; Okubo et al, 1992), but like Northern blotting, RNase protection, and reverse transcriptase- polymerase chain reaction (RT-PCR™) analysis (Alwine et al, 1977; Zinn et al, 1983; Veres et al, 1987) the approach only evaluates a limited number of genes at a time.
Two major strategies for global gene expression analysis have recently become available. Serial analysis of gene expression (SAGE) (U.S. Patent No. 5,866,330, Kinzler, et al, 1995) is based on the use of short (i.e. 9-10 base pair) nucleotide sequence tags that identify a defined position in an mRNA and are used to ascertain the identity of the corresponding transcript and gene. The cDNA tags are generated from mRNA samples, randomly paired, concatenated, cloned, and sequenced. While this method allows the analysis of a large number of transcripts, the identification of individual genes requires sequencing of tens of thousands of tags for comparison of even a small number of samples. Although SAGE provides a comprehensive picture of gene expression, it cannot be specifically directed at a small subset of the transcriptome (Zhang et al, 1997; Velculescu et al, 1995). Data on the most abundant transcripts is the easiest and fastest to obtain, while about a megabase of sequencing data is needed for confident analysis of low abundance transcripts.
The second method utilizes hybridization of cDNAs or mRNAs to microarrays containing hundreds or thousands of individual cDNA fragments or oligonucleotides specific for particular genes or ESTs. The matrix for hybridization is either a DNA chip, a slide or a membrane. This method can be used to direct a search towards specific subsets of genes, but cannot be used to identify novel genes. In addition, arrays are expensive to produce (DeRisi et α/.,1996; Schena et al, 1995). For those methods using cDNA arrays, a library of individually cloned DNA fragments must be maintained with at least one clone for each gene to be analyzed. Because much of the expense of utilizing microarrays lies in maintaining the fragment libraries and programming equipment to construct the microarray, it is only cost-efficient to produce large numbers of identical arrays. These two techniques lack the flexibility to easily change the subset of the transcriptome being analyzed or to focus on smaller subsets of genes for more detailed analyses. As described above, current techniques for analysis of gene expression either monitor one gene at a time, are designed for the simultaneous and therefore more laborious analysis of thousands of genes or do not adequately restrict the signal to message ratio. There is a need for improved methods which encompass both rapid, detailed analysis of global expression patterns of genes as well as expression patterns of defined sets of genes for the investigation of a variety of biological applications. This is particularly true for establishing changes in the pattern of gene expression in the same cell type, for example, in different developmental stages, under different physiologic or pathologic conditions, when treated with different pharmaceuticals, mutagens, carcinogens, etc. Identification of differential patterns of expression has several utilities, including the identification of appropriate therapeutic targets, candidate genes for gene therapy (including gene replacement), tissue typing, forensic identification, mapping locations of disease-associated genes, and for the identification of diagnostic and prognostic indicator genes.
The object of the present invention is to provide a method for gene expression analysis which exceeds the capabilities of the state of the art. The optimal method should be rapid and cost-effective, allow easily reproducible and quantitative results, have an adequate sensitivity in order to detect and quantify rare transcripts, and enable identification of amplification products by techniques that do not require an additional cloning or sequencing step. The technique should allow flexibility to analyze either a subset or the complete transcriptome, and should be useful for both gene discovery and to analyze previously identified genes.
SUMMARY OF THE INVENTION
In the present disclosure, a method has been developed which allows for the determination of changes in gene expression in multiple genes, known and unknown, in a rapid, quantitative and cost-effective fashion. This method has the capability for detecting the frequency distribution of all polyadenylated mRNAs in a sample at any selected time. The invention reduces the complexity of analysis by ensuring that only a single unique fragment is derived from each molecular species of polyadenylated mRNA. Either the entire genome or a subset can be analyzed, and a single set of reagents and reaction conditions is sufficient for analysis of the complete genome. The technique allows for multiple samples to be analyzed simultaneously. The results generated from this invention are quantitative and proportional to the level of expression of the particular gene.
A unique feature of this method that distinguishes it from all DDRT methods is that a one-to-one correspondence exists between each molecular species of polyadenylated RNA and a PCR™-product of a particular length derived with a particular pair of PCR™ primers. Knowledge of a gene sequence therefore can be used to pick the correct pair of primers to use for amplification and to predict the length of the corresponding product. This feature is also advantageous when combinatorially surveying the entire (genome) transcriptome. The length of the amplimer products, along with the information on the primers used, can be plugged into the database to identify the differentially expressed genes.
One embodiment of the invention involves a method comprising obtaining an DNA molecule, which includes an anchorable moiety, and cleaving the DNA molecule with a first restriction endonuclease. A linker is then ligated to the cut end of the DNA fragment, and the fragment is immobilized to an anchor via the anchorable moiety. The immobilized fragment is then digested with a second restriction enzyme, cleaving it from the anchor. A second linker is subsequently added to the second digest site, and the fragment is then amplified. The order of restriction digests may be reversed to isolate those fragments in which the order of restriction sites is reversed, thereby representing a more complete share of the DNA present in a sample. It is envisioned that the DNA molecule may be immobilized at its 5' end or at its 3'end.
It is envisioned that this technique may be used in the detection of specific DNA, be it genomic, non-genomic or synthetic as well as cDNA, reversed transcribed from RNA.
Where the DNA is cDNA, the immobilization of the DNA may take place prior to the reverse transcription of mRNA to cDNA, or the molecule may be subsequently immobilized. In another embodiment, the immobilization of the DNA may take place subsequent to the initial restriction digestion. In a further embodiment, the immobilization of the DNA may take place subsequent to the initial restriction digestion and linker ligation.
It is envisioned that the immobilization will occur at the anchorable moiety via a means of adhering. The means of adhering may facilitate either a covalent or non- covalent interaction. It is envisioned that the anchorable moiety may be located at either the 5' or 3' end of the DNA. The anchorable moiety may be a ligand, for example biotin or an antibody. Where the anchorable moiety includes a ligand, it is envisioned that this ligand is the means through which the DNA is immobilized to a substrate. Where the ligand is biotin, the biotin may be attached to streptavidin.
In a further embodiment of the invention, mRNA is reverse transcribed to cDNA with an oligo-dT primer. It is further envisioned that reverse transcription may also be initiated at a random hexamer. The oligo-dT primer may be attached to a ligand, for example biotin or an antibody. Where the oligo-dT includes a ligand, it is envisioned that this ligand is the means through which the cDNA is immobilized to a substrate. Where the ligand is biotin, the biotin may be attached to streptavidin.
In another embodiment of the invention, it is envisioned that the amplification of the fragment is initiated at primers of a sequence complementary to the first and second linkers respectively. It is further envisioned that this amplification reaction may include: a first amplification primer in which the 5' sequence of the primer is complementary to the first linker sequence and the 3' sequence comprises a specificity region; a second amplification primer, wherein the 5' sequence of said primer is complementary to said second linker sequence and the 3' sequence comprises a specificity region. This method may be further modified to consist of an array of combinations of alternate amplification primers such that the specificity region facilitates the amplification of a substantial percentage of the different sequences within a sample. Such an array may be simplified by carrying it out in a multi-well plate. Amplification of the samples may be further enhanced by pre-amplification with primer pairs complementary to the first and second linker sequences, respectively, prior to amplification with said amplification primers. Further, a partial nucleotide sequence identification of the amplified products may be facilitated by the sequence of the primers used for the amplification. It is envisioned that such identification may be carried out with the aid of a computer program. It is further envisioned that the identification of the amplified DNA may be based on length.
It is envisioned that the 3' specificity region of the first and second primers may be 3 nucleotides long. It is further envisioned that such 3' regions may be either 4,5,6,7 or even 8 base pairs long.
Amplification of the fragments may occur through either the polymerase chain reaction, nucleic acid sequence based amplification, transcription mediated amplification, strand displacement amplification, ligase chain reaction or any other method recognized by a person of ordinary skill in the art to be useful in the amplification of nucleic acid.
It is envisioned that the one or both of the restriction enzymes used to digest the immobilized DNA molecule have either a four, five, six, seven or eight base recognition site. In a preferred embodiment of the invention, the one or both of the restriction enzymes will have a four base pair recognition site. It is envisioned that such restriction enzymes might include but are not limited to: Nlalll, DpnII, Sau3AI, Hsp92II, Mbol, Ndell, Bspl431, Tsp509 I, Hhal, HinPlI, Hpall, Mspl, Taqalphal, MaeII or K2091.
In an additional embodiment of the invention, the amplified product will incorporate a means of detection such that the amplification may be detected and quantified. In a preferred embodiment the means of detection will be a label incoφorated into one of the primers used to amplify the fragment or alternatively as a labeled nucleotide incorporated during amplification.. It is envisioned that the label may be used to partially identify the sequence information of the amplified product.
It is envisioned that this label could include a chromophore, a flurophore, an affinity label or a dye. In a further embodiment of the invention a primer would contain an amino moiety and to which a flurophore could be covalently attached by the reaction of a succinimido ester of the flurophore to the 5' amino-modified primer. In this embodiment, the flurophore could include but is not limited to: Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY- R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy2, Cy3, Cy5,6-FAM, Fluorescein, HEX, 6- JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, ROX, TAMRA, TET, Tetramethylrhodamine, and Texas Red.
In another additional embodiment, the means of detection may be a nucleotide label incorporated into the product during amplification. It is envisioned that the label attached to the nucleotide could be biotin, DIG, AP, HRP, a fluorescent compound as mentioned in the paragraph above, DNP, or AMCA, to which any of these labels could be attached to after amplification.
While the products of amplification may be labeled for analysis, it is envisioned that other means of analysis may also be employed. The amplification products may be analyzed by polyacrylamide gel electrophoresis, capillary gel electrophoresis, mass spectrophotometry, energy transfer, real time PCR™, or the
Biostar or Luminex technologies.
Analysis may occur to quantify the products. Such quantification may be facilitated by measuring the ratio of each amplified product to a co-amplified reference-gene, or by measuring the ratio of each amplified product to a panel of co- amplified reference-genes.
Analysis of the amplification products may be performed in a multi-well plate, on a gel, on a membrane, or on a solid matrix. Where the analysis takes place on a solid substrate, it is envisioned that the solid substrate may be a DNA chip.
In a preferred embodiment of the invention, the method will be used to compare DNA in a normal cell to DNA in a different cell or tissue, or alternatively to an altered, modified or treated cell. It is envisioned that such alterations, modifications or treatments could include a cell or tissue treated with a pharmaceutical compound, a cell or tissue treated with a terato genie compound, a cell or tissue treated with a carcinogenic compound, a cell or tissue treated with a toxic compound, a cell or tissue treated with a biological response modifier, a cell or tissue treated with a hormone, a hormone agonist or a hormone antagonist, a cell or tissue treated with a cytokine, a cell or tissue treated with a growth factor, a cell or tissue treated with the ligand of a known biological receptor, a cell or tissue type obtained from different species, a cell or tissue at different stages of development, or a cell or tissue cultured in vitro under different conditions. It is further envisioned that the method could be used to compare a cell or tissue from two organisms of the same species. Such organisms could further have a known genetic difference. The method may also be used to compare gene expression in a normal cell with gene expression in a diseased cell. It is envisioned that such diseases could include diseases that are infectious, metabolic, genetic, congenital, adaptational, constitutional, drug-related or hereditary.
In an additional embodiment of the invention, the means necessary for performing the method of this invention are included in a kit for detection of gene expression. In a preferred embodiment, such a kit would consist essentially of a first restriction enzyme, a second restriction enzyme, a first, ligatable oligonucleotide tag, a second, ligatable oligonucleotide tag, a first amplification primer, wherein the 5' sequence of said primer is complementary to said first linker sequence and the 3' sequence comprises a specificity region, a second amplification primer, wherein the 5' sequence of said primer is complementary to said second linker sequence and the 3' sequence comprises a specificity region, and software capable of analyzing data generated from use of the kit. It is envisioned that the kit may contain as the first primer, a primer including the sequence GCTGTCTAGACG (SEQ ID NO:l). It is further envisioned that the kit may contain as the second primer a primer including the sequence CGGTGATGCATC (SEQ ID NO:2). The kit may also include restriction enzymes of a type as previously described.
It is contemplated that the method described herein and suitable modifications thereof will be used for determining global changes in gene expression patterns in a cell or tissue at any selected time. Appropriate examples include: changes in gene expression patterns due to developmental changes; changes in gene expression patterns due to cancerous transformation in cells; changes in gene expression patterns due to treatment of the cell or organism with a pharmaceutical compound; changes in gene expression patterns due to treatment of the cell or organism with a carcinogen. It is also contemplated that the method will be used for determining gene expression of a transcriptome at any selected time, for new gene discovery, and for diagnostic and or prognostic purposes.
BRIEF DESCRIPTION OF THE DRAWINGS
The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
FIG. 1. Preparation of genetag templates. The method is illustrated with the cDNA for annexin III.
FIG 2 Selective detection of expressed genes. A. COP primers specific for Brcal, Anx3 (annexin III), or an anonymous cDNA clone, 2C1 IB (UOl 139) were combined with B/A genetags prepared from murine keratinocytes and PCR amplification carried out for 27 cycles. PCR products were analyzed by polyacrylamide gel electrophoresis. Wedges above the lanes indicate increasing concentrations of template (0.15 to 1.2 ng for Anx3 -specific reactions, 2 to 8 ng for Brcal- and 2C1 IB-specific reactions); -', no template controls; 'M', molecular size markers. B. The integrated intensities of the rø;3-specific amplimers in panel A were determined by densitometry, and are plotted as a function of template concentration. C.
Figure imgf000013_0001
COP reactions were carried out as described, but the number of PCR cycles was varied from 22 to 30. The natural logarithm of the integrated intensity is plotted as a function of the number of cycles. D. COP primers specific for HSPB1 (HSP27), RPS5 (ribosomal protein S5), or TRAF4 (MLN62 oncogene) were combined with A B genetags prepared from normal human mammary epithelial cells, and PCR products were analyzed as in panel A. Amplimer intensities increased linearly with template concentration up to about 0.4 ng/reaction for HSP27 and S5, and up to at least 3.8 ng/reaction for MLN62. FIG 3 Reproducibility of analyses. cDNA was prepared from normal human mammary epithelial cells, and 4 independent genetag templates (labeled a-d) were prepared. Quadruplicate PCR reactions were analyzed using primers specific for: A. CAPN4 (42 bp amplimer, Calpain); B. TRAF4 (151 bp amplimer, MLN62); or C. PSMD12 (146 bp amplimer, p55).
FIG. 4. Tactics for competitive RT-PCR™ with COP primers. The portion of the HSP27 cDNA sequence indicated with the heavy underline below can be amplified by the standard primers COP 32 and COP 46. Primer CRT004, containing the COP 32 sequence, a 5 bp insert (identified by the box), and the next 8 bp from HSP27 ("clamp" sequence, identified by overline) were synthesized. When CRT004 and COP 46 were used in a PCR™ reaction containing the HSP27 template, an amplimer identified as CRT32/46 was produced. As CRT32/46 contains all of the HSP27 sequences plus the 5 bp insert it can be used as a competitive template.
FIG. 5. Competitive RT-PCR™ with COP primers for HSP27. PCR™ reactions were set up with primers designed to assay HSP27 and 1.0 ng of cDNA derived from SKBR3 cells (lane 2-10) and no template was added to the control reaction (lane 1). The competitive template CRT32/46 was added in increasing amounts to reactions analyzed in lanes 3-10. The reaction analyzed in lane 11 contained only CRT32/46 as template. Reactions were analyzed on 5% polyacrylamide gels, stained with VistraGreen and visualized on a Fluorlmager.
FIG. 6. Quantitation of competitive RT-PCR™. The gel shown in FIG. 5 was quantitated, and the ratio of the standard intensity (i.e., the CRT32/46 competitor) to the target intensity (i.e., HSP27) was determined and plotted versus the standard concentration. The log-log plot is shown.
Fig. 7. Sensitivity of detection of MLN 62. A. The structure of the
ICMLN62 DNA is shown. B. cDNA from normal human mammary epithelial cells (500 ng) was mixed with the ICMLN62 DNA (25 pg), and genetags were prepared. The genetags were used as template for duplicate MLN62-specific COP reactions as follows: 1, no template; 2, 0.3 ng; 3, 0.5 ng; 4, 0.7 ng; 5, 0.9 ng. The reactions analyzed in lanes 6 contained 20 fg of ICMLN62 as template. The intensity of the ICMLN62-specific amplimer band (open arrowhead) increased linearly with template at least up to 80 fg/reaction (data not shown). C. The intensities of the endogenous MLN62-specific amplimer (151 bp, closed symbols) and the ICMLN62-specific amplimer (161 bp, open symbols) were determined and are plotted as a function of genetag concentration. The ratio of the slopes of the two linear least-square fit lines was 1.28.
FIG. 8. Partial sequence of MLN 62 mRNA. Primers for COP are highlighted, and the poly(A) addition signal sequence is underlined. The A-end primer sequence (C ATGCCTT), starting at position 1760, contains the CATG that is closest to the 3' end of the mRNA. The highlighted B-end primer sequence (TGAGATC), starting at position 1880, contains the first GATC following the A-end primer. Note that the actual B-end primer contains the reverse complement of the highlighted sequence (GATCTCA). This decreases the number of positions queried at the B-end by one, thus reducing the number of experiments by a factor of four.
FIG. 9. COP analysis of four expressed genes in the SKBR3 cell line.
PCR™ reactions were set up with 1.0 ng of cDNA derived from SKBR3 cells (lanes 1, 2, 5, 6, 9, 10, 13, and 14) or with no template (lanes 3, 4, 7, 9, 11, 12, 15, and 16) and COP primers designed for the four genes indicated in Table 2 as follows: lanes 1- 4: HSP27; lanes 5-8: S5; lanes 9-12: MLN62; lanes 13-16: S16. After 28 cycles of amplification, samples were analyzed on a 5% polyacrylamide gel, stained with ethidium bromide and visualized on a UV light box. DNA size markers (20 and 100 bp ladders) were run for comparison in adjacent lanes.
FIG. 10. Analysis of COP reactions: dependence on number of cycles. PCR™ reactions were set up with 1.0 ng of cDNA derived from SKBR3 cells and 80 ng of each of three COP primers that were selected to produce three major amplimers of approximately 40, 99 and 153 bp. Aliquots were removed after the indicated number of cycles and analyzed on a 5% polyacrylamide gel. The gel was stained with Vistra Green and visualized with a Fluorlmager. Marker DNAs (20 and 100 bp ladders) were loaded in the two right-hand lanes. FIG. 11. Dependence of band intensity on number of cycles. The gel image in FIG. 10 was quantitated using Image Quant software, and the logarithm of the intensity of each band was plotted versus the number of PCR™ cycles. All three bands exhibit an exponential increase at least for 27 cycles.
FIG. 12. Dependence on template concentration. PCR™ reactions were set up with the indicated amount of cDNA derived from SKBR3 cells and 80 ng each of three COP primers that were selected to produce three major amplimers of approximately 40, 99 and 153 bp. After 27 cycles, samples were analyzed on a 5% polyacrylamide gel. The gel was stained with Vistra Green and visualized with a Fluorlmager. Marker DNAs (20 and 100 bp ladders) were loaded in the two left lanes.
FIG. 13. Dependence of band intensity on template concentration. The gel image in FIG. 12 was quantitated using Image Quant software, and band intensity for the 150 bp band was plotted versus the amount of cDNA used as template in each PCR™ reaction. Similar data were also obtained for the 40 and 100 bp bands.
FIG. 14. Specificity of COP reactions for Annexin HI. Brcal and 2C1 IB.
FIG. 15 E2F1 -dependent changes in expression of selected genes. COP PCR analysis was performed, using genetags prepared from wild-type (-) or K5-E2F1 transgenic (+) keratinocytes. Reactions contained COP primers chosen to amplify specific genes and the expected amplimers are indicated in the Figure by black dots between the lanes. The selected genes and the size of the expected amplimers were: 1, Actg, 98 bp; 2, Rpl5, 130 bp; 3, Lmna, 291 bp; 4, Cdk7, 392 bp; 5, Yyl, 248 bp; 6, Hβι2, 254 bp; 7, Cdkn2a/pl9ARF , 508 bp; 8, Brcal, 291 bp.
FIG. 16. Changes in expression of E2F1 -target genes. cDNA and genetags were prepared from keratinocyte cultures derived from newborn wild-type mice (-) or their K5 E2F1 transgenic siblings (+). Replicate, paired PCR reactions were analyzed using primers specific for: A, Cdc2 and Ccne; B, Actb.
FIG. 17. Validation of expression changes by Northern analyses. A. Northern analyses were performed using 20 μg of total RNA from wild type (-) or K5E2F1 transgenic (+) keratinocytes and probes specific for Cdkn2alpl9 , Cdc2 or Actg. B. Similar analyses were carried out for 6 additional genes, and the expression ratio was determined after quantitation of the hybridized bands using a phosphorimager. The expression ratios for each of the 9 genes determined from Northern analysis (abcissa) is compared with the expression ratios obtained by COP analysis (ordinate). The line is that expected for perfect agreement between the two techniques.
FIG. 18. Expression changes in mouse skin and keratinocytes. RNA, cDNA & genetags were prepared from A. newborn keratinocytes or B. epidermal extracts derived from adult wild type (-) or K5 E2F1 transgenic (+) mice. In panels A & B, PCR reactions contained COP primers chosen to amplify:
1, Rps5, 108bp; 2, Actb, 176 bp; 3, Ode, 202 bp; 4, Ccng, 109 bp; 5, Cdkn2alpl9ARF , 508 bp. Other symbols as in Figure 6. C. Northern analyses were performed using 20 μg of total RNA from either newborn keratinocytes or adult skin of wild-type or transgenic mice and a probe specific for Cdkn2alp 19ARF.
FIG. 19. Model for E2F1 effects on p53 and apoptosis. Darkened ovals represent genes that exhibit increased expression in the transgenic keratinocytes. Overexpression of E2F1 in keratinocytes leads to increased expression of CDK7, Brcal and pl9ARF, which in turn increase p53 activity by the mechanisms indicated. This selectively increases the expression of three downstream targets of p53, Mdm2, cyclin G and Bax-α, but not in p21. This may predispose the cells to enter the apoptotic pathway under the influence of appropriate external stimuli, such as, carcinogen-induced DNA damage.
FIG. 20 . COP analysis of GADD45 and ATF3 Genetags were prepared from HME87 cells 4 h after treatment with BPDE (lanes marked "E") or with solvent only (lanes marked "C"). Analyses in the left hand panel represent COP reactions with primers specific for the GADD45 gene product (expected length = 204 bp). The band marked with the star was quantitated as GADD45. Lanes marked "M" contain DNA size markers. Analyses in the right hand panel represent COP reactions with primers specific for the ATF-3 gene product (expected length = 155 bp). The band marked with the star was quantitated as ATF-3.
FIG. 21 Flow chart of one suitable embodiment of a computer program for analyzing COP data
DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
A. The Present Invention
Improved methods that allow rapid, detailed analysis of DNA, global expression patterns of genes, as well as expression patterns of defined sets of genes, are required. A preferred embodiment of the inventions comprises the ability to detect changes in the pattern of gene expression, for example, in the same cell type in different developmental stages, under different physiologic or pathologic conditions, when treated with different pharmaceuticals, mutagens, carcinogens, etc. allows the identification of genes as candidates for gene based therapies. It is however envisioned that the methods of the present invention may be utilized to analyze cellular DNA, genomic DNA, mitochondrial DNA, cDNA and synthetic DNA.
The present invention describes methods that allow rapid and quantitative detection of expression patterns of known as well as unknown genes. The overall strategy for these methods is described herein. In a preferred embodiment two common and frequently cutting restriction enzymes, such as 4-base-cutters, called for illustrating purposes A and B, are used to excise a unique fragment with defined sticky ends from each DNA. Short linker oligonucleotides, for example 12-mers with appropriate sticky ends, are added to each end, creating a collection of "genetags." It is an important feature of the present invention that when evaluating gene expression, no single molecular species of cDNA gives rise to more than one fragment in the collection of "genetags."
To ensure that a single, unique fragment is derived from each cDNA, prior to restriction digestion the cDNAs are immobilized through an attachment of one end of each cDNA to a solid substrate. For the purposes of illustration, this attachment may be through a biotin label incoφorated at the 3' end of the cDNA. A substrate with covalently attached streptavidin can be utilized conveniently to immobilize the cDNA through specific, high affinity binding of biotin to streptavidin. In a preferred embodiment of the invention, the use of a biotinylated oligo dT for reverse transcription would also facilitate the isolation of the resulting cDNA molecule. Using biotinylated oligo dT allows for the isolation of labeled cDNA after it has been reverse transcribed from the mRNA, after an initial digestion or alternatively facilitates the initial isolation of mRNA on biotinylated oligo dT coated streptavidin beads followed by reverse transcription of the immobilized molecules. It is further envisioned that the DNA may be immobilized via its 5' end. In this embodiment, an anchorable moiety may be incoφorated on the 5' end of the polynucleotide molecule through TdT incoφoration of labeled nucleotides at the 5' terminus of the molecule (Ying, 1999).
In the context of the present invention, the inventors envision the term "immobilized" to encompass a meaning including; appended, attached, covalently or non-covalently bound, adhered, ligated, affixed, joined or fused. It is envisioned that the immobilizing may comprise an interaction between the DNA molecule and a substrate that may be either permanent or transitory. In the context of the present invention, the inventors envision the term anchorable moiety to encompass of a means of adherence or alternatively a means of immobilization.
The immobilized DNA is initially cut with restriction enzyme A, and the fragments that remain immobilized on the substrate are retained. These fragments contain only those sequences present in the original DNA between the last recognition sequence for restriction enzyme A, and the 3' end of the DNA molecule. These fragments are then cut with restriction enzyme B, and the fragments that are no longer immobilized are collected. Digestion in this fashion results in at most one unique fragment of each DNA molecule obtained in this procedure, with one A-specific sticky end, and one B-specific sticky end. Linker oligonucleotides of two different sequences are added to these fragments, producing a preparation called "A/B genetags," due to the use of restriction enzyme A prior to restriction enzyme B. The use of 4-base cutter restriction enzymes in the preparation of genetags permits the analysis of virtually any DNA molecule since recognition sites for both the enzymes will be present in virtually any DNA. However, only about half of the DNAs will have a B recognition site closer to the 3' end than any A recognition site. Thus, after the first restriction cut, only about half of the retained DNAs will contain a B restriction recognition sequence, and thus produce a fragment in the A/B genetags. The remaining half of the DNAs will have an A recognition site closer to the 3' end than any B recognition site. In a preferred embodiment the order in which the A and B cuts are made is reversed, allowing appropriate fragments to be obtained from the other portion of the genome. After addition of linkers these fragments are designated "B/A genetags." The combination of B/A and A/B genetags would therefore encompass virtually all of the expressed genes present in a given sample. In the context of evaluating gene expression, while effectively all of the message in a sample should be present in a combination of B/A and A/B genetags, the immobilization of the cDNA during digestion insures that each mRNA molecule is subsequently represented by only a single amplimer product.
It is further envisioned that to amplify the amplimer product, a first set of primers may be constructed for the A end of the genetag, containing the sequence of the A-end linker, the A restriction enzyme recognition sequence, and a specificity region extending 3-8 nucleotides past the A restriction enzyme recognition sequence. Primers containing all possible combinations of A, C, G and T at each position of the specificity region comprise the set of A-end primers. For the puφoses of illustration, the specificity region can be constructed to be 4 nucleotides in length, producing a set of 256 different A-end primers (4 x 4 x 4 x 4 = 256), wherein each possible nucleotide is represented at each respective site in the specificity region.
A second set of primers may be constructed for the B end of the genetag, containing the sequence of the B-end linker, the B restriction enzyme recognition sequence, and a specificity region extending 3-8 nucleotides past the B restriction enzyme recognition sequence. Primers containing all possible combinations of A, C, G and T at each position of the specificity region comprise the set of B-end primers. For the puφoses of illustration, the specificity region can be constructed to be 3 nucleotides in length, producing a set of 64 different B-end primers (4 x 4 x 4 = 64).
A particular pair of A-end and B-end primers is combined with either A/B or B/A genetags, and PCR™ reactions are carried out under conditions where amplification is proportional to the template concentration. An amplimer product is produced if a gene tag is present whose specificity region sequence corresponds to the sequences of the specificity regions of the A-end and B-end primers. These amplimers are quantitated by means well known to practitioners of the art, and in the context of evaluating gene expression, the amount of a given amplimer is proportional to the level of expression of the corresponding gene in the cDNA preparation.
In order to standardize the amount of genetag from one sample to another, a set of amplification reactions will be carried out using pairs of primers that amplify known constitutively expressed genes. Because individual primers in each set have very similar base compositions, differing from each other only in the specificity regions, all amplification reactions can be carried out under the same conditions of ionic strength and annealing temperature, typically from 58 - 62 ° C. In reactions where the specificity regions of the primers are rich in A and T nucleotides, it is sometimes advantageous to use the lower annealing temperature (58°C). In reactions where the specificity regions of the primers are rich in G and C nucleotides, it is sometimes advantageous to use the higher annealing temperature (62°C).
In the illustrative example, the total number of unique reactions that can be performed is the product of the number of genetag preparations (2), the number of A- end primers (256) and the number of B-end primers: 2 x 256 x 64 = 32,768.
Assuming the human genome contains about 60,000 - 90,000 genes, each unique reaction is expected to produce amplimers corresponding to 2-3 genes, on average.
To obtain a unique specification, further information can be obtained by size fractionation of the amplimer products or by testing for the presence of other restriction enzyme recognition sequences or by determining the sequence of the amplimer. Changes in the length of the two specificity regions, in an alternative embodiment, will alter the total number of unique reactions that must be performed to assay the entire genome. If n is the sum of the lengths of the two specificity regions, the number of unique reactions is 2 x 4 .
In principle, relative measurements of the expression of all genes in the genome can be obtained with the method described above by carrying out all 32,768 unique reactions and measuring the amount of each amplimer formed. In practice, it often is desirable to measure the expression levels for a particular subset of known genes, for example, all known genes that code for cyclins. To do this, prior knowledge of the sequence of each mRNA is needed in order to predict the exact sequences of the primers to be used for its amplification, and to predict the length, or other identifying properties, of the corresponding amplimer.
Computer code that can be executed on a digital computer has been written and used to construct a database for this puφose. One method implementing such a program involves importing clustering information from publicly available databases of the National Library of Medicine, importing mRNA sequence information from publicly available databases of the National Library of Medicine. The necessary information is then extracted and manipulated and the data from the different databases integrated (primer locations and sequences, polyA signals, coding sequences, LocusLink and Unigene numbers,etc). The information is then stored in a local database and a user interface provided for data display and searches (Fig. 21). With the benefit of the present disclosure, those having skill in the art will recognize that other methods for forming a computer program with the disclosed function are available.
All mRNA sequences existing in the publicly available GenBank database that are derived from human, mouse and rat, have been separately loaded into this database, and the positions, sequences, orientations and lengths of the corresponding genetags that would be obtained with two particular restriction enzymes, Nlalll and DpnII, have been extracted from the sequence information, as well as the sequences of the A-end and B-end primers needed to amplify these genetags. In addition, computer code has been written and used to update the database each month, adding information from sequences that have recently been deposited in GenBank. Additionally, computer code has been written that allows individual GenBank files to be searched for the above information, and also that allows GenBank libraries to be searched for entries that would be amplified by a given pair of A-end and B-end primers.
Nucleic Acids
Genes are sequences of DNA in an organism's genome encoding information that is converted into various products making up a whole cell. They are expressed by the process of transcription, which involves copying the sequence of DNA into RNA. Most genes encode information to make proteins, but some encode RNAs involved in other processes. If a gene encodes a protein, its transcription product is called mRNA ("messenger" RNA). After transcription in the nucleus (where DNA is located), the mRNA must be transported into the cytoplasm for the process of translation, which converts the code of the mRNA into a sequence of amino acids to form protein. In order to direct transport into the cytoplasm, the 3' ends of mRNA molecules are post- transcriptionally modified by addition of several adenylate residues to form the "poly A" tail. This characteristic modification distinguishes gene expression products destined to make protein from other molecules in the cell, and thereby provides one means for detecting and monitoring the gene expression activities of a cell.
Some of the exemplary genes that may be monitored for expression are genes involved in cancer pathways, for example, oncogenes, rumor suppressor genes, DNA repair genes, genes involved in signal transduction, etc. Loss of control of cell-cycle regulatory genes, or genes controlling apoptotic pathways can lead to the development of cancers.
Other genes that may be monitored for changes in expression levels are genes that change in response to a pharmaceutical compound, or genes that are involved in metabolism and disposition of pharmaceutical compounds, hormones or toxicants. This can pinpoint genes involved in pathways of the pathological condition.
Yet other genes that can be monitored are genes that change in response to development and growth, or that are responsible for controlling developmental pathways. Studies directed towards aging for example can benefit vastly from these type of experiments . Furthermore, gene expression changes may be monitored in response to treatment of cells or tissues with a host of chemical compounds such as mutagens, teratogens, carcinogens, pesticides, pollutants, etc., or biological compounds such as hormones, growth factors, cytokines, etc.
Patterns of expression for genes not connected with the pathways mentioned previously, as well as genes whose function is not yet identified, can be monitored for the puφose of establishing expression patterns that may be of diagnostic or prognostic values, or may be indicative of past or current exposure to certain pharmaceutical compounds, toxicants or drugs of abuse.
B. Detection of Nucleic Acids
1. Oligonucleotide Probes and Primers
Nucleic acid sequences that are "complementary" are those that are capable of base-pairing according to the standard Watson-Crick complementary rules. As used herein, the term "complementary sequences" means nucleic acid sequences that are substantially complementary, as may be assessed by the same nucleotide comparison set forth above, or as defined as being capable of annealing to the nucleic acid segment being described under relatively stringent conditions such as those described herein.
Primers should be of sufficient length to provide specific annealing to a RNA or DNA tissue sample. The use of a primer of between about 10-14, 15-20, 21-30 or 31 -40 nucleotides in length allows the formation of a duplex molecule that is both stable and selective. Molecules having complementary sequences over stretches greater than 20 bases in length are generally preferred, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of particular hybrid molecules obtained.
Sequences of 17 bases long should occur only once in the human genome and, therefore, suffice to specify a unique target sequence. Although shorter oligomers are easier to make and increase in vivo accessibility, numerous other factors are involved in determining the specificity of hybridization. Both binding affinity and sequence specificity of an oligonucleotide to its complementary target increases with increasing length. It is contemplated that exemplary oligonucleotides of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more base pairs will be used, although others are contemplated. Longer polynucleotides encoding 250, 300, 500, 600, 700, 800, and longer are contemplated as well. Accordingly, nucleotide sequences may be selected for their ability to selectively form duplex molecules with complementary stretches of genes or RNAs or to provide primers for amplification of DNA or RNA from cells, cell lysates and tissues. The method of using probes and primers of the present invention is in the selective amplification and detection of genes, changes in gene expression, gene polymoφhisms, single nucleotide polymoφhisms, changes in mRNA expression wherein one could be detecting virtually any gene or genes of interest from any species. The target polynucleotide will be RNA molecules, mRNA, cDNA, DNA or amplified DNA. By varying the stringency of annealing, and the region of the primer, different degrees of homology may be discovered.
The particular amplification primers of the present invention will be specific oligonucleotides which encode particular features including the recognition site for frequently cutting restriction enzymes, primer sequences, and degenerate sequences of 3, 4, 5, 6, 7, 8 or more consecutive bases to ensure amplification of all target genes. Generally, the present invention may involve the use of a variety of other PCR™ primers which hybridize to a variety of other target sequences.
Amplification primers may be chemically synthesized by methods well known within the art (Agrawal, 1993). Chemical synthesis methods allow for the placement of detectable labels such as fluorescent labels, radioactive labels etc. to be placed virtually anywhere within the polynucleic acid sequence. Solid phase method of synthesis also may be used.
The amplification primers may be attached to a solid-phase, for example, a latex bead; or the surface of a chip. Thus, the amplification carried out using these primers will be on a solid support/surface.
Furthermore, some primers of the present invention will have a recognition moiety attached. A wide variety of appropriate recognition means are known in the art, including fluorescent labels, radioactive labels, mass labels, affinity labels, chromophores, dyes, electroluminescence, chemiluminescence, enzymatic tags, or other ligands, such as avidin/biotin, or antibodies, which are capable of being detected and are described below.
2. Amplification . PCR ™
In some embodiments, poly-A mRNA is isolated and reverse transcribed (referred to as RT) to obtain cDNA which is then used as a template for polymerase chain reaction (referred to as PCR™) based amplification. In other embodiments, cDNA may be obtained and used as a template for the PCR™ reaction. In PCR™, pairs of primers that selectively hybridize to nucleic acids are used under conditions that permit selective hybridization. The term primer, as used herein, encompasses any nucleic acid that is capable of priming the synthesis of a nascent nucleic acid in a template-dependent process. Primers may be provided in double-stranded or single-stranded form, although the single-stranded form is preferred.
The primers are used in any one of a number of template dependent processes to amplify the target-gene sequences present in a given template sample. One of the best known amplification methods is PCR™ which is described in detail in U.S. Patent No's. 4,683,195, 4,683,202 and 4,800,159, each incoφorated herein by reference.
In PCR™, two primer sequences are prepared which are complementary to regions on opposite complementary strands of the target-gene(s) sequence. The primers will hybridize to form a nucleic-acid:primer complex if the target-gene(s) sequence is present in a sample. An excess of deoxyribonucleoside triphosphates are added to a reaction mixture along with a DNA polymerase, e.g., Taq polymerase, that facilitates template-dependent nucleic acid synthesis.
If the target-gene(s) sequence :primer complex has been formed, the polymerase will cause the primers to be extended along the target-gene(s) sequence by adding on nucleotides. By raising and lowering the temperature of the reaction mixture, the extended primers will dissociate from the target-gene(s) to form reaction products, excess primers will bind to the target-gene(s) and to the reaction products and the process is repeated. These multiple rounds of amplification, referred to as "cycles", are conducted until a sufficient amount of amplification product is produced.
Next, the amplification product is detected. In certain applications, the detection may be performed by visual means. Alternatively, the detection may involve indirect identification of the product via fluorescent labels, chemiluminescence, radioactive scintigraphy of incoφorated radiolabel or incoφoration of labeled nucleotides, mass labels or even via a system using electrical or thermal impulse signals (Affymax technology).
A reverse transcriptase PCR™ amplification procedure may be performed in order to quantify the amount of mRNA amplified. Methods of reverse transcribing
RNA into cDNA are well known and described in Sambrook et al, 1989. Alternative methods for reverse transcription utilize thermostable DNA polymerases. These methods are described in WO 90/07641, filed December 21, 1990.
ii. LCR Another method for amplification is the ligase chain reaction ("LCR"), disclosed in European Patent Application No. 320,308, incoφorated herein by reference. In LCR, two complementary probe pairs are prepared, and in the presence of the target sequence, each pair will bind to opposite complementary strands of the target such that they abut. In the presence of a ligase, the two probe pairs will link to form a single unit. By temperature cycling, as in PCR™, bound ligated units dissociate from the target and then serve as "target sequences" for ligation of excess probe pairs. U.S. Patent 4,883,750, incoφorated herein by reference, describes a method similar to LCR for binding probe pairs to a target sequence.
Hi. Qbeta Replicase Qbeta Replicase, described in PCT Patent Application No. PCT/US87/00880, also may be used as still another amplification method in the present invention. In this method, a replicative sequence of RNA which has a region complementary to that of a target is added to a sample in the presence of an RNA polymerase. The polymerase will copy the replicative sequence which can then be detected. iv. Isothermal Amplification
An isothermal amplification method, in which restriction endonucleases and ligases are used to achieve the amplification of target molecules that contain nucleotide 5'-[α-thio]-triphosphates in one strand of a restriction site also may be useful in the amplification of nucleic acids in the present invention. Such an amplification method is described by Walker et al 1992, incoφorated herein by reference.
v. Strand Displacement A mpliβcation
Strand Displacement Amplification (SDA) is another method of carrying out isothermal amplification of nucleic acids which involves multiple rounds of strand displacement and synthesis, i.e., nick translation. A similar method, called Repair Chain Reaction (RCR), involves annealing several probes throughout a region targeted for amplification, followed by a repair reaction in which only two of the four bases are present. The other two bases can be added as biotinylated derivatives for easy detection. A similar approach is used in SDA.
vi. Cyclic Probe Reaction
Target specific sequences can also be detected using a cyclic probe reaction (CPR). In CPR, a probe having 3' and 5' sequences of non-specific DNA and a middle sequence of specific RNA is hybridized to DNA which is present in a sample. Upon hybridization, the reaction is treated with RNase H, and the products of the probe identified as distinctive products which are released after digestion. The original template is annealed to another cycling probe and the reaction is repeated.
vii. Transcription-Based A mplification
Other nucleic acid amplification procedures include transcription-based amplification systems (TAS), including nucleic acid sequence based amplification (NASBA) and 3SR, Kwoh et al, 1989; PCT Patent Application WO 88/10315 et al, 1989, each incoφorated herein by reference).
In NASBA, the nucleic acids can be prepared for amplification by standard phenol/chloroform extraction, heat denaturation of a clinical sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidinium chloride extraction of RNA. These amplification techniques involve annealing a primer which has target specific sequences. Following polymerization, DNA/RNA hybrids are digested with RNase H while double stranded DNA molecules are heat denatured again. In either case the single stranded DNA is made fully double stranded by addition of second target specific primer, followed by polymerization. The double-stranded DNA molecules are then multiply transcribed by a polymerase such as T7 or SP6. In an isothermal cyclic reaction, the RNA's are reverse transcribed into double stranded DNA, and transcribed once against with a polymerase such as T7 or SP6. The resulting products, whether truncated or complete, indicate target specific sequences.
viii. Other Amplification Methods
Other amplification methods, as described in British Patent Application No. GB 2,202,328, and in PCT Patent Application No. PCT/US89/01025, each incoφorated herein by reference, may be used in accordance with the present invention. In the former application, "modified" primers are used in a PCR™ like, template and enzyme dependent synthesis. The primers may be modified by labeling with a capture moiety (e.g., biotin) and/or a detector moiety (e.g., enzyme). In the latter application, an excess of labeled probes are added to a sample. In the presence of the target sequence, the probe binds and is cleaved catalytically. After cleavage, the target sequence is released intact to be bound by excess probe. Cleavage of the labeled probe signals the presence of the target sequence.
Davey et al, European Patent Application No. 329,822 (incoφorated herein by reference) disclose a nucleic acid amplification process involving cyclically synthesizing single-stranded RNA ("ssRNA"), ssDNA, and double-stranded DNA (dsDNA), which may be used in accordance with the present invention.
The ssRNA is a first template for a first primer oligonucleotide, which is elongated by reverse transcriptase (RNA-dependent DNA polymerase). The RNA is then removed from the resulting DNA:RNA duplex by the action of ribonuclease H (RNase H, an RNase specific for RNA in duplex with either DNA or RNA). The resultant ssDNA is a second template for a second primer, which also includes the sequences of an RNA polymerase promoter (exemplified by T7 RNA polymerase) 5' to its homology to the template. This primer is then extended by DNA polymerase (exemplified by the large "Klenow" fragment of E. coli DNA polymerase I), resulting in a double-stranded DNA ("dsDNA") molecule, having a sequence identical to that of the original RNA between the primers and having additionally, at one end, a promoter sequence. This promoter sequence can be used by the appropriate RNA polymerase to make many RNA copies of the DNA. These copies can then re-enter the cycle leading to very swift amplification. With proper choice of enzymes, this amplification can be done isothermally without addition of enzymes at each cycle. Because of the cyclical nature of this process, the starting sequence can be chosen to be in the form of either DNA or RNA.
Miller et al, PCT Patent Application WO 89/06700 (incoφorated herein by reference) disclose a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. This scheme is not cyclic, i.e., new templates are not produced from the resultant RNA transcripts.
Other suitable amplification methods include "race" and "one-sided PCR™" (Frohman, 1990; Ohara et al, 1989, each herein incoφorated by reference). Methods based on ligation of two (or more) oligonucleotides in the presence of nucleic acid having the sequence of the resulting "di-oligonucleotide", thereby amplifying the di-oligonucleotide, also may be used in the amplification step of the present invention, Wu et al, 1989, incoφorated herein by reference).
3. Restriction Enzymes
Restriction-enzymes recognize specific short DNA sequences four to eight nucleotides long (see Table 1), and cleave the DNA at a site within this sequence. In the context of the present invention, restriction enzymes are used to cleave cDNA molecules at sites corresponding to various restriction-enzyme recognition sites. Frequently cutting enzymes, such as the four-base cutter enzymes, are preferred as this yields DNA fragments that are in the right size range for subsequent amplification reactions. Some of the preferred four-base cutters are Nlalll, Dpnll, Sau3AI, Hsp92II, Mbol, Ndell, Bspl431, Tsp509 I, Hhal, HinPlI, Hpall, Mspl, Taq alphal, MaeII or K2091.
As the sequence of the recognition site is known (see list below), primers can be designed comprising nucleotides corresponding to the recognition sequences. If the primer sets have in addition to the restriction recognition sequence, degenerate sequences corresponding to different combinations of nucleotide sequences, one can use the primer set to amplify DNA fragments that have been cleaved by the particular restriction enzyme. The list below exemplifies the currently known restriction enzymes that may be used in the invention.
TABLE 1: RESTRICTION ENZYMES
Enzyme Name Recognition Sequence
Aatll GACGTC
Acc65 I GGTACC
Ace I GTMKAC
Aci l CCGC
Acl l AACGTT
Afe l AGCGCT
Afl ll CTTAAG
Afl lll ACRYGT
Age I ACCGGT
Ahd l GACNNNNNGTC
Alu l AGCT
Alw l GGATC
AlwN I CAGNNNCTG
Apa l GGGCCC
ApaL I GTGCAC
Apo l RAATTY
Asc I GGCGCGCC
Ase l ATTAAT
Ava l CYCGRG
Ava il GGWCC
Avr ll CCTAGG
Bae l NACNNNNGTAPyCN
BamH I GGATCC
Ban I GGYRCC
Ban II GRGCYC
Bbs l GAAGAC TABLE 1 (CONTINUED)
Bbvl GCAGC
BbvCI CCTCAGC
Beg I CGANNNNNNTGC
BciVI GTATCC
Bell TGATCA
Bfal CTAG
Bgll GCCNNNNNGGC
Bglll AGATCT
Blpl GCTNAGC
Bmrl ACTGGG
Bpml CTGGAG
BsaAI YACGTR
BsaBI GATNNNNATC
BsaHI GRCGYC
Bsal GGTCTC
BsaJI CCNNGG
BsaWI WCCGGW
BseRI GAGGAG
Bsgl GTGCAG
BsiEI CGRYCG
BsiHKA I GWGCWC
BsiWI CGTACG
Bsll CCNNNNNNNGG
BsmAI GTCTC
BsmBI CGTCTC
BsmFI GGGAC
Bsml GAATGC
BsoBI CYCGRG
Bspl286I GDGCHC
BspDI ATCGAT
BspEI TCCGGA
BspHI TCATGA
BspMI ACCTGC
BsrBI CCGCTC
BsrDI GCAATG
BsrFI RCCGGY
BsrGI TGTACA
Bsrl ACTGG
BssH II GCGCGC
BssKI CCNGG
Bst4C I ACNGT
BssSI CACGAG
BstAP I GCANNNNNTGC
BstBI TTCGAA
BstE II GGTNACC
BstF5 I GGATGNN TABLE 1 (CONTINUED)
BstNI CCWGG
BstUI CGCG
BstXI CCANNNNNNTGG
BstYI RGATCY
BstZ17I GTATAC
Bsu36 I CCTNAGG
Btgl CCPuPyGG
Btrl CACGTG
Cac8I GCNNGC
Clal ATCGAT
Ddel CTNAG
Dpnl GATC
Dpnll GATC
Dral TTTAAA
Dra III CACNNNGTG
Drdl GACNNNNNNGTC
Eae I YGGCCR
Eagl CGGCCG
Earl CTCTTC
Ecil GGCGGA
EcoNI CCTNNNNNAGG
EcoO109I RGGNCCY
EcoRI GAATTC
EcoRV GATATC
Faul CCCGCNNNN
Fnu4H I GCNGC
Fokl GGATG
Fse I GGCCGGCC
Fspl TGCGCA
Haell RGCGCY
Hae III GGCC
Hgal GACGC
Hhal GCGC
Hinc II GTYRAC
Hind III AAGCTT
Hinfl GANTC
HinPl I GCGC
Hpal GTTAAC
Hpall CCGG
Hphl GGTGA
Kasl GGCGCC
Kpnl GGTACC
Mbol GATC
MboII GAAGA
Mfel CAATTG
Mlul ACGCGT
Mlyl GAGTCNNNNN TABLE 1 (CONTINUED)
Mnll CCTC
Msc I TGGCCA
Mse I TTAA
Msll CAYNNNNRTG
MspAl I CMGCKG
Mspl CCGG
Mwo I GCNNNNNNNGC
Nael GCCGGC
Narl GGCGCC
Neil CCSGG
Ncol CCATGG
Ndel CATATG
NgoMI V GCCGGC
Nhel GCTAGC
Nla III CATG
NlalV GGNNCC
Not I GCGGCCGC
Nrul TCGCGA
Nsil ATGCAT
Nspl RCATGY
Pad TTAATTAA
PaeR7 I CTCGAG
Pcil ACATGT
PflFI GACNNNGTC
PflMI CCANNNNNTGG
Plel GAGTC
Pmel GTTTAAAC
Pmll CACGTG
PpuMI RGGWCCY
PshAI GACNNNNGTC
Psil TTATAA
PspGI CCWGG
PspOM I GGGCCC
Pstl CTGCAG
Pvul CGATCG
PvuII CAGCTG
Rsal GTAC
RsrII CGGWCCG
Sac I GAGCTC
Sac II CCGCGG
Sail GTCGAC
Sap I GCTCTTC
Sau3A I GATC
Sau96 I GGNCC
Sbfl CCTGCAGG TABLE 1 (CONTINUED)
Seal AGTACT
ScrFI CCNGG
SexAI ACCWGGT
SfaNI GCATC
Sfcl CTRYAG
Sfil GGCCNNNNNGGCC
Sfol GGCGCC
SgrAI CRCCGGYG
Smal CCCGGG
Smll CTYRAG
SnaBI TACGTA
Spel ACTAGT
Sphl GCATGC
Sspl AATATT
Stul AGGCCT
Sty I CCWWGG
Swa I ATTTAAAT
Taql TCGA
Tfil GAWTC
Tlil CTCGAG
Tsel GCWGC
Tsp45 I GTSAC
Tsp509 I AATT
TspRI CAGTG
Tthl 11 I GACNNNGTC
Xbal TCTAGA
Xcml CCANNNNNNNNNTGG
Xhol CTCGAG
Xmal CCCGGG
Xmnl GAANNNNTTC
4. Other Enzymes Other enzymes that may be used in conjunction with the invention include nucleic acid modifying enzymes listed in the following tables. TABLE 2: POLYMERASES AND REVERSE TRANSCRIPTASES
Thermostable DNA Polymerases: OmniBase™ Sequencing Enzyme
Pfu DNA Polymerase Taq DNA Polymerase Taq DNA Polymerase, Sequencing Grade TaqBead™ Hot Start Polymerase AmpliTaq Gold
Tfl DNA Polymerase Tli DNA Polymerase Tth DNA Polymerase DNA Polymerases:
DNA Polymerase I, Klenow Fragment, Exonuclease Minus DNA Polymerase I
DNA Polymerase I Large (Klenow) Fragment Terminal Deoxynucleotidyl Transferase
T4 DNA Polymerase
Reverse Transcriptases: AMV Reverse Transcriptase
M-MLV Reverse Transcriptase
TABLE 3: DNA/RNA MODIFYING ENZYMES
Ligases:
T4 DNA Ligase
Kinases
T4 Polynucleotide Kinase
5. Labels Recognition moieties incoφorated into primers, incoφorated into the amplified product during amplification, or attached to probes are useful in identification of the amplified molecules. A number of different labels may be used for the puφose such as fluorophores, chromophores, radio-isotopes, enzymatic tags, antibodies, chemiluminescence, electroluminescence, affinity labels, etc. One of skill in the art will recognize that these and other fluorophores not mentioned herein can also be used with success in this invention.
Examples of affinity labels include but are not limited to the following: an antibody, an antibody fragment, a receptor protein, a hormone, biotin, DNP, or any polypeptide/protein molecule that binds to an affinity label and may be used for separation of the amplified gene.
Examples of enzyme tag include enzymes such as such as urease, alkaline phosphatase or peroxidase to mention a few and colorimetric indicator substrates can be employed to provide a detection means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid-containing samples. All these examples are generally known in the art and the skilled artisan will recognize that the invention is not limited to the examples described above.
The following fluorophores are specifically contemplated to be useful in practicing the present invention. Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy2, Cy3, Cy5,6-FAM, Fluorescein, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, ROX, TAMRA, TET, Tetramethylrhodamine, and Texas Red.
6. Methods of Immobilization
Immobilization of the DNA may be achieved by a variety of methods involving either non-covalent or covalent interactions between the immobilized DNA comprising an anchorable moiety and an anchor. In a preferred embodiment of the invention immobilization consists of the non-covalent coating of a solid phase with streptavidin or avidin and the subsequent immobilization of a biotinylated polynucleotide (Holmstrom, 1993). It is further envisioned that immobilization may occur by precoating a polystyrene or glass solid phase with poly-L-Lys or poly L-Lys, Phe, followed by the covalent attachment of either amino- or sulfhydryl-modified polynucleotides using bifunctional crosslinking reagents (Running, 1990 and Newton, 1993). Immobilization may also take place by the direct covalent attachment of short, 5'-phosphorylated primers to chemically modified polystyrene plates ("Covalink" plates, Nunc) Rasmussen, (1991). The covalent bond between the modified oligonucleotide and the solid phase surface is introduced by condensation with a water-soluble carbodiimide. This method facilitates a predominantly 5 '-attachment of the oligonucleotides via their 5'-phosphates.
Nikiforov et al. (U.S. Patent 5610287 incoφorated herein by reference) describes a method of non-covalently immobilizing nucleic acid molecules in the presence of a salt or cationic detergent on a hydrophilic polystyrene solid support containing a hydrophilic moiety or on a glass solid support. The support is contacted with a solution having a pH of about 6 to about 8 containing the synthetic nucleic acid and a cationic detergent or salt. The support containing the immobilized nucleic acid may be washed with an aqueous solution containing a non-ionic detergent without removing the attached molecules.
Another commercially available method envisioned by the inventors to facilitate immobilization is the "Reacti-Bind.TM. DNA Coating Solutions" (see "Instructions-Reacti-Bind.TM. DNA Coating Solution" 1/1997). This product comprises a solution that is mixed with DNA and applied to surfaces such as polystyrene or polypropylene. After overnight incubation, the solution is removed, the surface washed with buffer and dried, after which it is ready for hybridization. It is envisioned that similar products, i.e. Costar "DNA-BIND™" or. Immobilon-AV Affinity Membrane (IAV, Millipore, Bedford, MA) are equally applicable to immobilize the respective fragment.
7. Separation and Quantitation Methods Following amplification, it may be desirable to separate the amplification products of several different lengths from each other and from the template and the excess primer for the puφose analysis or more specifically for determining whether specific amplification has occurred. i. Gel electrophoresis
In one embodiment, amplification products are separated by agarose, agarose-acrylamide or polyacrylamide gel electrophoresis using standard methods (Sambrook et al, 1989).
ii. Chromatographic Techniques
Alternatively, chromatographic techniques may be employed to effect separation. There are many kinds of chromatography which may be used in the present invention: adsoφtion, partition, ion-exchange and molecular sieve, and many specialized techniques for using them including column, paper, thin-layer and gas chromatography (Freifelder, 1982). In yet another alternative, labeled cDNA products, such as biotin or antigen can be captured with beads bearing avidin or antibody, respectively.
Hi. Microfluidic Techniques
Microfluidic techniques include separation on a platform such as microcapillaries, designed by ACLARA BioSciences Inc., or the LabChip™ "liquid integrated circuits" made by Caliper Technologies Inc. These microfluidic platforms require only nanoliter volumes of sample, in contrast to the microliter volumes required by other separation technologies. Miniaturizing some of the processes involved in genetic analysis has been achieved using microfluidic devices. For example, published PCT Application No. WO 94/05414, to Northrup and White, incoφorated herein by reference, reports an integrated micro-PCR™ apparatus for collection and amplification of nucleic acids from a specimen. U.S. Patent Nos.
5,304,487 and 5,296,375, discuss devices for collection and analysis of cell containing samples and are incoφorated herein by reference. U.S. Patent No. 5,856,174 describes an apparatus which combines the various processing and analytical operations involved in nucleic acid analysis and is incoφorated herein by reference.
iv. Capillary Electrophoresis
In some embodiments, it may be desirable to provide an additional, or alternative means for analyzing the amplified genes. In these embodiment, micro capillary arrays are contemplated to be used for the analysis. Microcapillary array electrophoresis generally involves the use of a thin capillary or channel which may or may not be filled with a particular separation medium. Electrophoresis of a sample through the capillary provides a size based separation profile for the sample. The use of microcapillary electrophoresis in size separation of nucleic acids has been reported in, for example, Woolley and Mathies, 1994. Microcapillary array electrophoresis generally provides a rapid method for size-based sequencing, PCR™ product analysis and restriction fragment sizing. The high surface to volume ratio of these capillaries allows for the application of higher electric fields across the capillary without substantial thermal variation across the capillary, consequently allowing for more rapid separations. Furthermore, when combined with confocal imaging methods, these methods provide sensitivity in the range of attomoles, which is comparable to the sensitivity of radioactive sequencing methods. Microfabrication of microfluidic devices including microcapillary electrophoretic devices has been discussed in detail in, for example, Jacobsen et al, 1994; Effenhauser et al, 1994; Harrison et al, 1993; Effenhauser et al, 1993; Manz et al, 1992; and U.S. Patent No. 5,904,824, here incoφorated by reference. Typically, these methods comprise photolithographic etching of micron scale channels on a silica, silicon or other crystalline substrate or chip, and can be readily adapted for use in the present invention. In some embodiments, the capillary arrays may be fabricated from the same polymeric materials described for the fabrication of the body of the device, using the injection molding techniques described herein.
Tsuda et al, 1990, describes rectangular capillaries, an alternative to the cylindrical capillary glass tubes. Some advantages of these systems are their efficient heat dissipation due to the large height-to-width ratio and, hence, their high surface- to-volume ratio and their high detection sensitivity for optical on-column detection modes. These flat separation channels have the ability to perform two-dimensional separations, with one force being applied across the separation channel, and with the sample zones detected by the use of a multi-channel array detector.
In many capillary electrophoresis methods, the capillaries, e.g., fused silica capillaries or channels etched, machined or molded into planar substrates, are filled with an appropriate separation/sieving matrix. Typically, a variety of sieving matrices are known in the art may be used in the microcapillary arrays. Examples of such matrices include, e.g., hydroxyethyl cellulose, polyacrylamide, agarose and the like. Generally, the specific gel matrix, running buffers and running conditions are selected to maximize the separation characteristics of the particular application, e.g., the size of the nucleic acid fragments, the required resolution, and the presence of native or undenatured nucleic acid molecules. For example, running buffers may include denaturants, chaotropic agents such as urea or the like, to denature nucleic acids in the sample.
v. Mass Spectroscopy Mass spectrometry provides a means of "weighing" individual molecules by ionizing the molecules in vacuo and making them "fly" by volatilization. Under the influence of combinations of electric and magnetic fields, the ions follow trajectories depending on their individual mass (m) and charge (z). For low molecular weight molecules, mass spectrometry has been part of the routine physical-organic repertoire for analysis and characterization of organic molecules by the determination of the mass of the parent molecular ion. In addition, by arranging collisions of this parent molecular ion with other particles (e.g., argon atoms), the molecular ion is fragmented forming secondary ions by the so-called collision induced dissociation (CID). The fragmentation pattern/pathway very often allows the derivation of detailed structural information. Other applications of mass spectrometric methods in the known in the art can be found summarized in Methods in Enzymology, Vol. 193: "Mass Spectrometry" (J. A. McCloskey, editor), 1990, Academic Press, New York.
Due to the apparent analytical advantages of mass spectrometry in providing high detection sensitivity, accuracy of mass measurements, detailed structural information by CID in conjunction with an MS/MS configuration and speed, as well as on-line data transfer to a computer, there has been considerable interest in the use of mass spectrometry for the structural analysis of nucleic acids. Reviews summarizing this field include Schram, 1990 and Crain, 1990 here incoφorated by reference. The biggest hurdle to applying mass spectrometry to nucleic acids is the difficulty of volatilizing these very polar biopolymers. Therefore, "sequencing" had been limited to low molecular weight synthetic oligonucleotides by determining the mass of the parent molecular ion and through this, confirming the already known sequence, or alternatively, confirming the known sequence through the generation of secondary ions (fragment ions) via CID in an MS/MS configuration utilizing, in particular, for the ionization and volatilization, the method of fast atomic bombardment (FAB mass spectrometry) or plasma desoφtion (PD mass spectrometry). As an example, the application of FAB to the analysis of protected dimeric blocks for chemical synthesis of oligodeoxynucleotides has been described (Koster et al. Biomedical Environmental Mass Spectrometry 14, 111-116 (1987)).
Two ionization/desoφtion techniques are electrospray/ionspray (ES) and matrix-assisted laser desoφtion ionization (MALDI). ES mass spectrometry was introduced by Fenn, 1984; PCT Application No. WO 90/14148 and its applications are summarized in review articles, for example, Smith 1990 and Ardrey, 1992. As a mass analyzer, a quadrupole is most frequently used. The determination of molecular weights in femtomole amounts of sample is very accurate due to the presence of multiple ion peaks which all could be used for the mass calculation.
MALDI mass spectrometry, in contrast, can be particularly attractive when a time-of-flight (TOF) configuration is used as a mass analyzer. The MALDI-TOF mass spectrometry has been introduced by Hillenkamp 1990. Since, in most cases, no multiple molecular ion peaks are produced with this technique, the mass spectra, in principle, look simpler compared to ES mass spectrometry. DNA molecules up to a molecular weight of 410,000 daltons could be desorbed and volatilized (Williams, 1989). More recently, this the use of infra red lasers (IR) in this technique (as opposed to UV-lasers) has been shown to provide mass spectra of larger nucleic acids such as, synthetic DNA, restriction enzyme fragments of plasmid DNA, and RNA transcripts upto a size of 2180 nucleotides (Berkenkamp, 1998). Berkenkamp also describe how DNA and RNA samples can be analyzed by limited sample purification using MALDI- TOF IR.
In Japanese Patent No. 59-131909, an instrument is described which detects nucleic acid fragments separated either by electrophoresis, liquid chromatography or high speed gel filtration. Mass spectrometric detection is achieved by incoφorating into the nucleic acids atoms which normally do not occur in DNA such as S, Br, I or Ag, Au, Pt, Os, Hg.
vii. Energy Transfer
Labeling hybridization oligonucleotide probes with fluorescent labels is a well known technique in the art and is a sensitive, nonradioactive method for facilitating detection of probe hybridization. More recently developed detection methods employ the process of fluorescence energy transfer (FET) rather than direct detection of fluorescence intensity for detection of probe hybridization. FET occurs between a donor fluorophore and an acceptor dye (which may or may not be a fluorophore) when the absoφtion spectrum of one (the acceptor) overlaps the emission spectrum of the other (the donor) and the two dyes are in close proximity. Dyes with these properties are referred to as donor/acceptor dye pairs or energy transfer dye pairs. The excited-state energy of the donor fluorophore is transferred by a resonance dipole-induced dipole interaction to the neighboring acceptor. This results in quenching of donor fluorescence. In some cases, if the acceptor is also a fluorophore, the intensity of its fluorescence may be enhanced. The efficiency of energy transfer is highly dependent on the distance between the donor and acceptor, and equations predicting these relationships have been developed by Forster, 1948. The distance between donor and acceptor dyes at which energy transfer efficiency is 50% is referred to as the Forster distance (Ro). Other mechanisms of fluorescence quenching are also known including, for example, charge transfer and collisional quenching.
Energy transfer and other mechanisms which rely on the interaction of two dyes in close proximity to produce quenching are an attractive means for detecting or identifying nucleotide sequences, as such assays may be conducted in homogeneous formats. Homogeneous assay formats are simpler than conventional probe hybridization assays which rely on detection of the fluorescence of a single fluorophore label, as heterogeneous assays generally require additional steps to separate hybridized label from free label. Several formats for FET hybridization assays are reviewed in Nonisotopic DNA Probe Techniques (1992. Academic Press, Inc., pgs. 311-352). Homogeneous methods employing energy transfer or other mechanisms of fluorescence quenching for detection of nucleic acid amplification have also been described. Higuchi, 1992, discloses methods for detecting DNA amplification in realtime by monitoring increased fluorescence of ethidium bromide as it binds to double- stranded DNA. The sensitivity of this method is limited because binding of the ethidium bromide is not target specific and background amplification products are also detected. Lee, 1993, discloses a real-time detection method in which a doubly- labeled detector probe is cleaved in a target amplification-specific manner during PCR™. The detector probe is hybridized downstream of the amplification primer so that the 5'-3' exonuclease activity of Taq polymerase digests the detector probe, separating two fluorescent dyes which form an energy transfer pair. Fluorescence intensity increases as the probe is cleaved. Published PCT application WO 96/21144 discloses continuous fluorometric assays in which enzyme-mediated cleavage of nucleic acids results in increased fluorescence. Fluorescence energy transfer is suggested for use in the methods, but only in the context of a method employing a single fluorescent label which is quenched by hybridization to the target.
Signal primers or detector probes which hybridize to the target sequence downstream of the hybridization site of the amplification primers have been described for use in detection of nucleic acid amplification (U.S. Pat. No. 5,547,861). The signal primer is extended by the polymerase in a manner similar to extension of the amplification primers. Extension of the amplification primer displaces the extension product of the signal primer in a target amplification-dependent manner, producing a double-stranded secondary amplification product which may be detected as an indication of target amplification. The secondary amplification products generated from signal primers may be detected by means of a variety of labels and reporter groups, restriction sites in the signal primer which are cleaved to produce fragments of a characteristic size, capture groups, and structural features such as triple helices and recognition sites for double-stranded DNA binding proteins.
Many donor/acceptor dye pairs known in the art and may be used in the present invention. These include, for example, fluorescein isothiocyanate
(FITC)/tetramethylrhodamine isothiocyanate (TRITC), FITC/Texas Red.™. (Molecular Probes), FITC/N-hydroxysuccinimidyl 1 -pyrenebutyrate (PYB), FITC/eosin isothiocyanate (EITC), N-hydroxysuccinimidyl 1 -pyrenesulfonate (PYS)/FITC, FITC/Rhodamine X, FITC/tetramethylrhodamine (TAMRA), and others. The selection of a particular donor/acceptor fluorophore pair is not critical. For energy transfer quenching mechanisms it is only necessary that the emission wavelengths of the donor fluorophore overlap the excitation wavelengths of the acceptor, i.e., there must be sufficient spectral overlap between the two dyes to allow efficient energy transfer, charge transfer or fluorescence quenching. P-(dimethyl aminophenylazo) benzoic acid (DABCYL) is a non-fluorescent acceptor dye which effectively quenches fluorescence from an adjacent fluorophore, e.g., fluorescein or 5- (2'-aminoethyl) aminonaphthalene (EDANS). Any dye pair which produces fluorescence quenching in the detector nucleic acids of the invention are suitable for use in the methods of the invention, regardless of the mechanism by which quenching occurs. Terminal and internal labeling methods are both known in the art and maybe routinely used to link the donor and acceptor dyes at their respective sites in the detector nucleic acid.
viii. Chip Technologies
Specifically contemplated by the present inventors are chip-based DNA technologies such as those described by Hacia et al, 1996 and Shoemaker et al, 1996. These techniques involve quantitative methods for analyzing large numbers of genes rapidly and accurately. By tagging genes with oligonucleotides or using fixed probe arrays, one can employ chip technology to segregate target molecules as high density arrays and screen these molecules on the basis of hybridization, Pease et al, 1994; Fodor et α/., 1991.
In the present invention, the inventors contemplate the preparation of a high- density array of COP primers on a chip (or on any other solid surface) and conduct the DNA amplification on this solid-phase. ix. OIA
The inventor's envision the use of BioStar's OIA technology to quantitate the amplified product. OIA uses the mirror-like surface of a silicon wafer as a substrate.
A thin film optical coating and capture antibody is attached to the silicon wafer. White light reflected through the coating appears as a golden background color. This color does not change until the thickness of the optical molecular thin film is changed.
When a positive sample is applied to the wafer, binding occurs between the ligand and the antibody. When substrate is added to complete the mass enhancement, a corresponding change in color from gold to puφle/blue results from the increased thickness in the molecular thin film.
x. Real time PCR
RNA or DNA may be quantitated using the Real-Time PCR technique (Higuchi, 1992). By determining the concentration of the amplified products of the target DNA in PCR reactions that have completed the same number of cycles and are in their linear ranges, it is possible to determine the relative concentrations of the specific target sequence in the original DNA mixture. If the DNA mixtures are cDNAs synthesized from RNAs isolated from different tissues or cells, the relative abundance of the specific mRNA from which the target sequence was derived can be determined for the respective tissues or cells. This direct proportionality between the concentration of the PCR products and the relative mRNA abundance is only true in the linear range of the PCR reaction.
The final concentration of the target DNA in the plateau portion of the curve is determined by the availability of reagents in the reaction mix and is independent of the original concentration of target DNA. Therefore, the first condition that must be met before the relative abundance of a RNA or DNA species can be determined by Real-Time PCR for a collection of RNA or DNA populations is that the concentrations of the amplified PCR products must be sampled when the PCR reactions are in the linear portion of their curves. The second condition that must be met for an RT-PCR experiment to successfully determine the relative abundance of a particular mRNA species is that relative concentrations of the amplifiable cDNAs must be normalized to some independent standard. The goal of an Real-Time PCR experiment is to determine the abundance of a particular RNA or DNA species relative to the average abundance of all RNA or DNA species in the sample.
xi. Luminex
The Luminex technology allows the quantitation of nucleic acid products immobilized on color coded microspheres. The magnitude of the biomolecular reaction is measured using a second molecule called a reporter. The reporter molecule signals the extent of the reaction by attaching to the molecules on the microspheres. As both the microspheres and the reporter molecules are color coded, digital signal processing allows the translation of signals into real-time, quantitative data for each reaction.
8. Identification Methods
Amplification products must be visualized in order to confirm amplification of the target-gene(s) sequences. One typical visualization method involves staining of a gel with for example, a flourescent dye, such as ethidium bromide or Vistra Green and visualization under UV light. Alternatively, if the amplification products are integrally labeled with radio- or fluorometrically-labeled nucleotides, the amplification products can then be exposed to x-ray film or visualized under the appropriate stimulating spectra, following separation.
In one embodiment, visualization is achieved indirectly, using a nucleic acid probe. Following separation of amplification products, a labeled, nucleic acid probe is brought into contact with the amplified gene(s) sequence. The probe preferably is conjugated to a chromophore but may be radiolabeled. In another embodiment, the probe is conjugated to a binding partner, such as an antibody or biotin, where the other member of the binding pair carries a detectable moiety. In other embodiments, the probe incoφorates a fluorescent dye or label. In yet other embodiments, the probe has a mass label that can be used to detect the molecule amplified. Other embodiments also contemplate the use of Taqman™ and Molecular Beacon™ probes. In still other embodiments, solid-phase capture methods combined with a standard probe may be used as well.
The type of label incoφorated in PCR™ products is dictated by the method used for analysis. When using capillary electrophoresis, microfluidic electrophoresis, HPLC, or LC separations, either incoφorated or intercalated fluorescent dyes are used to label and detect the PCR™ products. Samples are detected dynamically, in that fluorescence is quantitated as a labeled species moves past the detector. If any electrophoretic method, HPLC, or LC is used for separation, products can be detected by absoφtion of UV light, a property inherent to DNA and therefore not requiring addition of a label. If polyacrylamide gel or slab gel electrophoresis is used, primers for the PCR™ can be labeled with a fluorophore, a chromophore or a radioisotope, or by associated enzymatic reaction. Enzymatic detection involves binding an enzyme to primer, e.g., via a bioti avidin interaction, following separation of PCR™ products on a gel, then detection by chemical reaction, such as chemiluminescence generated with luminol. A fluorescent signal can be monitored dynamically. Detection with a radioisotope or enzymatic reaction requires an initial separation by gel electrophoresis, followed by transfer of DNA molecules to a solid support (blot) prior to analysis. If blots are made, they can be analyzed more than once by probing, stripping the blot, and then reprobing. If PCR™ products are separated using a mass spectrometer no label is required because nucleic acids are detected directly.
A number of the above separation platforms can be coupled to achieve separations based on two different properties. For example, some of the PCR™ primers can be coupled with a moiety that allows affinity capture, and some primers remain unmodified. Modifications can include a sugar (for binding to a lectin column), a hydrophobic group (for binding to a reverse-phase column), biotin (for binding to a streptavidin column), or an antigen (for binding to an antibody column). Samples are run through an affinity chromatography column. The flow-through fraction is collected, and the bound fraction eluted (by chemical cleavage, salt elution, etc.). Each sample is then further fractionated based on a property, such as mass, to identify individual components. 9. Analysis of Data
Gathering data from the various analysis operations will typically be carried out using methods known in the art. For example, microcapillary arrays may be scanned using lasers to excite fluorescently labeled targets that have hybridized to regions of probe arrays, which can then be imaged using charged coupled devices ("CCDs") for a wide field scanning of the array. Alternatively, another particularly useful method for gathering data from the arrays is through the use of laser confocal microscopy which combines the ease and speed of a readily automated process with high resolution detection. Scanning devices of this kind are described in U.S. Patent Nos. 5,143,854 and 5,424,186.
Following the data gathering operation, the data will typically be reported to a data analysis operation. To facilitate the sample analysis operation, the data obtained by a reader from the device will typically be analyzed using a digital computer. Typically, the computer will be appropriately programmed for receipt and storage of the data from the device, as well as for analysis and reporting of the data gathered, i.e., inteφreting fluorescence data to determine the sequence of hybridizing probes, normalization of background and single base mismatch hybridizations, ordering of sequence data in SBH applications, and the like, as described in, e.g., U.S. Patent Nos. 4,683,194, 5,599,668 and 5,843,651 incoφorated herein by reference.
10. Kits
The materials and reagents required for detecting and quantitating gene expression from a biological sample may be assembled together in a kit. The kits of the invention generally will comprise a set of restriction endonucleases used to digest the cDNA. Preferred kits will comprise frequent cutters such as four-base cutter, five base cutter or six base cutter restriction enzymes.
The kits of the invention also will generally comprise one or more preselected primer sets and/or probes that may be either specific or non-specific for the genes to be amplified. Preferably, the kits will comprise, in suitable container means, one or more nucleic acid probes and/or primer sets and means for detecting nucleic acids. In certain embodiments, such as in kits for use in amplification reactions, the means for detecting the nucleic acids may be a label, such as a fluorophore, a radiolabel, an enzyme tag, etc., that is linked to the nucleic acid primer or the nucleotides themselves. It is envisioned that kits may contain pairs of primers for standardization of gentags.
Preferred kits are those suitable for use in PCR™. In PCR™ kits, two primers will preferably be provided that have sequences from, and that hybridize to, spatially distinct regions of the target gene. Preferred pairs of primers will have two parts, a first subsequence, corresponding to a recognition-sequence of a four-base cutter and a second subsequence, corresponding to a specificity region designed to amplify any possible combination of nucleotides adjacent to the restriction site. Kits of this embodiment will be used to amplify all genes, unknown and/or known, that respond to certain treatments or stimuli. In other embodiments, the second subsequence following the restriction-enzyme sequence will correspond to a known gene or set of genes. The kits of this embodiment will be used to detect and quantitate all known genes that belong to a family or all known genes that respond to a treatment or stimulus. Other preferred pairs of primers for amplifying nucleic acids are selected to amplify the sequences specified herein. Also included in PCR™ kits may be enzymes suitable for amplifying nucleic acids, including various polymerases (RT, Taq, etc.), deoxynucleotides and buffers to provide the necessary reaction mixture for amplification.
The kits of the present invention, although containing at least one sequence corresponding to a restriction-enzyme recognition sequence, as disclosed herein, also may contain one or more of a variety of other target-gene sequences as described above. The kits of the present invention may also include the anchorable moiety, components necessary for second strand cDNA synthesis, linkers, ligase, and kinase.
In each case, the kits will preferably comprise distinct containers for each individual reagent and enzyme, as well as for each probe or primer pair. Each biological agent will generally be suitable aliquoted in their respective containers. The container means of the kits will generally include at least one vial or test tube. Flasks, bottles and other container means into which the reagents are placed and aliquoted are also possible. The individual containers of the kit will preferably be maintained in close confinement for commercial sale. Suitable larger containers may include injection or blow-molded plastic containers into which the desired vials are retained. Instructions may be provided with the kit.
D. Differential Gene Expression Analyzed by COP 1. Description of the COP Technique The details of the method are given in FIG. 1 using the cDNA for annexin III as an illustrative example. cDNA was synthesized with biotinylated oligo (dT) as first strand primer, digested with a frequent-cutting restriction endonuclease (Dpnll), and the 3'-most fragment recovered by binding to a streptavidin-coated bead. To provide a common priming sequence, a 16-bp adapter with a Dpnll compatible sticky end ("B-linker") was ligated onto the cDNA fragments. The fragments were then digested with a second frequent cutting restriction endonuclease, (Nlalll) and a second common priming site ("A-linker") was added by ligation. This procedure resulted in a template preparation ("B/A genetags") that contained a single gene-specific target sequence from each cDNA, with common A and B linkers at the two ends. Because each of the two enzymes used has a recognition site on average every 256 bp, the average size of the gene-specific target sequences was expected to be about 128 bp.
Thus, the sequence complexity of the genetag preparation was reduced by about 15- fold relative to the cDNA population, assuming an average mRNA size of about 2kb.
The scheme illustrated in FIG. 1 will not produce an amplifiable genetag from cDNAs in which there is no Nlalll restriction site between the last Dpnll restriction site and the poly(A) tail. To prepare a template suitable for analysis of these cDNAs, a second preparation, A/B genetags, was made by reversing the order in which the Dpnll and Nlalll cuts were made. cDNAs in which Dpnll and Nlalll restriction sites are absent or separated by less than 6 bp are refractory to this analysis; empirically this corresponds to about 5-10% of the transcriptome.
PCR™ reactions using primers containing only the A- and B- linker sequences would be expected to amplify all of the gene-specific targets in these genetag preparations. To provide specificity to the PCR™ reactions, COP primers were constructed containing the A-linker sequence (16 nt) followed by 4 variable nt (256 different primers) or the B-linker sequence (16 nt) followed by 3 variable nt (64 different primers). These primers can be combined pairwise with the two orientations of genetags to produce (256 x 64 x 2) = 32,768 unique reactions. The presence of relatively long common regions in the COP primers allows near optimal amplification with all primers under a single set of PCR™ conditions. For cDNAs of known sequence, a single pair of primers that will amplify the gene-specific target in one genetag orientation can be predicted from the sequence, as well as the size of the resulting fragment (amplimer). Current estimates of the number of genes in the human transcriptome range from about 60,000 to 100,000. Since the COP method effectively divides the transcriptome randomly among 32,768 unique reactions, each pair of COP primers tested may give several amplimers (2-3 on average), only one of which corresponds to the gene being assayed. In general, these amplimers can be distinguished by size.
2. Specificity Of COP
As an example of the specificity of the method, reactions were performed with primers predicted to produce a 291 bp amplimer from the murine Brcal gene. As template for these reactions, mRNA was prepared from cultures of mouse keratinocytes. Epidermal keratinocyte cultures were derived from newborn mice and maintained as described, Pierce et al, 1998a. Total RNA was prepared by extraction into a chaotropic salt solution and organic solvent extraction using either a QIAGEN (Valencia, CA). mRNA was prepared using a QIAGEN kit, and double-stranded cDNA was synthesized using a GIBCO/BRL kit but substituting biotinylated ρ(dT))8 as the primer for first strand synthesis. Double stranded linkers with overhangs complementary to the ends created by restriction with Nla III (A-linker) and Dpn II (B-linker) were prepared separately by mixing equal amounts of the following oligonucleotides, warming to 90°C for 2 min and slowly cooling to room temperature: A-linker - 5'-CGTCTAGACAGC (previously phosphorylated with T4 polynucleotide kinase) and 5'- GCTGTCTAGACGCATG; B-linker - 5' - CGGTGATGCATC and 5' -GATCGATGCATCACCG (previously phosphorylated with T4 polynucleotide kinase). cDNA (1.5 μg) was digested with Dpn II, the 3'-most Dpn II fragment of each cDNA was absorbed to streptavidin/magnetic beads (Dynal, Lake Success, NY) and non-biotinylated fragments were removed. B-linker (217 ng) was added to the cDNA fragments bound to the beads, warmed to 50°C for 2 min, cooled to room temperature for 15 min, then cooled on ice. Ligation was accomplished by adding 10 U T4 DNA ligase (GIBCO/BRL) and incubating in a final volume of 50 μL for 2 hr at 16°C. The preparation was then digested with Nlalll, and fragments released from the beads were recovered and ligated to the A-linker (217 ng) under similar conditions. These fragments of cDNA, containing the gene-specific targets ligated to the B and A linkers, are referred to as B/A genetags. A second preparation, A/B genetags, was obtained by performing Nla III restriction and A-linker ligation prior to Dpn II restriction and B-linker ligation.
To test the selectivity of the method, two pairs of primers that differed by a single nucleotide from the Brcal primers were also chosen that were expected to produce amplimers of 117 and 197 bp from the genes for annexin III and an anonymous cDNA (clone 2C11B), respectively. Two sets of primers for COP PCR™ reactions were synthesized, corresponding to the A- and B- linkers above, but containing 3 or 4 nucleotide specificity regions at the 3' end. The sequences of these primer sets were:
A-end (256 primers)-5'-GCTGTCTAGACGCATGNNN ;
B-end (64 primers)-5'-CGGTGATGCATCGATCNNN.
PCR™ reactions contained (total volume, 25 μL) genetags equivalent to 0.1 to 4 ng cDNA, 40 pg of each COP primer, 0.25 μL AmpliTaq (Perkin Elmer Co.) and lx
"D" buffer (Epicentre Technologies, Madison WI). Reactions were run in a
Stratagene RoboCycler with an initial denaturation of 5 min at 95°C, 2 min at 60°C and 1 min at 72°C followed by 26 cycles of 0.5 min at 95°C, 1 min at 60°C and 1 min at 72°C. The final extension at 72°C was increased to 6 min. After addition of 1/10 vol lOx sample buffer (7.0 M urea, 0.4% bromphenol blue, 50mM Tris, 20mM
EDTA, pH 7.5), portions of the reactions were analyzed by electrophoresis on 8% polyacrylamide gels. DNA fragments were stained with Vistra Green (Molecular
Probes, Eugene, OR) and digitized fluorescent images were obtained with a
Fluorlmager (Molecular Dynamics, Sunnyvale, CA). A relative measure of the amount of product in each of the bands ("amplimers") seen on the gel image was obtained by densitometry, using the volume integration facility of the ImageQuant software supplied with the Fluorlmager. An amplimer of the expected size was produced in PCR™ reactions with each of these three pairs of primers (FIG. 2 A), and in each case the expected amplimer was the major product. Significantly, production of the Brcal -specific amplimer was not detected in reactions designed to amplify annexin III or 2C11B, and vice versa. A similar experiment was carried out using the COP primers predicted for 3 human genes, HSP27, RPS5, and MLN62, with genetags prepared from the human breast cancer cell line SKBR3. SKBR3 human breast tumor cells were grown in DMEM containing 10% fetal bovine serum. Cell monolayers were rinsed with saline, and RNA isolated as described above for keratinocytes. Again the primers selectively gave rise to amplimers of the expected sizes (FIG. 2D), in each case the expected amplimer was the major product, and the HSP27-specific product was not obtained in reactions designed to amplify RPS5 and MLN62 and vice versa.
To verify that the products were indeed those expected, the 291 bp amplimer obtained with primers specific for the Brcal gene (see FIG. 2A) was gel-purified and sequenced in both directions with the same primers used in the initial reaction; the experimentally determined sequence exactly matched the predicted sequence. To further validate the specificity of COP reactions, primer pairs were selected for 9 other murine genes, including several high abundance, housekeeping genes, Ode, Rpl5, and Actg, and also lower abundance genes, Mdm2, Ccng, Cdkn2a, Cdkl and transcription factors Yyl and Hflι2. Similarly, primer pairs were selected for 14 human genes: HSPBl(t e gene for HSP27), TRAF4 (the gene for MLN62), RPS5, RPS16, RPL31, CAPN4, XPC, IGFBP2, ARF3, PSMD12, CREB2, TOP3, TCEB3, ETR101. Reactions were run with the appropriate primer pairs and genetag templates, reaction products of the expected size were again gel-purified and sequenced, and in each case the sequence obtained was greater than 95% identical to the expected product.
3. Quantitation with COP
There are two major requirements that must be met to obtain quantitative data from PCR™ reactions: the signal must increase linearly with the amount of template and the PCR™ reactions must be in the exponential phase rather than the stationary phase, i.e. the signal must increase exponentially with cycle number. Densitometry of the stained gel shown in FIG. 2A indicated that the integrated intensity of the amplimer bands increased linearly with the amount of genetag template up to about 0.6 ng cDNA for annexin III and up to about 4 ng cDNA for Brcal and 2C11B (FIG. 2B). In addition, when the number of PCR™ cycles was varied, the integrated intensities increased exponentially with increasing cycle number from 22 to 28 (FIG. 2C). Similarly for the experiment with human genes shown in FIG. 2D, the intensity of the bands increased linearly with template concentration over a defined range, and exponentially with PCR™ cycle number from 24 to 28 cycles.
To assess the reproducibility of the technique, replicate genetag preparations were assayed for the expression of three representative genes that displayed a wide range of expression. Four samples of A/B genetags were prepared independently from a single cDNA preparation from SKBR3 cells, and quadruplicate reactions were carried out using 3 non-overlapping pairs of COP primers specific for the small subunit of calpain (FIG. 3 A), MLN62 (Figure 3B), or the gene for the p55 component of the proteasome (FIG. 3C). The amplimers expected in these reactions, as well as 2 unidentified products of approximate lengths 76 and 130 bp seen in FIG. 3 A, were quantitated. Although the relative expression levels for this group of amplimers varied over a 25-fold range, the overall coefficients of variation were all between 0.23 and 0.27. Analysis of these data by multiple ANOVA indicated that the overall dispersion is due to variance in repeated PCR™ measurements of a single genetag preparation, and to differences between the genetag preparations. By performing multiple analyses on selected genes of interest, statistical significance can be attained for changes in gene expression that extend below the 2-fold level . Power calculations (assuming a lognormal distribution of the ratio data) indicate that with a minimum of 4 observations, a two-fold difference in the expression ratio can be detected with a power of 95%. This power is similar to that of other techniques for differential gene expression analysis as is well known in the art.
4. Quantitation by competitive RT-PCR
However, it is widely felt that the ultimate quantitative method for PCR™ determination of mRNA levels is competitive RT-PCR™. In this technique, for each target gene that is analyzed, a competitive template must be made that is amplified by the same primers with approximately the same efficiency as the target. By co-amplifying a constant amount of unknown cDNA with different known amounts of the competitive template the concentration of the unknown target cDNA can be accurately evaluated. Generally, the competitive template is engineered to contain the same sequences as the target, with a small insertion or mutation built in that allows the products derived from the target and the competitor to be distinguished, either by size or by sensitivity to digestion by one or more restriction enzyme. Typically, a large amount of time and effort is expended to design, produce and validate the competitive template. In the present invention, the inventors have designed a general strategy for the production of competitive templates for target genes of known sequence using COP. A specific example of this strategy is outlined in FIG. 4, using the gene for HSP27 for illustration. The COP genetag sequence for HSP27 and the associated COP primers (COP32 and COP46) are shown in the center of FIG. 4. The inventors synthesized a primer (CRT004) that contains the COP32 sequence and 5 or more nucleotides of the target genetag sequence ("clamp"). Between the COP32 and clamp sequences the inventors inserted 5 bp of arbitrary sequence, in this case ACACA. When a PCR™ reaction was run using CRT004 and COP 46 as primers and a genetag preparation from SKBR3 cells known to contain the HSP27 target as the template, an amplimer was produced in high yield that contained the same sequences as the HSP27 genetag but with the insertion of 5 bp (ACACA). This was verified by direct sequencing. This amplimer, identified in FIG. 4 as CRT 32/46, was purified from polyacrylamide gels, quantitated by the PicoGreen assay, and used as a competitive template in reactions with COP32 and COP46 as primers and SKBR3 genetags as unknown template. As shown in FIG. 5, the target product obtained in the absence of competitor (lane 2) was easily distinguished from the 5 bp longer product obtained from the competitive template in the absence of genetags (lane 11). When increasing amounts of competitor were added to a constant amount of genetags (FIG. 5: lanes 3 through 10), the intensity of the longer band increased linearly. When the two bands are of equal intensity, the concentrations of the target genetag and the competitor are considered to be equal. This equivalence point can be estimated from linear plots of the ratio of the intensities of the two bands versus the concentration of competitor. However, some authorities recommend using log-log plots of the data to verify that the reactions are within the required parameters. Such plots should be linear with a slope of approximately 1. As shown in FIG. 6, the competitive log-log plot for the HSP27 assay is linear with a slope of 1 around the equivalence point. Note also that the assay is extremely sensitive - the equivalence point corresponds to the addition of 0.042 fg of competitive template to the PCR™ reaction. The inventors have also used this strategy for the preparation of a competitive RT-PCR™ assay for MLN62, but in this case the target amplimer was 153 bp and a 10 bp insert was introduced. Again, log-log plots were linear with a slope of about 1.
5. Sensitivity of COP analysis To assess the sensitivity of the technique, an internal control template for the
MLN62 gene
Figure imgf000057_0001
was constructed using methods analogous to those described in the previous section. This template contained (FIG. 7A) the gene-specific target for the MLN62 gene with a 10 bp insertion, the A-end and B-end linkers, and a biotin label at one end. As expected, amplification of this template with MLN62-specific COP primers gave rise to a product 10 bp longer than the MNL62-specific amplimer (FIG. 7B, lane 6, arrowheads). A normal human mammary epithelial cell line, HME87 (Gazdar et al, 1998), was grown in serum-free medium (MEGM, Clonetics, Walkersville, MD) and cDNA was prepared as described above for SKBR3 cells.
The ICM N62 DNA was mixed with cDNA prepared from HME87 normal human mammary epithelial cells at a 1 :20,000 weight ratio, and A B genetags were prepared.
PCR™ reactions were performed using the MLN-specific COP primers, and amplimers corresponding in size to the MLN62 cDNA (closed arrowhead) and to the
ICMLN 2 (open arrowhead) were obtained (FIG. 7B, lanes 2-5). The intensity of both bands increased linearly with template concentration (FIG. 7C). From the ratio of intensities of these two bands in FIG. 7B and the known level of addition of the ICMLN62 to the cDNA, the molar concentration of the endogenous MLN62-specific genetag could be calculated as 0.6 amol/ng cDNA. Assuming an average mRNA length of
2000 nt this corresponded to an mRNA abundance of -0.07%. Expression levels at least 8-fold lower than that of MLN62 can easily be detected in this system (compare MLN62 with p55, FIG. 3), suggesting that the lower limit of detectability is less than
0.01%) or about 30 molecules of mRNA per cell. 6. Standardization
One method by which COP experiments can be normalized is by the use of sets of control or standardization genes. This method uses essentially an external standard approach. A set of genes is identified whose expression is relatively constant among different biological samples. These are usually comprised of "housekeeping" genes, such as ribosomal protein genes and genes for intermediary metabolic enzymes. COP amplifications for these genes are performed in parallel with COP amplification for the genes of interest, and the results compared. Tables 4 and 5 give examples of sets of standardization genes for both orientations of human and mouse genetags, respectively.
Table 4
HUMAN STANDARDIZATION GENE SET FOR RAGE
GENE ACCESSION # ORIEN SIZE Primer Primer
T. B
MALIC ENZYME M55905 B/A 570 185 314
L3 X06323 B/A 261 264 46
S7 M77233 B/A 278 170 323
L35 U 12465 B/A 160 174 304
S28 U 14973 B/A 158 218 306
L8 Z28407 B/A 153 212 307
S15a X84407 B/A 136 118 67
S26 X69654 B/A 110 194 46
S27 U57847 B/A 108 88 45
PHOSPHOGLYC J04173 B/A 102 78 67 ERATE MUTASE
PHOSPHOFRUC D25238 B/A 211 103 289 TOKEN ASE
CYTOKERATIN X98614 B/A 248 64 70 156 200 675
LAMIN M13452 B/A 157 65 23
A
BETA ACTIN X00351 B/A 163 28 67 34 92
CEBP/epsilon U48866 B/A 318 186 47 220
CYTOKERATIN XI 2883 B/A 103 59 69 18
190 TABLE 4 (CONTINUED)
270 350
NUCLEOPHOSM M23613 B/A 314 248 47
IN
220
190 186 290
L23 X53777 A/B 55 100 68
L23a U37230 A/B 232 85 300
68
315
P0 M17885 A/B 311 161 67
96 161 67
110 161 67
750 161 67
L10 L25899 A/B 175 214 285
L31 X69181 A/B 253 87 67 171 118 63
Sll X06617 A/B 67 248 23 103 127 197
L6 X69391 A/B 277 223 290
S18 X69150 A/B 105 261 286 73
L12 L06505 A/B 108 8 310
L26 X69392 A/B 241 32 332 120
L19 X63527 A/B 163 49 45
L30 M94314 A/B 64 87 331 119 TABLE 4 (CONTINUED)
TRANSKETOLA U55017 A/B 122 178 330
SE
75
PHOSPHOGLYCERATE KINASE A/B 77 48 68
V00572 120
200
345
S6 M20020 A/B 596 178 329
160
S16 M60854 A/B 349 39 45
900
295
170
130
98
Table 5
MOUSE STANDARDIZATION GENE SET
FOR COP
GENE ACCESSION # ORIENT SIZE Primer Primer
A B
RPL8 U67771 B/A 304 65 323
S26 U67770 B/A 110 194 302
PI U29402 B/A 268 237 285
L36 X75895 B/A 70 185 306
S4 M73436 B/A 132 247 47
S14 Y08307 B/A 114 186 332
S12 Y11682 B/A 153 54 310
L12 L04280 B/A 80 103 71
L3 Y00225 A/B 68 58 332
L29 X05021 A/B 43 130 71
P0 X15267 A/B 61 165 67 TABLE 5 (CONTINUED)
S24 X60289 A/B 170 179 326
A52 U28917 A/B 103 110 331
Sll U93864 A/B 67 248 24
S28 U11248 A/B 185 62 295
L29 L08651 A/B 295 65 331
S24 X60289 A/B 170 179 326
E. Examples The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
EXAMPLE 1
Use of COP for the Determining the Global Expression of Genes from the SKBR3 Cell-Line
To develop the COP concept experimentally, the inventors used a human breast cancer cell line, SKBR3, for which global gene expression data had been previously obtained using the SAGE technique. Four genes, known to be expressed in SKBR3 cells on the basis of SAGE studies, were chosen for initial tests. The mRNA sequences for these genes were obtained from GenBank and analyzed to design COP primers. FIG. 8 shows a portion of the sequence of one of these genes, MLN62, and the location of the COP primers, and Table 6 shows the four genes chosen; their approximate expression levels from the SAGE data; the COP primers; and the lengths of the amplimers expected. Poly A(+)RNA was prepared from SKBR3 cells, and a genetag preparation with A/B orientation was made using the enzymes Nlalll and Dpn II. PCR™ reactions (25 μL) were set up using the required primers and genetags were derived from 1.0 ng of cDNA per reaction. Aliquots of the PCR™ products were analyzed on 5% polyacrylamide gels and visualized by ethidium bromide staining. The results are shown in FIG. 9. For each pair of primers, reactions that lacked template gave no visible products. In the presence of the genetag template, each pair of primers produced a well-defined band ("amplimer") that matched the size expected for the corresponding gene. Although the primer pairs used differed from each other by 1, 2 or 3 nucleotides, in no case did a primer pair produce an amplimer that matched in size the amplimer expected from a different primer pair in this set (compare, for example, FIG. 9: lanes 5 and 6 with lanes 9 and 10). In some cases (for example, FIG. 9: lanes 9 and 10) one or more amplimers that did not match the expected size were also seen. This is not unexpected, since on the average each COP primer pair should amplify a unique fragment from 3-4 different genes, and these fragments are likely to be of different sizes. The identity of the 100 bp fragment seen in lanes 9 and 10 is currently unknown. For each of the four genes tested in this study, the amplimer band was excised from the gel, purified and sequenced. In all cases, the derived sequence matched the expected sequence. In Table 7 the inventors list 10 genes that have been tested to date and for which COP produces an amplimer of the expected size and sequence.
Table 6 GENES ANALYZED IN SKBR3 CELLS BY COP
GENE EXPRESSION LEVEL PRIMER A PRIMERBAMPLIMER
LENGTH
(%) (BP)
RPS16 0.38 CATGCCGT GATCTCC 351
RPS5 0.19 CATGCCTT GATCTCG 41
HSP27 0.16 CATGCCCA GATCTCG 60
MLN62 0.03 CATGCCTT GATCTCA 150
Expression level was determined in SKBR3 cells by SAGE analysis. Only the specificity regions of the A and B primers are listed. TABLE 7.
VALIDATION OF COP SPECIFICITY Gene Description Accession Matches / Positions
γ-actin M20826 69/69
RPL5 Z35311 106/106
CDK7 U11822 347/349
Brcal U36475 267/267
P19 ARF L76092 479/484
MDM2 U47934 61/61
ODC M12331 177/178
Cyclin G Z37110 85/85
YY-1 M73963 223/224
Genesis U41047 230/230
Quantitation with COP
The data shown above indicates that the amount of amplimer produced from a given template with a given pair of primers is fairly reproducible, specific and can be detected with a low background noise. Several other requirements must be met in order for the COP results to be considered quantitative reflections of the abundance of a given mRNA in the population. The literature on quantitative PCR™ yields two main prerequisites: the reactions must be analyzed during the exponential phase of the PCR™, and the amount of amplimer produced must be directly proportional to the concentration of template. To test these requirements, the inventors performed PCR™ reactions with SKBR3 genetags as the template and a combination of three COP primers that produced three strong amplimers, under varying number of cycles and varying template concentrations. Reaction products were analyzed as described above, except that staining was done with VistraGreen to obtain slightly better sensitivity. The stained gel was analyzed on a Fluorlmager (Molecular Dynamics) and the relevant bands were quantitated using ImageQuant software.
Results obtained when the number of PCR™ cycles were varied from 24 through 28 are shown in FIG. 10 and FIG. 11. For all three bands, an exponential increase in the amount of the amplimer was seen for at least the 25th through the 27th cycle. Results obtained when the template concentration were varied from 0.1 to 1.0 ng are shown in FIG. 12 and FIG. 13. For all three bands, the amount of amplimer produced increased linearly with template over this range. These studies demonstrate that COP is a quantitative procedure.
Informatics
The inventors have developed several kinds of bioinformatics tools needed to support the implementation of the methods described herein (Fig. 21). First they have developed several software programs that run on Macintosh digital computers. These include (1) a program to find the correct amplification primers for any given mRNA accession in GenBank; (2) a program to find all GenBank mRNA accessions that should be amplified from a suitable genetags preparation by a particular pair of amplification primers; (3) a program that analyzes and summarizes quantitative data obtained from COP experiments.
Second, they have constructed relational databases using commercially available software (Helix Express, FileMaker Pro) that support the design, execution and analysis of COP experiments. The first of these contains all mRNA sequence accessions from GenBank; databases have been created and are maintained for data from human, mouse and rat accessions. Information on the identity and positions of the correct amplification primers for the mRNA, the length and sequence of the expected product, the positions of the coding sequence and the polyA signal(s), and links to other databases are stored in the database. In addition, project-specific, laboratory information on cDNA preparations, genetag preparations, PCR reactions run and analyzed, and experimental data recorded can be stored and retrieved. Finally, experimentally observed amplimers can be compared to all possible amplimers predicted from the GenBank accession data, and matched on the basis of primer sequence, genetag orientation and amplimer length.
EXAMPLE 2
Differential Gene Expression in K5E2F1 Transgenic Mice
The COP technique is envisioned to have wide applications, both as a screening tool and as a low-cost adjunct to other global gene expression technologies. In this example the inventors demonstrate the use of this technology to study changes in gene expression. Changes in expression levels of genes in transgenic mouse keratinocytes overexpressing the human E2F1 gene, including the upregulation of several genes that act to increase p53 activity were determined using COP. Two genes not previously reported to be regulated by E2F1 : Brcal and CDK7, were also found to have an increased expression.
Overexpression of the cell cycle-regulated transcription factor E2F1 can bypass growth arrest induced by a variety of methods. This is due to the ability of E2F1 to transactivate genes important for cell cycle progression, including genes for DNA biosynthetic enzymes, factors that control the initiation of DNA synthesis, cell cycle regulators, and several proto-oncogenes (Johnson and Schneider-Broussard, 1998; Slansky and Farnham, 1996). In contrast to its positive effects on cell growth, E2F1 has also been shown to have a role in apoptosis in some systems. It has recently been reported that E2F1 mediates the induction of apoptosis by several oncoproteins, and this effect is mediated by stabilization of p53, in part by an induction of pl9ARF (Zindy et al, 1998; deStanchina et al, 1998; Bates et al, 1998). In other systems, however, p53 is not involved in the apoptotic response to E2F1, and in fact the transactivation domain of E2F1 may be dispensable (Phillips et al, 1997; Hsieh et al, 1997). Thus, it is not clear to what extent activation, derepression or repression of downstream target genes is involved in E2F1 -mediated apoptosis. The inventors recently described the generation of transgenic mice expressing E2F1 under the control of a keratin 5 (K5) promoter (Pierce et al, 1998a; Pierce et al, 1998b). Deregulated expression of E2F1 in basal keratinocytes results in epidermal hypeφlasia, hypeφroliferation and aberrant p53-dependent apoptosis. In the absence of functional p53, E2F1 -induced apoptosis is significantly reduced while E2Fl-induced hypeφroliferation is unchanged. Significantly, K5 E2F1 transgenic mice that are deficient (heterozygous or nullizygous) for p53 develop spontaneous skin carcinomas. The inventors previously demonstrated that K5 E2F1 keratinocytes overexpress at least one endogenous E2F target, the cyclin E gene. To further explore the molecular mechanisms underlying the phenotype of these transgenic mice, the inventors applied the COP technology to determine in further detail changes in endogenous gene expression resulting from overexpression of the K5 E2F1 transgene.
The method developed herein allows expression changes to be determined in about 90%) of the transcriptome in either a directed search of known genes, or an undirected survey of unknown genes. Unique, gene-specific targets are prepared from each cDNA by digestion with two restriction nucleases and poly(A) selection, ligated to common primer binding sites, and amplified by PCR™. The primers contain a common region, derived from the linker, plus a 3 '-specificity region of 3 or 4 nucleotides, allowing them to selectively amplify cDNAs from a small number of genes. For known genes, the identity of the cDNA amplified can be deduced from the sequence of the primers and the length of the amplimer produced. The intensity of the amplimer band on the gel is a relative measure of the frequency of the corresponding mRNA in the total population of mRNAs. As in other forms of RT-PCR analysis, proportionality is expected under conditions where the intensity of the signal increases linearly with increasing template concentration and exponentially with the number of cycles.
The details of the method for preparing genetags are shown in FIG. 1 using the cDNA for annexin III as an illustrative example. The gene-specific targets are partially purified by cutting cDNA with one restriction enzyme, selecting the poly(A)-containing, 3 '-most fragment, and then cutting with a second restriction enzyme. By ligating two different linkers (A and B) to the sticky ends produced by the restriction enzymes, only fragments containing the gene-specific target will contain both A and B linkers. The inventors call these fragments "genetags". This ensures that each cDNA molecule will give rise to only one "genetag", reducing the sequence complexity of the template population by an order of magnitude.
Preparation of GenetagTempIates
cDNA was synthesized using biotinylated-(dT)18 as the primer for first strand synthesis. Mice transgenic for the human E2F-1 gene, under the control of the bovine keratin 5 promoter, were maintained as heterozygotes. Epidermal keratinocyte cultures were derived from newborn mice carrying the transgene or from their wild type siblings as described. Total RNA was prepared by extraction into a chaotropic salt solution followed by organic solvent extraction using either a QIAGEN (Valencia, CA) or a GIBCO/BRL (Gaithersburg, MD) kit. Total RNA was used directly for Northern analyses. Alternatively, mRNA was prepared using a QIAGEN kit, and double-stranded cDNA was synthesized using biotinylated p(dT)ι as the primer for the first strand synthesis. cDNA was digested with Dpn II, the 3'-most Dpn II fragment of each cDNA was adsorbed to magnetic beads coated with streptavidin (Dynal, Lake Success, NY) and non-biotinylated fragments were washed from the beads. cDNA fragments still bound to the beads were ligated to the B-linker; then digested with Nla III; and fragments released from the beads by this treatment were selected and ligated to the A-linker. Double stranded linkers with overhangs complementary to the ends created by restriction with Nla III (A-linker) and Dpn II (B-linker) were prepared separately by mixing equal amounts of the following oligonucleotides: warming to 90°C for 2 min and slowly cooling to room temperature: A-linker - 5'-CGTCTAGACAGC (previously phosphorylated with T4 polynucleotide kinase) and 5'-GCTGTCTAGACGCATG; B-linker - 5' - CGGTGATGCATC and 5' - GATCGATGCATCACCG (previously phosphorylated with T4 polynucleotide kinase). Linkers (217 ng) were added to restricted cDNA fragments (initially 1.5 μg), warmed to 50°C for 2 min, cooled to room temperature for 15 min, then cooled on ice. Ligation was accomplished by adding 10 U T4 DNA ligase (GIBCO/BRL) and incubating in a final volume of 50 μL for 2h at 16°C. These fragments of cDNA, containing the gene-specific targets ligated to the B and A linkers, are referred to as B/A genetags. A second preparation, A/B genetags, is obtained when Nla III restriction and A-linker ligation preceded the Dpn II restriction and B-linker ligation. Also refer to FIG. 1.
The average gene specific target length is 128 bp, less than one-tenth the average mRNA length (2000 ntd). The scheme illustrated in FIG. 1 will not produce an amplifiable genetag from cDNAs in which there is no Nla III restriction site between the last Dpn II restriction site and the poly(A) tail. To analyze those genes, the inventors simply reverse the order in which the Dpn II and Nla III cuts are made. cDNAs that lack one or both enzyme recognition sites or in which the restriction sites are separated by less than 6 bp are refractory to this analysis. The inventors empirically found that this corresponds to about 5-10% of the transcriptome. To provide more specificity to the PCR™ reactions, COP primers were constructed containing the A-linker sequence (17 nucleotides) followed by 4 variable nucleotides (256 different primers) or the B-linker sequence (16 nucleotides) followed by 3 variable nucleotides (64 different primers). These primers can be combined pair- wise with the two orientations of genetags to produce (256 x 64 x 2) = 32,768 unique reactions. The presence of relatively long common regions in the COP primers allows near optimal amplification with all primers under a single set of PCR™ conditions. PCR™ reactions contained (in a total volume of 25 μL): genetags equivalent to 0.1 to 2 ng cDNA; 40 pg of each primer; 0.25 μL AmpliTaq (Perkin Elmer Co.); and lx "D" buffer (Epicentre Technologies, Madison WI). Reactions were run in a Stratagene RoboCycler with an initial denaturation of 5 min at 95°C, 2 min at 60°C and 1 min at 72°C followed by 26 cycles of 0.5 min at 95°C,1 min at 60°C and 1 min at 72°C. The final extension at 72°C was increased to 6 min. For cDNAs of known sequence, a single pair of primers that will amplify the gene-specific target in one genetag orientation can be predicted from the sequence.
Specificity of COP is demonstrated herein with examples of the genes Brcal, annexin III and 2C11B. As shown in FIG. 14, along the bottom of the gel, primers specific for Brcal (GenBank Accession No. U36475), annexin III (AJ001633), or 2C1 IB (UOl 139) were combined with B/A genetags and PCR™ amplification carried out for 27 cycles. PCR™ reactions contained (in a total volume of 25 μL): genetags equivalent to 0.1 to 2 ng cDNA, 40 pg of each primer, 0.25 μL AmpliTaq (Perkin Elmer Co.) and lx "D" buffer (Epicentre Technologies, Madison WI). Reactions were run in a Stratagene RoboCycler with an initial denaturation of 5 min at 95°C, 2 min at 60°C and 1 min at 72°C followed by 26 cycles of 0.5 min at 95°C, 1 min at 60°C and 1 min at 72°C. The final extension at 72°C was increased to 6 min. The reactions were analyzed on 8% polyacrylamide gels, stained with Vistra Green (Molecular Probes, Eugene, OR) and digitized fluorescent images were obtained with a Fluorlmager (Molecular Dynamics, Sunnyvale, CA). Arrows to the right indicate the expected molecular sizes of the three amplimers. Wedges above the lanes indicate increasing concentrations of template in the reactions (0.15 to 1.2 ng cDNA for annexin III specific reactions, 2 to 8 ng cDNA for Brcal- and 2C1 IB-specific reactions), no template controls; 'M', molecular size markers. The integrated intensity of the band corresponding in size to the expected amplimer was determined using ImageQuant software (Molecular Dynamics). For genetag concentrations in the linear range, the fluorescence intensity of the expected product increased exponentially with cycle number from 24-28 cycles.
To verify that the products were indeed those expected, the 291 bp Brcal amplimer was gel-purified and sequenced in both directions with the same primers used in the initial reaction. The experimentally determined sequence exactly matched the predicted sequence. To further validate the specificity of COP reactions, primers were selected for 9 other genes that varied widely in their expected expression levels and in the lengths of the predicted amplimers. Reaction products of the expected size were again gel-purified and sequenced. All 10 of the amplimers analyzed gave greater than 95% sequence identity to the expected product . These included the gene-specific targets of several high abundance, housekeeping genes, including ribosomal protein L5 and γ-actin, and also lower abundance genes, including transcription factors YY-1 and Genesis.
To detect changes in gene expression due to overexpression of E2F1, paired reactions were performed with genetag preparations derived from wild type or K5 E2F1 transgenic keratinocytes. Mice transgenic for the human E2F-1 gene under the control of the bovine keratin 5 promoter were maintained as heterozygotes. Epidermal keratinocyte cultures were derived from newborn mice carrying the transgene or from their wild type siblings as described. Total RNA was prepared by extraction into a chaotropic salt solution followed by organic solvent extraction using either a QIAGEN (Valencia, CA) or a GIBCO/BRL (Gaithersburg, MD) kit. Total RNA was used directly for Northern analyses. Alternatively, mRNA was prepared using a QIAGEN kit, and double-stranded cDNA was synthesized using biotinylated p(dT)ιg as the primer for first strand synthesis. The relative concentrations of wild type and transgenic genetags were adjusted to give approximately equal expression ratios for a set of control genes (ribosomal proteins L5 and SI 7, GAPDH, β-actin and γ-actin) whose expression was not expected to change significantly with E2F1 overexpression. In all, the inventors performed reactions for over 400 known murine genes, including genes previously shown to be regulated by E2F1 and other genes related to cell proliferation, apoptosis, transcriptional regulation and signal transduction. The inventors were able to detect the expected amplimers in reactions with 223 pairs of primers. The remaining genes may not be expressed in keratinocytes, or their expression levels may be below the detection limit of the COP technique. The amplimers produced by COP primers for several representative genes are shown in FIG. 15.
Eight genes previously shown to be transcriptionally regulated by E2F, Pierce et al, 1998a; Johnson ad Schneider-Broussard, 1998; Slansky and Farnham, 1996;
Bates et al, 1998, were analyzed first. Replicate, paired analyses for 2 of these E2F1- inducible genes, cyclin E and cdc2, as well as analyses of a control gene, β-actin, are shown in FIG. 16. While production of the β-actin-specific amplimer was identical with the wild-type and transgenic templates, the cdc2-specific amplimer was about 2- fold more abundant in transgenic keratinocytes and the cyclin E-specific amplimer was increased about 5-fold. The 5-fold increase in expression of cyclin E seen here agrees well with a previous determination by Northern hybridization, Pierce et al,
1998a, (~6-fold). Recent studies have shown an upregulation of the ARF mRNA product of the Cdkn2a locus by E2F1 overexpression, and implicated this induction in E2Fl-induced, p53-mediated apoptosis, Bates et al, 1998; Zindy et al, 1998; deStanchina et al, 1998. COP analyses indicated at least a 3-fold induction of
Cdkn2a/pl9ΛKF in the transgenic keratinocytes (FIG. 15, lane 7; Table 8). In all, six of the eight known E2F1 -target genes exhibited 2-5-fold increases in steady-state expression in E2F1 transgenic keratinocytes (Table 8), while two more targets changed less than 2-fold. In addition, several other cell-cycle related genes, including Ccnb2, the cyclin activating kinase Cdkl and Ode were upregulated 3 -6-fold in the transgenic keratinocytes. Increased expression of the genes for several transcription factors (Hfh2 & Yyl) and the Brcal tumor suppressor gene, genes not known to be E2F1 -regulated, was also seen; several of these are illustrated in FIG. 15. The Brcal gene has been shown to be cell cycle regulated, Vaughn et al, 1996; Gudas et al, 1996, and potential E2F sites are present in the Brcal promoter. Evidence for cell cycle regulation of Cdk7 expression in frbroblasts has recently been presented, Iyer et al, 1999. Three of the known downstream targets for p53 transactivation, cyclin G, Bax-α and MDM2 (Levine, 1997), were also expressed at higher levels (2-4-fold increased) in E2F1 transgenic keratinocytes (Table 8). A fourth target of p53, p21, was unchanged in the transgenic cells and GADD45 was among the 10% of the genome that could not be assayed.
To confirm the magnitude of changes in expression seen with the COP technique, we compared the expression of several selected genes between wild-type and transgenic keratinocytes by Northern analyses. While the expression of Actg, the gene for g-actin, was approximately equal in wild type and transgenic keratinocytes, the genes for Cdc2 and Cdkn2a/pl9ARF were upregulated by E2F1 overexpression (FIG. 17 A), in good agreement with the COP results (FIG. 15 and FIG. 16, Table 8). Expression ratios were determined for 9 genes by both COP and Northern analyses, and the ratios were plotted as a scattergram (FIG. 17B). The data were well-fit by a straight line with slope close to 1.0, indicating a high degree of concordance between the two techniques. TABLE 8. DETERMINATION OF GENE EXPRESSION CHANGES BY COP
The expression ratio is calculated as the band intensity seen with the transgenic template divided by the intensity seen with a paire reaction using wild type template. The statistical significance of alterations in this ratio for each gene in the first two groups compared to t expression ratio seen for the control genes was evaluated using unpaired t-tests. The differences were significant at the p<0.01 level for all gen listed with the exception of Ccna.
E2F Target Genes Other Genes D53 Target Genes Control Genes
Gene Expression Ratio Gene Expression Ratio Gene Expression Ratio Gene Expression Ratio
Ccne 5.1 ± 1.0 Ccnb2 6.4 ± 4.1 Ccng 2.3 ± 0.5 Actb 1.1 ± 0.2
Cdkn2a 2.7 ± 0.6 Hflι2 4.9 ± 3.3 Box 2.0 ± 0.7 Rpsiγ 1.1 ± 0.1
Tkl 2.6 ± 1.2 Vegf 3.7 ± 1.7 Mdm.2 2.0 ± 0.2 Gapd 1.0 ± 0.1
Polai 2.4 ± 0.4 Ode 3.6 ± 1.0 Cdknia 1.4 ± 0.2 Hmgi4 0.9 ± 0.1
Cdc2 2.4 ± 0.9 Yyi 3-i ± 1-8 Lmna 1.1 ± 0.2
Mybl2 2.1 ± 0.2 Cdkγ 3.1 ± 0.3 Actg 1.1 ± 0.2
Myc 1.4 ± 0.2 Brcal 2.6 ± 1.0 Rpl5 1.0 ± 0.2
Ccna2 1.1 ± 0.1 Caspγ 2.4 ± 1.5 Casp 8 2.1 ± 0.3
COP analyses can also be conducted using tissue samples from experimental animals. To prepare mouse epidermal RNA, adult mice were sacrificed and dorsal skin was dissected, heated to 55°C in DEPC-treated H2O for 30 s, and cooled to 40°C for 30 s. Skin samples were placed epidermal side down in 5 ml Trizol (GIBCO/BRL) for 30 s, and the epidermal layer was then scraped into the Trizol with the edge of a glass microscope slide. RNA extraction proceeded as described above. RNA was prepared from the epidermis of wild type and E2F1 transgenic mice, and either used in Northern analyses or to prepare genetags for COP analysis. As shown in FIG. 18A and FIG. 18B, COP analysis indicated a dramatic upregulation of expression of several genes, including Ode, Ccng, and Cdkn2a/pl9ARF, due to overexpression of the E2F1 transgene, in both newborn keratinocytes and adult epidermis. The increase in Cdkn2a/pl9ARF was particularly striking, and this induction was confirmed by Northern analyses (FIG. 18C).
The expected effects of CDK7, Brcal and pW^1" on p53 are indicated in the model of FIG. 19. Each has the potential to increase p53 activity by an independent post-translational mechanism, and therefore indicating that they may cooperate in p53 upregulation. Indeed, three downstream targets of p53, cyclin G, Bax-α and Mdm-2, are all modestly unregulated in the transgenic keratinocytes, while a fourth target- gene involved in growth arrest, p21, is unaffected. This indicates that not only is p53 activity increased, but it is increased in a differential manner, with some downstream targets induced more than others. Several p53 mutants are known in which the effect of p53 on apoptosis and growth arrest are uncoupled, Ludwig et al, 1996; Rowan et al. 1996; Friedlander et al, 1996; Aurelio et al, 1998, providing a precedent for the possibility of differential regulation.
Overexpression of E2F1 in mouse fibroblasts leads to pl9ARF mediated apoptosis, Zindy et al, 1998; deStanchina et al, 1998; Bates et al, 1998, and Brcal overexpression has also been linked to p53-dependent apoptosis, Zhang et al, 1998; Shao et al, 1996. The E2Fl-mediated transcriptional effects on genes that modulate p53 activity and on downstream targets of p53 may be manifested as an increased propensity of the transgenic keratinocytes to enter apoptosis in response to other stimuli. This is consistent with the finding of areas of increased apoptosis in the epidermis of the transgenic mice, and the fact that apoptosis is reduced in a p53 null backgrounds, Pierce et al, 1998. Interestingly, while K5 E2Fl/p53 null mice have an increased incidence of spontaneous skin tumors, the single transgenics are resistant to chemical carcinogenesis in the skin (Johnson et al, in preparation). It will be of interest to determine whether cells "initiated" by a chemical carcinogen in K5 E2F1 mice are more susceptible to elimination by apoptosis than their wild type counteφarts.
EXAMPLE 3
Gene Discovery by COP As noted above, each COP reaction has the potential to amplify several genes, and many non-targeted amplimer bands were noted in the course of these studies (see for example reaction 7 in FIG. 15). Five non-targeted amplimer bands that exhibited changes in expression greater than three-fold in transgenic keratinocytes were identified (Table 9), and these amplimers were sequenced. Two amplimer sequences matched several ESTs, exemplified by AA245406 for EIG-1 and AV076207 for EIG- 5. Subsequent to sequencing of EIG-2, an apoptosis-related gene, AIP1 (Vito et al, 1999) was described (AF119955) that contains a sequence 99% identical to EIG-2. EIG-3 and -4 had no matches in GenBank.
TABLE 9. EXPRESSION CHANGES IN NON-TARGET GENES
Gene COP Primers Amplimer Expression Database
Length Ratio Match
EIG-1 CATGGGG 147 3.6 EST AA24506 GATCCAG
EIG-2 CATGCGCA 167 18.1 AJ005073 (partial GATCTGA match) TABLE 9 (CONTINUED)
EIG-3 CATGCTTT / 95 3.6 No match GATCCTG
EIG-4 CATGGCCA 157 6.1 No match GATCTTC
EIG-5 CATGATTT 132 EST AV076207 GATCAGC
EXAMPLE 4
Differential Gene Expression After Carcinogen Treatment
Previous studies have shown that several important transcription factors, including Spl, E2F1 and E2F4, bind in vitro with high affinity to DNA that has been damaged by the carcinogen BPDE (Butler, 1997; Johnson, 1997; MacLeod, 1995; MacLeod, 1996; MacLeod, 1996). The data suggest that many transcription factors may behave similarly and that this may cause disruption of normal mechanisms that regulate gene expression shortly after carcinogen treatment. Indeed, disruption of Spl dependent transcription by BPDE-damaged DNA has been directly demonstrated in cell cultures transfected with damaged DNA (Butler, 1997). Very little is known about changes in gene expression that follow treatment of cells with BPDE. COP analysis has therefore been applied to an experimental system derived from normal human mammary tissue.
Cultures of the HME87 line of normal human mammary epithelial cells were treated for 30 min with the ultimate carcinogen BPDE (±7r,8t-dihydroxy-9,10t-epoxy- 7,8,9, 10-tetrahydro-benzo[a]pyrene, ChemSyn Laboratories, Lenexa, KS) in MEBM (Clonetics, San Diego, CA); the carcinogen was dissolved in tetrahydrofuran and the final concentration of tetrahydrofuran in the medium was 0.3%. Control cultures were treated with tetrahydrofuran only. The treatment with BPDE is not demonstrably toxic for at least 48 h, but induces a high level of DNA damage in the treated cells. After treatment, the cells were returned to growth medium (MEGM) and held under normal growth conditions (37°C, 1.7% CO2) for 4, 10 or 24 h before harvesting RNA. Preparation of mRNA, cDNA and genetags proceeded as described for SKBR3 cells. For each gene of interest, duplicate, paired PCR™ reactions were performed with appropriate primers and genetags from either control or BPDE-treated cultures. For selected genes, a total of at least 4 determinations were made since power calculations give this as the minimum number of determinations needed to reliably detect 2-fold differences in expression.
A total of over 450 genes have been analyzed at one or more time points in this system. The majority of the genes analyzed showed no significant changes in expression. Data for several control genes that were not expected to change (genes for ribosomal proteins, structural proteins, housekeeping enzymes) are given in Table 10. In addition, several transcription factors were assayed that did not demonstrate BPDE-related changes (Table 10 CEBPE, c-myc, BTF3, SL1, p53). Although p53 activity often increases in response to DNA damage, this is normally post-transcriptionally modulated and changes in the expression of the p53 gene are not expected.
TABLE 10.
UNCHANGED GENE EXPRESSION AFTER CARCINOGEN TREATMENT
Gene E/C 4 h E/C lO h E/C 24 h
RPS27 0.9 ± 0.3 1.2 ± 0.4 0.9 ± 0.2
RPS15a 1.0 ± 0.3 1.4 ± 0.6 1.2 ± 0.3
RPS7 1.1 ± 0.2 1.4 ± 0.5 1.7 ± 0.8
RPL35 1.2 ± 0.3 1.1 ± 0.4 1.2 ± 0.6
RPS26 1.2 ± 0.3 1.3 ± 0.5 1.5 ± 0.6
RPS29 1.1 ± 0.2 1.3 ± 0.6 1.7 ± 1.2
RPP1 1.4 ± 0.1 1.0 ± 0.4 1.7 ± 1.0
RPS16 - 0.8 ± 0.1 0.9 ± 0.2
RPL23a 0.6 ± 0.1 1.1 ± 0.3 1.0 ± 0.2
RPL30 0.8 ± 0.1 1.0 ± 0.1 1.0 ± 0.2
ACTB 1.1 ± 0.2 0.9 ± 0.2 1.3 ± 0.4
LMNA 0.7 ± 0.2 1.1 ± 0.3 0.9 ± 0.3
PGK - 1.0 ± 0.2 1.1 ± 0.2
IMPD - - 0.8 ± 0.2
CEBPE 0.9 ± 0.3 - 1.0 ± 0.3
MYC - - 1.2 ± 0.5 TABLE 10 (CONTINUED)
BTF3 1.0 ± 0.2 0.9 ± 0.2
NFKB - 1.5 ± 0.4
SL1 - 1.0 ± 0.3
TP53 1.1 ± 0.4 0.9 ± 0.1 0.8 ± 0.3
TABLE 11.
GENE EXPRESSION CHANGES AFTER CARCINOGEN TREATMENT
Gene E/C 4 h E/C lO h E/C 24 h
ATF3 7.8 ± 4.0 9.2 ± 3.9 2.4 ± 0.7 p21 1.0 ± 0.1 1.1 ± 0.2 2.3 ± 0.7
GADD45 2.1 ± 0.7 1.9 ± 0.7 0.8 ± 0.4
Beclin 2.1 ± 1.4 2.0 ± 1.1 -
Data for several genes whose expression did change at one or more time points is listed in Table 11 with two prominent examples shown in FIG. 20. The most dramatic change was in the expression of the transcription factor ATF3, which increased 8-9 fold at 4 and 10 h, then dropped to a 2.4-fold increase at 24 h. Changes in ATF3 expression in response to damage induced by BPDE or related compounds have not previously been described, and it will be very interesting to determine both the mechanism and the consequences of this induction. The p21/WAFl gene, a downstream target of p53, is a mediator of Gl arrest in response to DNA damage (Levine, 1997). Interestingly, it is not induced at early times after BPDE treatment, but does increase about 2-fold at 24 h. Parallel measurements of cell cycle parameters in these cells have indicated that there is no Gl arrest at 4 and 10 h after BPDE treatment, but there does appear to be a Gl arrest by 24 h. The genes for several other interesting proteins, a transcription factor CP2, and a protein related to apoptosis (beclin), are also upregulated at one or more time points. Thus, the COP analyses performed in this system have given a variety of clues concerning mechanisms operative in cells soon after BPDE treatment. The COP technique has proven to be of great utility in these studies. It provides expression information on selected genes that is reliable and semi-quantitative. The technique can be performed at a relatively low cost and with a high degree of flexibility. Simultaneously, information on non-targeted genes is obtained giving the possibility of identifying novel genes whose expression changes in the system being analyzed. By sequencing the novel amplimer enough information is generally obtained (the average gene specific target length is about 128 bp) to design primers that allow the entire cDNA to be obtained. The sets of genes target for analysis can easily be altered based on the results of initial studies with multiple time points or dose regimens. Indeed, COP may have utility as a complement to SAGE or microarray methods. Initial screens by these techniques can provide a focused set of genes that can then be studied in detail by COP in a cost-effective manner. The set of reagents that must be maintained for COP analyses (256 A-end primers and 64 B-end primers) is fairly small, can be generated easily by synthetic methods, and is the same for all species. This contrasts with microarray technologies where much larger sets of clones must be maintained, or even larger sets of oligonucleotides must be designed and tested, and where each set of reagents is species-specific. The inventors are currently working on ways to speed up the analyses of the amplimers, possibly allowing COP to be performed in a high-throughput mode in which the entire transcriptome could be analyzed in a short period of time.
All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims. REFERENCES
The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incoφorated herein by reference.
Adams et al, Nat Genet, 4:373-80, 1993
Alwine et al, Proc Natl Acad Sci USA., 74:5350-4, 1977.
Ardrey, Electrospray Mass Spectrometry, Spectroscopy Europe, 4, 10-18 (1992).
Aurelio et al, Cancer Res., 58:2190-5, 1998. Bates et al, Nature, 395:124-125, 1998.
Bauer et al, Nucleic Acids Res., 21 :4272-80, 1993
Berkenkamp et al, Science, 281 :260-2, 1998
Bertioli et al, Nucleic Acids Res., 23:4520-3, 1995
Butler et al, Carcinogenesis 18, 239-244, 1997. Crain, Mass Spectrometry Reviews, 9: 505-554, 1990.
DE 43 17 414
DeRisi, et al, Nature Genetics, 14:457-460, 1996. deStanchina et al, Genes Dev., 12:2434-2442, 1998.
Effenhauser, et al Anal Chem., 66:2949-2953, 1994. Effenhauser, et al. Anal. Chem., 65:2637-2642, 1993.
EP No. 320,308
EP No. 329,822
Fenn et al, J. Phys. Chem. 88, 4451-59, 1984.
Fodor et α/., Nature, 364:555-556, 1993.. Forster, 1948. Ann. Phys. 2, 55-75
Friedlander, et al, Mol Cell Biol 16:4961-71, 1996.
Freifelder, Physical Biochemistry Applications to Biochemistry and Molecular Biology, 2nd ed. Wm. Freeman and Co., New York, NY, 1982.
Frohman, In: PCR Protocols: A Guide To Methods And Applications, Academic Press, N.Y., 1990.
Gazdar, et al, Int. J. Cancer, 78:766-74, 1998.
GB 2,202,328
Gudas et al, Cell Growth Differ., 7:717-723, 1996. Habu, et al. Biochem Biophys Res Commun. 234(2):516-21, 1997.
Hacia, et al, Nature Genet, 14:441-449, 1996.
Harrison et al, Science, 261 :895-897, 1993.
Hedrick et al, Nature, 308:153-8 1984. Higuchi et al, Biotechnology 10:413-417 1992
Hillenkamp et al. "Matrix Assisted UV-Laser Desoφtion/Ionization: A New Approach to Mass Spectrometry of Large Biomolecules," in Biological Mass Spectrometry eds. Burlingame and McCloskey, Elsevier Science Publishers, Amsterdam, pp. 49-60, 1990. Holmstrom et al, Anal. Biochem. 209:278-283, 1993.
Hsieh et β/., Genes Dev., 11 :1840-1852, 1997.
Ito et al., FEBSLett,351 :231-6, 1994.
Iyer et al, Science, 283:83-87, 1999.
Jacobson, et al, Anal. Chem., 66:1107-1113, 1994 Johnson, et al., Frontiers in Bioscience, 3:447-458, 1998.
Johnson et al, Carcinogenesis 20, 216-223, 1997
J.P. No. 59-131909
Kamijo et al, Proc. Nat'lAcad. Sci. USA, 95:8292-8297, 1998.
Koster et al. Biomedical Environmental Mass Spectrometry 14: 111-116 (1987). Kwoh et al, Proc. Nat. Acad. Sci. USA, 86: 1173, 1989
Levine, Cell, 88:323-331, 1997.
Liang and Pardee, Science, 257:967-71, 1992.
Liang et al. , Nucleic Acids Res 21 :3269-75, 1993.
Lockhart, et al. Nature Biotech., 14:1675-1680, 1996. Lu, et al, Mol Cell. Biol, 17:5923-5934, 1997.
Ludwig et α/., Mol Cell Biol., 16(9):4952-60, 1996.
Manz, et al, ,J. Chromatogr., 593:253-258, 1992.
MacLeod et al, Carcinogenesis 16, 975-983, 1995.
MacLeod Mol. Carcinogenesis 15, 241-250, 1996. MacLeod et al, Mol. Carcinogenesis 16, 44-52, 1996
Methods in Enzymology, Vol. 193: "Mass Spectrometry" (McCloskey, ed.), Academic Press, New York, 1990.
Newton, et al. Nucl Acids Res. 21 :1155-1162, 1993. Ohara et al, Proc. Nat'l Acad. Sci. USA, 86:5673-5677, 1989.
Okubo et al, Nat Genet., 2: 173-9. 1992.
Ouchi, et tf/., røc. Nat'l Acad. Sci. USA, 95:2302-2306, 1998.
PCT/US87/00880 PCT/US89/01025
Pease et al, Proc. Natl Acad. Sci. USA, 91 :5022-5026, 1994.
Phillips, et al, Genes Dev., 11 :1853-1863, 1997.
Pierce, et al, Proc. Nat'l Acad. Sci. USA, 95:8858-8863, 1998b.
Pierce, et al, Oncogene, 16:1267-1276, 1998a. Pomerantz, et al, Cell, 92:713-723, 1998.
Putney et al, Nature, ;302: 718-21. 1983.
Rasmussen, et al, Anal. Biochem, 198:138-142, 1991.
Rowan et al. EMBO J., 15:827-38, 1996.
Running. J. A. et al, BioTechniques 8:276-277, 1990. Sambrook et al, "Molecular Cloning," A Laboratory Manual, 2d Ed., Cold Spring
Harbor Laboratory Press, New York, 13.7-13.9:1989.
Schena, et al, Science, 270:467-470, 1995. Methods Biochem Anal, 34: 203-287 1990.
Shimkets et al, Nat Biotechnol. 17:798-803, 1999. Shoemaker et al. , Nature Genetics 14:450-456, 1996.
Slansky and Famham, In: Current Topics in Microbiology and Immunology, Transcriptional Control of Cell Growth: The E2F Gene Family, P. Famham (ed.), Springer-Verlag, Berlin, 208:1-30, 1996.
Smith et al, Anal. Chem. 62, 882-89, 1990. Song and Osborn, Plant Mol Biol. 26:1065-71. 1994.
Stone and Wharton, Nucleic Acids Res., 22:2612-8, 1994.
Tsuda et α/., Anal. Chem., 62:2149-2152, 1990.
U.S. Patent No. 5,904,824
U.S. Patent No. 5,856,174 U.S. Patent No. 5,866,330
U.S. Patent No 5,843,651.
U.S. Patent No.5,610,287
U.S. Patent No. 5,599,668 U.S. Patent No 5,424,186
U.S. Patent Nos. 5,304,487
U.S. Patent Nos 5,296,375
U.S. Patent Nos. 5,143,854 U.S. Patent Nos. 4,683,194
U.S. Patent No. 4,683,195,
U.S. Patent No. 4,683,202
U.S. Patent No. 4,800,159
U.S. Patent No. 4,883,750 Vaughn et al, Cell Growth Differ. , 7:711-715, 1996.
Velculescu, et al, Science, 270:484-487, 1995.
Velculescu, et al, Cell, 88:243-251, 1997.
Veres, et al. Science 1987 Jul 24;237(4813):415-7, 1987
Vito, et al, Science, 271 :521-525, 1996. Vito, et al, J. Biol Chem., 274:1533-40, 1999.
Wang and Feuerstein, Biotechniques, 18:448-53, 1995.
Williams et al, Science, 246: 1585-87, 1989
Woolley and Mathies, Proc Natl Acad Sci USA, 9\ :\ 1348-52, 1994
WO 94/05414 WO 93/18176
WO 90/14148
WO 90/07641
WO 89/06700
WO 88/10315 Wu et al, Genomics, 4:560-569; 1989.
Ying, et al, BioTechniques, 27:410-414; 1999.
Zhang et al, Oncogene, 16:1713-1721, 1998.
Zhang, et al, Science, 276:1268-1272, 1997.
Zhang, et al, Cell, 92:725-734, 1998a. Zindy et al, Genes Dev., 12:2424-2433, 1998.
Zinn et α/, Cell, 34(3):865-79. 1983

Claims

CLAIMS:
1. A method comprising: a) obtaining a DNA comprising an anchorable moiety; b) cleaving said DNA with a first restriction endonuclease; c) ligating a linker molecule to said DNA; d) immobilizing the DNA fragment that includes said anchorable moiety to an anchor; e) cleaving said immobilized DNA from said anchor with a second restriction endonuclease; f) ligating a second linker molecule to said cleaved DNA; g) amplifying said ligated DNA.
2. The method of claim 1, wherein said DNA is immobilized prior to cleaving with said first endonuclease.
3. The method of claim 1, wherein said DNA is non-genomic DNA.
4. The method of claim 1, wherein said DNA is cDNA.
5. The method of claim 1, wherein said anchorable moiety comprises a means of adhering.
6. The method of claim 5, wherein said means of adhering comprises a means of establishing a non-covalent interaction.
7. The method of claim 5, wherein said means of adhering comprises a means of establishing a covalent interaction.
8. The method of claim 5, wherein said means of adhering comprises a ligand.
9. The method of claim 5, wherein said means of adhering is biotin.
10. The method of claim 5, wherein said means of adhering comprises an antibody.
11. The method of claim 1 , wherein said anchorable moiety is located at the 3 ' end.
12. The method of claim 4, wherein said cDNA is reverse transcribed from messenger RNA.
13. The method of claim 12, wherein said reverse transcription is initiated at an oligo dT.
14. The method of claim 12, wherein said reverse transcription is initiated at a random hexamer.
15. The method of claim 13 , wherein said oligo dT is biotinylated.
16. The method of claim 13 wherein said cDNA is immobilized on a substrate by means of said biotinylated oligo dT.
17. The method of claim 16, wherein said substrate is streptavidin.
18. The method of claim 1, wherein the order of said first and said second restriction endonucleases is reversed.
19. The method of claim 1, wherein said amplification is initiated at primers comprising a sequence complementary to said first and said second linkers respectively.
20. The method of claim 1, wherein said ligated DNA is amplified with a primer set comprising: a) a first amplification primer, wherein the 5' sequence of said primer is complementary to said first linker sequence and the 3' sequence comprises a specificity region; b) a second amplification primer, wherein the 5' sequence of said primer is complementary to said second linker sequence and the 3' sequence comprises a specificity region.
21. The method of claim 20, wherein said amplification is performed with an array of combinations of alternate amplification primers.
22. The method of claim 20 wherein said DNA fragment is preamplified.
23. The method of claim 1 , further comprising, identifying the amplified DNA.
24. The method of claim 23, wherein said identification is based upon length.
25. The method of claim 23, wherein said identification is performed by a computer program.
26. The method of claim 21 , wherein said array of amplifications is performed in a multi-well plate.
27. The method of claim 20, wherein the specificity region of the primers of the first primer set is 3,4,5,6,7 or 8 base pairs long.
28. The method of claim 20, wherein the specificity region of the primers of the second primer set is 3,4,5,6,7 or 8 base pairs long.
29. The method of claim 1, wherein said amplification comprises polymerase chain reaction, nucleic acid sequence based amplification, transcription mediated amplification, strand displacement amplification or ligase chain reaction.
30. The method of claim 1, wherein said first restriction endonuclease has a four base pair recognition site.
31. The method of claim 1, wherein said first restriction endonuclease has a recognition site of five, six, seven or eight base pairs.
32. The method of claim 30, wherein said first restriction endonuclease is Nlalll, Dpnll, Sau3AI, Hsp92II, Mbol, Ndell, Bspl431, Tsp509 I, Hhal, HinPlI, Hpall, Mspl, Taqalphal, Maell or K2091.
33. The method of claim 1, wherein said second restriction endonuclease has a four base pair recognition site.
34. The method of claim 1, wherein said second restriction endonuclease has a recognition site of five, six, seven or eight base pairs.
35. The method of claim 33, wherein the restriction endonuclease is Nlalll, Dpnll, Sau3AI, Hsp92II, Mbol, Ndell, Bspl431, Tsp509 I, Hhal, HinPlI, Hpall, Mspl, Taqalphal, Maell or K2091.
36. The method of claim 1, wherein a label is incoφorated into said amplified DNA.
37. The method of claim 36, wherein said label is incoφorated by means of a labeled primer.
38. The method of claim 36, further comprising, partial nucleotide sequence identification of the amplified products by the identity of the label.
39. The method of claim 36, wherein said label is a chromophore.
40. The method of claim 36, wherein said label is a fluorophore.
41. The method of claim 36, wherein said label is an affinity label.
42. The method of claim 36, wherein said label is a dye.
43. The method of claim 37, wherein the 5' end of said primer comprises an amino moiety and a flurophore is covalently attached by the reaction of a succinimido ester of the flurophore to the 5' amino-modified primer.
44. The method of claim 40, wherein said fluorophore is Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G,
BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy2, Cy3, Cy5,6-FAM, Fluorescein, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, ROX, TAMRA, TET, Tetramethylrhodamine, and Texas Red.
45. The method of claim 1 , wherein the products of said amplification are analyzed.
46. The method of claim 45, wherein said analysis of amplification products is by polyacrylamide gel electrophoresis.
47. The method of claim 45,wherein said analysis of amplification products is by capillary gel electrophoresis.
48. The method of claim 45, wherein said analysis of amplification products is by mass spectrophotometry.
49. The method of claim 45, wherein said analysis of amplification products is by energy transfer.
50. The method of claim, 45, wherein said analysis of amplification products is by the BioStar technology.
51. The method of claim 45, wherein said analysis of amplification products is by the Luminex technology.
52. The method of claim 45, wherein said analysis of amplification products comprises quantifying amplification products.
53. The method of claim 52, wherein said quantifying is by measuring the ratio of each amplified product to a co-amplified reference-gene.
54. The method of claim 52, wherein said quantifying is by measuring the ratio of each amplified product to a panel of co-amplified reference-genes.
55. The method of claim 52, wherein said analysis of amplification products is by Real-Time PCR.
56. The method of claim 45, wherein said analysis of amplification products is performed in a multi-well plate.
57. The method of claim 45, wherein said analysis of amplification products is performed on a membrane.
58. The method of claim 45, wherein said analysis of amplification products is performed on a solid matrice.
59. The method of claim 58, wherein said solid matrice is a DNA chip.
60. The method of claim 1 , performed on DNA derived from a normal cell or tissue and on DNA derived from a different cell or tissue.
61. The method of claim 1 , performed on DNA derived from a normal cell or tissue and on DNA derived from a cancerous cell or tissue.
62. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a pharmaceutical compound.
63. The method of claim 1 , performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a teratogenic compound.
64. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a carcinogenic compound.
65. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a toxic compound.
66. The method of claim 1 , performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a biological response modifier.
67. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a hormone, a hormone agonist or a hormone antagonist.
68. The method of claim 1, performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a cytokine.
69. The method of claim 1 , performed on DNA derived from a normal cell or tissue and on DNA derived from a cell or tissue treated with a growth factor.
70. The method of claim 1 , performed on DNA derived from a normal cell or tissue and on the DNA derived from a cell or tissue treated with the ligand of a known biological receptor.
71. The method of claim 1 , performed on DNA derived from a cell or tissue type obtained from a different species.
72. The method of claim 1 , performed on DNA derived from a cell or tissue type obtained from a different organism.
73. The method of claim 1, performed on DNA derived from a cell or tissue at different stages of development.
74. The method of claim 1, performed on DNA derived from a normal cell or tissue and on the DNA derived from a cell or tissue that is diseased.
75. The method of claim 1 , performed on DNA derived from a cell or tissue cultured in vitro under different conditions.
76. The method of claim 1 , performed on the DNA derived from a cell or tissue from two organisms of the same species with a known genetic difference.
77. A kit for detection of gene expression comprising: a) a first restriction enzyme; b) a second restriction enzyme; c) a first, ligatable, oligonucleotide tag; d) a second, ligatable, oligonucleotide tag; e) a first amplification primer, wherein the 5' sequence of said primer is complementary to said first linker sequence and the 3 ' sequence comprises a specificity region; f) a second amplification primer, wherein the 5' sequence of said primer is complementary to said second linker sequence and the 3' sequence comprises a specificity region; g) software capable of analyzing data generated from said kit.
78. The kit of claim 77, wherein said first restriction endonuclease is a four base pair cutter.
79. The kit of claim 78, wherein said first restriction endonuclease is Nlalll, Dpnll, Sau3AI, Hsp92II, Mbol, Ndell, Bspl431, Tsp509 I, Hhal, HinPlI,
Hpall, Mspl, Taqalphal, Maell or K2091.
80. The kit of claim 77, wherein said second restriction endonuclease is a four base pair cutter.
81. The kit of claim 80, wherein said second restriction endonuclease is Nlalll,
Dpnll, Sau3AI, Hsp92II, Mbol, Ndell, Bspl431, Tsp509 I, Hhal, HinPlI, Hpall, Mspl, Taqalphal, Maell or K2091.
82. The kit of claim 77, wherein said first primer set comprises the sequence
GCTGTCTAGACG (SEQ ID NO:l).
83. The kit of claim 77, wherein said second primer set comprises the sequence CGGTGATGCATC (SEQ ID NO:2).
84. The method of claim 1, wherein said anchorable moiety is located at the 5' end.
PCT/US2000/028076 1999-10-08 2000-10-06 Combinatorial oligonucleotide pcr: a method for rapid, global expression analysis WO2001027329A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002386410A CA2386410A1 (en) 1999-10-08 2000-10-06 Combinatorial oligonucleotide pcr: a method for rapid, global expression analysis
EP00970778A EP1259641A2 (en) 1999-10-08 2000-10-06 Combinatorial oligonucleotide pcr: a method for rapid, global expression analysis
AU80106/00A AU8010600A (en) 1999-10-08 2000-10-06 Combinatorial oligonucleotide pcr: a method for rapid, global expression analysis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/414,847 1999-10-08
US09/414,847 US6221600B1 (en) 1999-10-08 1999-10-08 Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis

Publications (2)

Publication Number Publication Date
WO2001027329A2 true WO2001027329A2 (en) 2001-04-19
WO2001027329A3 WO2001027329A3 (en) 2002-09-12

Family

ID=23643235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/028076 WO2001027329A2 (en) 1999-10-08 2000-10-06 Combinatorial oligonucleotide pcr: a method for rapid, global expression analysis

Country Status (5)

Country Link
US (2) US6221600B1 (en)
EP (1) EP1259641A2 (en)
AU (1) AU8010600A (en)
CA (1) CA2386410A1 (en)
WO (1) WO2001027329A2 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008461A2 (en) * 2000-07-21 2002-01-31 Global Genomics Ab A METHOD AND AN ALGORITHM FOR mRNA EXPRESSION ANALYSIS
WO2002059359A2 (en) * 2001-01-24 2002-08-01 Syngenta Participations Ag Method for non-redundant library construction
WO2003064689A2 (en) * 2002-01-29 2003-08-07 Global Genomics Ab Methods for identifying polyadenylation sites and genes thereof
WO2008098142A2 (en) 2007-02-08 2008-08-14 Sequenom, Inc. Nucleic acid-based tests for rhd typing, gender determination and nucleic acid quantification
EP2112229A2 (en) 2002-11-25 2009-10-28 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
EP2236623A1 (en) 2006-06-05 2010-10-06 Cancer Care Ontario Assessment of risk for colorectal cancer
WO2010115016A2 (en) 2009-04-03 2010-10-07 Sequenom, Inc. Nucleic acid preparation compositions and methods
EP2243834A1 (en) 2007-03-05 2010-10-27 Cancer Care Ontario Assessment of risk for colorectal cancer
WO2011056688A2 (en) 2009-10-27 2011-05-12 Caris Life Sciences, Inc. Molecular profiling for personalized medicine
WO2012055069A1 (en) 2010-10-27 2012-05-03 Capitalbio Corporation Luminophore-labeled molecules coupled with particles for microarray-based assays
US8206926B2 (en) 2008-03-26 2012-06-26 Sequenom, Inc. Restriction endonuclease enhanced polymorphic sequence detection
WO2013128204A1 (en) * 2012-03-02 2013-09-06 The Babraham Institute Method of identifying vdj recombination products
EP2759603A1 (en) 2013-01-29 2014-07-30 ArticDx Inc. Method for determining a therapeutic approach for the treatment of age-related macular degeneration (AMD)
US8846924B2 (en) 2003-07-02 2014-09-30 Atto-Tec Gmbh Sulfonamide derivatives of polycyclic dyes used for analytical applications
US9051608B2 (en) 2006-12-05 2015-06-09 Agena Bioscience, Inc. Detection and quantification of biomolecules using mass spectrometry
US9605313B2 (en) 2012-03-02 2017-03-28 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9803236B2 (en) 2010-08-06 2017-10-31 Tsinghua University Microarray-based assay integrated with particles for analyzing molecular interactions
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US9926593B2 (en) 2009-12-22 2018-03-27 Sequenom, Inc. Processes and kits for identifying aneuploidy
EP3301446A1 (en) 2009-02-11 2018-04-04 Caris MPI, Inc. Molecular profiling of tumors
US10167499B2 (en) 2013-12-05 2019-01-01 Capitalbio Technoloogy Corporation Luminophore-labeled molecules coupled with particles for microarray-based assays
US10612086B2 (en) 2008-09-16 2020-04-07 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US10662421B2 (en) 2006-05-31 2020-05-26 Sequenom, Inc. Methods and compositions for the extraction and amplification of nucleic acid from a sample
WO2020113237A1 (en) 2018-11-30 2020-06-04 Caris Mpi, Inc. Next-generation molecular profiling
US10738358B2 (en) 2008-09-16 2020-08-11 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US11060145B2 (en) 2013-03-13 2021-07-13 Sequenom, Inc. Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus
US11332791B2 (en) 2012-07-13 2022-05-17 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US11365447B2 (en) 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11842805B2 (en) 2019-12-02 2023-12-12 Caris Mpi, Inc. Pan-cancer platinum response predictor
US11952569B2 (en) 2020-04-15 2024-04-09 Sequenom, Inc. Methods and compositions for the extraction and amplification of nucleic acid from a sample

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382386A3 (en) * 1992-02-19 2004-12-01 The Public Health Research Institute Of The City Of New York, Inc. Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids
US5710000A (en) * 1994-09-16 1998-01-20 Affymetrix, Inc. Capturing sequences adjacent to Type-IIs restriction sites for genomic library mapping
US6048734A (en) 1995-09-15 2000-04-11 The Regents Of The University Of Michigan Thermal microvalves in a fluid flow method
US6143496A (en) * 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
US6692834B1 (en) * 1999-06-28 2004-02-17 Medtronic, Inc. Method for coating implantable devices
US6221600B1 (en) * 1999-10-08 2001-04-24 Board Of Regents, The University Of Texas System Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis
US6841348B1 (en) * 1999-10-21 2005-01-11 Affymetrix, Inc. Methods for identifying and using maintenance genes
EP1356096A2 (en) * 2000-06-30 2003-10-29 Syngenta Participations AG Method for identification, separation and quantitative measurement of nucleic acid fragments
US20020152196A1 (en) * 2000-07-07 2002-10-17 Westbrook Carol A. cDNA database and biochip for analysis of hematopoietic tissue
EP1317569B1 (en) * 2000-09-14 2009-11-18 Caliper Life Sciences, Inc. Microfluidic devices and methods for performing temperature mediated reactions
US20030104393A1 (en) * 2000-11-28 2003-06-05 Sharp Frank R. Blood assessment of injury
KR20040034582A (en) * 2000-12-04 2004-04-28 프리마겐 홀딩 비.브이. Testing endosymbiont cellular organelles and compounds identifiable therewith
CA2431170C (en) * 2000-12-12 2011-07-26 Aisin Seiki Kabushiki Kaisha Method of analyzing expression of gene
US7083951B2 (en) * 2001-02-14 2006-08-01 The Regents Of The University Of California Flow cytometric detection method for DNA samples
US6692700B2 (en) 2001-02-14 2004-02-17 Handylab, Inc. Heat-reduction methods and systems related to microfluidic devices
US20030013137A1 (en) * 2001-03-13 2003-01-16 Barak Larry S. Automated methods of detecting receptor activity
US6852287B2 (en) 2001-09-12 2005-02-08 Handylab, Inc. Microfluidic devices having a reduced number of input and output connections
US7323140B2 (en) 2001-03-28 2008-01-29 Handylab, Inc. Moving microdroplets in a microfluidic device
US7010391B2 (en) 2001-03-28 2006-03-07 Handylab, Inc. Methods and systems for control of microfluidic devices
US7829025B2 (en) 2001-03-28 2010-11-09 Venture Lending & Leasing Iv, Inc. Systems and methods for thermal actuation of microfluidic devices
US8895311B1 (en) 2001-03-28 2014-11-25 Handylab, Inc. Methods and systems for control of general purpose microfluidic devices
WO2002090599A1 (en) * 2001-05-09 2002-11-14 Genetic Id, Inc. Universal microarray system
US7065451B2 (en) * 2001-05-24 2006-06-20 Board Of Regents, The University Of Texas System Computer-based method for creating collections of sequences from a dataset of sequence identifiers corresponding to natural complex biopolymer sequences and linked to corresponding annotations
DE60213730T2 (en) * 2001-08-31 2007-08-16 The University Of Utah Research Foundation, Salt Lake City Real-time quantification with internal standards
US20030096782A1 (en) * 2001-09-11 2003-05-22 The Regents Of The University Of Colorado Expression profiling in the intact human heart
EP1425403B1 (en) * 2001-09-14 2008-12-31 Oxford Biomedica (UK) Limited Lentiviral vectors for the treatment of pain
AU2003244370A1 (en) * 2002-02-05 2003-09-02 Baylor College Of Medecine Substituted 4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene compounds for 8-color dna sequencing
US6977162B2 (en) * 2002-03-01 2005-12-20 Ravgen, Inc. Rapid analysis of variations in a genome
NZ535045A (en) * 2002-03-01 2008-04-30 Ravgen Inc Rapid analysis of variations in a genome
CA2478605A1 (en) * 2002-03-07 2003-09-18 University Of Utah Research Foundation Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US7348142B2 (en) * 2002-03-29 2008-03-25 Veridex, Lcc Cancer diagnostic panel
US7052840B2 (en) * 2002-04-03 2006-05-30 Capitol Genomix, Inc. Reversible association of nucleic acid with a carboxylated substrate
US7081339B2 (en) * 2002-04-12 2006-07-25 Primera Biosystems, Inc. Methods for variation detection
US7445893B2 (en) * 2002-04-12 2008-11-04 Primera Biosystems, Inc. Sampling method for amplification reaction analysis
US20060052320A1 (en) * 2002-05-06 2006-03-09 Limin Li Mammalian genes involved in rapamycin resistance and tumorgenesis annexin XIII genes
US7727720B2 (en) * 2002-05-08 2010-06-01 Ravgen, Inc. Methods for detection of genetic disorders
US7442506B2 (en) * 2002-05-08 2008-10-28 Ravgen, Inc. Methods for detection of genetic disorders
US20070178478A1 (en) * 2002-05-08 2007-08-02 Dhallan Ravinder S Methods for detection of genetic disorders
US7115370B2 (en) * 2002-06-05 2006-10-03 Capital Genomix, Inc. Combinatorial oligonucleotide PCR
US7094345B2 (en) * 2002-09-09 2006-08-22 Cytonome, Inc. Implementation of microfluidic components, including molecular fractionation devices, in a microfluidic system
EP1418241A1 (en) * 2002-11-08 2004-05-12 PrimaGen Holding B.V. Method for quantifying a ratio between at least two nucleic acid sequences
US20050089875A1 (en) * 2002-11-21 2005-04-28 Sention Inc. Quantitative analysis of expression profiling information produced at various stages of an amplification process
US20060147926A1 (en) * 2002-11-25 2006-07-06 Emmert-Buck Michael R Method and apparatus for performing multiple simultaneous manipulations of biomolecules in a two-dimensional array
EP2402089A1 (en) 2003-07-31 2012-01-04 Handylab, Inc. Processing particle-containing samples
US7344850B2 (en) * 2003-12-30 2008-03-18 Princeton University Identification of active-site inhibitors of glycosyltransferases using a generalizable high-throughput screen
WO2005108620A2 (en) 2004-05-03 2005-11-17 Handylab, Inc. Processing polynucleotide-containing samples
US8852862B2 (en) 2004-05-03 2014-10-07 Handylab, Inc. Method for processing polynucleotide-containing samples
US20060008823A1 (en) * 2004-05-12 2006-01-12 Kemp Jennifer T DNA profiling and SNP detection utilizing microarrays
US7338765B2 (en) * 2004-09-07 2008-03-04 The Board Of Trustees Of The Leland Stanford Junior University Representational fragment amplification
WO2007044937A2 (en) * 2005-10-13 2007-04-19 President And Fellows Of Harvard College Compositions and methods to modulate memory
US8088616B2 (en) 2006-03-24 2012-01-03 Handylab, Inc. Heater unit for microfluidic diagnostic system
US7998708B2 (en) 2006-03-24 2011-08-16 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
EP2001990B1 (en) 2006-03-24 2016-06-29 Handylab, Inc. Integrated system for processing microfluidic samples, and method of using same
US10900066B2 (en) 2006-03-24 2021-01-26 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
US11806718B2 (en) 2006-03-24 2023-11-07 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
WO2008060604A2 (en) 2006-11-14 2008-05-22 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
WO2008061165A2 (en) 2006-11-14 2008-05-22 Handylab, Inc. Microfluidic cartridge and method of making same
US8652780B2 (en) 2007-03-26 2014-02-18 Sequenom, Inc. Restriction endonuclease enhanced polymorphic sequence detection
USD621060S1 (en) 2008-07-14 2010-08-03 Handylab, Inc. Microfluidic cartridge
US8133671B2 (en) 2007-07-13 2012-03-13 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US20090136385A1 (en) 2007-07-13 2009-05-28 Handylab, Inc. Reagent Tube
US8105783B2 (en) 2007-07-13 2012-01-31 Handylab, Inc. Microfluidic cartridge
US9186677B2 (en) 2007-07-13 2015-11-17 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US8182763B2 (en) 2007-07-13 2012-05-22 Handylab, Inc. Rack for sample tubes and reagent holders
US8287820B2 (en) 2007-07-13 2012-10-16 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
EP3741869A1 (en) 2007-07-13 2020-11-25 Handylab, Inc. Polynucleotide capture materials and methods of using same
US9618139B2 (en) 2007-07-13 2017-04-11 Handylab, Inc. Integrated heater and magnetic separator
US9404150B2 (en) 2007-08-29 2016-08-02 Sequenom, Inc. Methods and compositions for universal size-specific PCR
WO2009042522A2 (en) * 2007-09-26 2009-04-02 University Of Louisville Research Foundation Microfluidic lysis
USD618820S1 (en) 2008-07-11 2010-06-29 Handylab, Inc. Reagent holder
WO2010005444A1 (en) * 2008-07-11 2010-01-14 Handylab, Inc. Polynucleotide capture materials, and methods of using same
USD787087S1 (en) 2008-07-14 2017-05-16 Handylab, Inc. Housing
US20110003703A1 (en) * 2009-07-01 2011-01-06 Charles Ma Nucleic Acid Hybridization and Detection Using Enzymatic Reactions on a Microarray
US11022573B2 (en) * 2010-08-31 2021-06-01 Canon U.S.A., Inc. Positive controls
CA2833262C (en) 2011-04-15 2020-08-18 Becton, Dickinson And Company Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection
USD692162S1 (en) 2011-09-30 2013-10-22 Becton, Dickinson And Company Single piece reagent holder
KR102121853B1 (en) 2011-09-30 2020-06-12 벡톤 디킨슨 앤드 컴퍼니 Unitized reagent strip
CN104040238B (en) 2011-11-04 2017-06-27 汉迪拉布公司 Polynucleotides sample preparation apparatus
CA2863637C (en) 2012-02-03 2021-10-26 Becton, Dickinson And Company External files for distribution of molecular diagnostic tests and determination of compatibility between tests
WO2013123440A1 (en) * 2012-02-17 2013-08-22 Institute For Systems Biology Rnase h-based rna profiling
US20140125286A1 (en) * 2012-05-14 2014-05-08 Korea Advanced Institute Of Science And Technology Method for controlling the charging of segments for an online electric vehicle

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0534858A1 (en) * 1991-09-24 1993-03-31 Keygene N.V. Selective restriction fragment amplification : a general method for DNA fingerprinting
EP0761822A2 (en) * 1995-09-12 1997-03-12 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US5922535A (en) * 1995-11-07 1999-07-13 Huo; Li Identifying sequence differences in nucleic acid populations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4865707A (en) * 1986-10-21 1989-09-12 Northeastern University Capillary gel electrophoresis columns
US5053336A (en) * 1989-07-17 1991-10-01 Regents Of The University Of California Monoclonal antibodies for the separate detection of halodeoxyuridines and method for their use
US5139940A (en) * 1989-10-26 1992-08-18 Isaacs Stephen T Activation compounds and methods of synthesis of activation compounds
US5104792A (en) * 1989-12-21 1992-04-14 The United States Of America As Represented By The Department Of Health And Human Services Method for amplifying unknown nucleic acid sequences
WO1991011534A1 (en) * 1990-01-24 1991-08-08 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce A rapid and sensitive test for detecting hepatitis a virus
US5817462A (en) * 1995-02-21 1998-10-06 Applied Spectral Imaging Method for simultaneous detection of multiple fluorophores for in situ hybridization and multicolor chromosome painting and banding
US5784162A (en) * 1993-08-18 1998-07-21 Applied Spectral Imaging Ltd. Spectral bio-imaging methods for biological research, medical diagnostics and therapy
US5521084A (en) * 1992-11-10 1996-05-28 Biostar, Inc. Bovine heat shock promoter and uses thereof
US5650274A (en) * 1993-06-25 1997-07-22 Hitachi, Ltd. DNA analyzing method
US5804380A (en) * 1993-11-12 1998-09-08 Geron Corporation Telomerase activity assays
US5654419A (en) * 1994-02-01 1997-08-05 The Regents Of The University Of California Fluorescent labels and their use in separations
US5869255A (en) * 1994-02-01 1999-02-09 The Regents Of The University Of California Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis
US5698394A (en) * 1994-06-01 1997-12-16 Board Of Regents Of The University Of Nebraska Nucleotide sequences and methods for detection of Serpulina hyodysenteriae
US5656470A (en) * 1994-09-13 1997-08-12 Cubist Pharmaceuticals, Inc. Recombinant mycobacterial seryl-tRNA synthetase genes, tester strains and assays
US5605797A (en) * 1994-09-15 1997-02-25 Board Of Trustees Operating Michigan State University Bovine β-mannosidase gene and methods of use
EP0721987A1 (en) 1995-01-16 1996-07-17 Keygene N.V. Amplification of simple sequence repeats
US5994058A (en) * 1995-03-20 1999-11-30 Genome International Corporation Method for contiguous genome sequencing
KR960034413A (en) * 1995-03-24 1996-10-22 권계홍 Apoptosis regulatory genes
US5736330A (en) * 1995-10-11 1998-04-07 Luminex Corporation Method and compositions for flow cytometric determination of DNA sequences
US5871697A (en) 1995-10-24 1999-02-16 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US5830657A (en) * 1996-05-01 1998-11-03 Visible Genetics Inc. Method for single-tube sequencing of nucleic acid polymers
US5759781A (en) * 1995-12-22 1998-06-02 Yale University Multiparametric fluorescence in situ hybridization
US5767288A (en) * 1996-01-05 1998-06-16 California Institute Of Technology Photolabile linkers and probes
US5851772A (en) * 1996-01-29 1998-12-22 University Of Chicago Microchip method for the enrichment of specific DNA sequences
EP1011729B1 (en) * 1996-05-20 2008-01-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligonucleotides which specifically bind retroviral nucleocapsid proteins
US5853990A (en) * 1996-07-26 1998-12-29 Edward E. Winger Real time homogeneous nucleotide assay
US6310193B1 (en) * 1996-08-16 2001-10-30 Smithkline Beecham Corporation MurC from Streptococcus pneumoniae
EP1007730A4 (en) 1996-08-30 2004-04-28 Invitrogen Corp METHODS FOR IDENTIFICATION AND ISOLATION OF SPECIFIC NUCLEOTIDE SEQUENCES IN cDNA AND GENOMIC DNA
US6329140B1 (en) * 1996-09-19 2001-12-11 Affymetrix, Inc. Identification of molecular sequence signatures and methods involving the same
US5853992A (en) * 1996-10-04 1998-12-29 The Regents Of The University Of California Cyanine dyes with high-absorbance cross section as donor chromophores in energy transfer labels
US5912147A (en) * 1996-10-22 1999-06-15 Health Research, Inc. Rapid means of quantitating genomic instability
US5770716A (en) * 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
WO1998059233A1 (en) * 1997-06-23 1998-12-30 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6002817A (en) * 1997-09-29 1999-12-14 The Regents Of The University Of Michigan Optical sensors for the detection of nitric oxide
US6124120A (en) * 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6090572A (en) * 1998-06-26 2000-07-18 Biostar, Incorporated Filtration and extraction device and method of using the same
US6262334B1 (en) * 1998-08-31 2001-07-17 Bayer Corporation Human genes and expression products: II
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression
US6521428B1 (en) * 1999-04-21 2003-02-18 Genome Technologies, Llc Shot-gun sequencing and amplification without cloning
US6221600B1 (en) * 1999-10-08 2001-04-24 Board Of Regents, The University Of Texas System Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0534858A1 (en) * 1991-09-24 1993-03-31 Keygene N.V. Selective restriction fragment amplification : a general method for DNA fingerprinting
EP0761822A2 (en) * 1995-09-12 1997-03-12 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US5922535A (en) * 1995-11-07 1999-07-13 Huo; Li Identifying sequence differences in nucleic acid populations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1259641A2 *

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008461A3 (en) * 2000-07-21 2002-05-10 Global Genomics Ab A METHOD AND AN ALGORITHM FOR mRNA EXPRESSION ANALYSIS
WO2002008461A2 (en) * 2000-07-21 2002-01-31 Global Genomics Ab A METHOD AND AN ALGORITHM FOR mRNA EXPRESSION ANALYSIS
WO2002059359A2 (en) * 2001-01-24 2002-08-01 Syngenta Participations Ag Method for non-redundant library construction
WO2002059359A3 (en) * 2001-01-24 2003-08-07 Syngenta Participations Ag Method for non-redundant library construction
US6727068B2 (en) 2001-01-24 2004-04-27 Syngenta Participations Ag Method for non-redundant library construction
WO2003064689A2 (en) * 2002-01-29 2003-08-07 Global Genomics Ab Methods for identifying polyadenylation sites and genes thereof
WO2003064689A3 (en) * 2002-01-29 2003-11-13 Global Genomics Ab Methods for identifying polyadenylation sites and genes thereof
EP2112229A2 (en) 2002-11-25 2009-10-28 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US8846924B2 (en) 2003-07-02 2014-09-30 Atto-Tec Gmbh Sulfonamide derivatives of polycyclic dyes used for analytical applications
US10662421B2 (en) 2006-05-31 2020-05-26 Sequenom, Inc. Methods and compositions for the extraction and amplification of nucleic acid from a sample
EP2236623A1 (en) 2006-06-05 2010-10-06 Cancer Care Ontario Assessment of risk for colorectal cancer
US9051608B2 (en) 2006-12-05 2015-06-09 Agena Bioscience, Inc. Detection and quantification of biomolecules using mass spectrometry
US8173370B2 (en) 2007-02-08 2012-05-08 Sequenom, Inc. Nucleic acid-based tests for RHD typing, gender determination and nucleic acid quantification
WO2008098142A2 (en) 2007-02-08 2008-08-14 Sequenom, Inc. Nucleic acid-based tests for rhd typing, gender determination and nucleic acid quantification
US8551707B2 (en) 2007-02-08 2013-10-08 Sequenom, Inc. Nucleic acid-based tests for RhD typing, gender determination and nucleic acid quantification
EP2243834A1 (en) 2007-03-05 2010-10-27 Cancer Care Ontario Assessment of risk for colorectal cancer
US8206926B2 (en) 2008-03-26 2012-06-26 Sequenom, Inc. Restriction endonuclease enhanced polymorphic sequence detection
US10612086B2 (en) 2008-09-16 2020-04-07 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US10738358B2 (en) 2008-09-16 2020-08-11 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
EP3722810A2 (en) 2009-02-11 2020-10-14 Caris MPI, Inc. Molecular profiling of tumors
EP3301446A1 (en) 2009-02-11 2018-04-04 Caris MPI, Inc. Molecular profiling of tumors
EP3211095A1 (en) 2009-04-03 2017-08-30 Sequenom, Inc. Nucleic acid preparation compositions and methods
US10858645B2 (en) 2009-04-03 2020-12-08 Sequenom, Inc. Nucleic acid preparation compositions and methods
WO2010115016A2 (en) 2009-04-03 2010-10-07 Sequenom, Inc. Nucleic acid preparation compositions and methods
EP3964586A1 (en) 2009-04-03 2022-03-09 Sequenom, Inc. Nucleic acid preparation compositions and methods
US9850480B2 (en) 2009-04-03 2017-12-26 Sequenom, Inc. Nucleic acid preparation compositions and methods
EP3514244A1 (en) 2009-04-03 2019-07-24 Sequenom, Inc. Nucleic acid preparation compositions and methods
US10053685B2 (en) 2009-04-03 2018-08-21 Sequenom, Inc. Nucleic acid preparation compositions and methods
WO2011056688A2 (en) 2009-10-27 2011-05-12 Caris Life Sciences, Inc. Molecular profiling for personalized medicine
US9926593B2 (en) 2009-12-22 2018-03-27 Sequenom, Inc. Processes and kits for identifying aneuploidy
US11180799B2 (en) 2009-12-22 2021-11-23 Sequenom, Inc. Processes and kits for identifying aneuploidy
US9803236B2 (en) 2010-08-06 2017-10-31 Tsinghua University Microarray-based assay integrated with particles for analyzing molecular interactions
WO2012055069A1 (en) 2010-10-27 2012-05-03 Capitalbio Corporation Luminophore-labeled molecules coupled with particles for microarray-based assays
US9310375B2 (en) 2010-10-27 2016-04-12 Capitalbio Corporation Luminophore-labeled molecules coupled with particles for microarray-based assays
WO2013128204A1 (en) * 2012-03-02 2013-09-06 The Babraham Institute Method of identifying vdj recombination products
US11312997B2 (en) 2012-03-02 2022-04-26 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US9797014B2 (en) 2012-03-02 2017-10-24 The Babraham Institute Method of identifying VDJ recombination products
US9605313B2 (en) 2012-03-02 2017-03-28 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US10738359B2 (en) 2012-03-02 2020-08-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US11306354B2 (en) 2012-05-21 2022-04-19 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
US11332791B2 (en) 2012-07-13 2022-05-17 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
EP2759603A1 (en) 2013-01-29 2014-07-30 ArticDx Inc. Method for determining a therapeutic approach for the treatment of age-related macular degeneration (AMD)
US11060145B2 (en) 2013-03-13 2021-07-13 Sequenom, Inc. Methods and compositions for identifying presence or absence of hypermethylation or hypomethylation locus
US10982267B2 (en) 2013-12-05 2021-04-20 Capitalbio Technology Corporation Luminophore-labeled molecules coupled with particles for microarray-based assays
US10167499B2 (en) 2013-12-05 2019-01-01 Capitalbio Technoloogy Corporation Luminophore-labeled molecules coupled with particles for microarray-based assays
US11365447B2 (en) 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2020113237A1 (en) 2018-11-30 2020-06-04 Caris Mpi, Inc. Next-generation molecular profiling
US11315673B2 (en) 2018-11-30 2022-04-26 Caris Mpi, Inc. Next-generation molecular profiling
US11842805B2 (en) 2019-12-02 2023-12-12 Caris Mpi, Inc. Pan-cancer platinum response predictor
US11952569B2 (en) 2020-04-15 2024-04-09 Sequenom, Inc. Methods and compositions for the extraction and amplification of nucleic acid from a sample

Also Published As

Publication number Publication date
US7294487B2 (en) 2007-11-13
WO2001027329A3 (en) 2002-09-12
AU8010600A (en) 2001-04-23
EP1259641A2 (en) 2002-11-27
CA2386410A1 (en) 2001-04-19
US6221600B1 (en) 2001-04-24
US20030027141A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
US7294487B2 (en) Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis
US6638722B2 (en) Method for rapid amplification of DNA
CA2398107C (en) Methods for analysis of gene expression
US6403319B1 (en) Analysis of sequence tags with hairpin primers
US20030175908A1 (en) Methods and means for manipulating nucleic acid
Zhang et al. Differential display of mRNA
JP2004504059A (en) Method for analyzing and identifying transcribed gene, and finger print method
CN111808854A (en) Balanced joint with molecular bar code and method for quickly constructing transcriptome library
US7115370B2 (en) Combinatorial oligonucleotide PCR
WO2005118791A1 (en) Exhaustive gene expression profiling analysis using microsample
MacLeod et al. Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis
CN117305467A (en) Kit for detecting hair shaft mRNA and detection method thereof
Hof et al. Digital analysis of cDNA abundance; expression profiling by means of restriction fragment fingerprinting
AU2002320095A1 (en) Method for rapid amplification of DNA
John et al. Approaches to the analysis of gene expression using mRNA
WO2003064689A2 (en) Methods for identifying polyadenylation sites and genes thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2386410

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000970778

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000970778

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP